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Injectable Hyaluronic Acid Hydrogels For The Delivery Of Cell-Based Therapeutics
To The Heart
Abstract
Cardiovascular disease is a leading cause of death in the United States, and while mortality rates from
acute myocardial infarctions (MI) are declining, many of these surviving patients will develop heart failure
as a result of adverse left ventricular remodeling initiated by the ischemic attack. Cell therapies have been
broadly explored in the clinic to promote cardiac repair after MI, but low engraftment of delivered cells has
limited their translation and clinical efficacy. Additionally, the positive benefits of cell therapies may be
due to paracrine signals that cells produce rather than the cells themselves, which has motivated the
direct delivery of cell-derived therapies, such as growth factors, cytokines, and extracellular vesicles
(EVs). However, with all of these therapies, new strategies to improve their engraftment and sustained
presentation after MI are needed.
To address this concern, this dissertation engineers an injectable hydrogel through the mixing of
hyaluronic acid functionalized with either adamantane or -cyclodextrin groups. This supramolecular
assembly imparts shear-thinning and self-healing properties into the hydrogel that allows injection into
the myocardium. After a thorough characterization of the hydrogel properties, select formulations are
explored for the delivery of various cell-based therapeutics, including endothelial progenitor cells (EPCs),
interleukin-10 (IL-1), and mesenchymal stromal cell (MSC)-derived EVs. These therapeutics are intended
to improve outcomes after MI, through alterations in vascularization and the inflammatory response
during remodeling.
Hydrogel delivery of EPCs significantly improves EPC retention when compared to the direct injection of
EPCs in saline. This enhanced cell retention is correlated with improved cardiac function, reduced scar
fraction, and increased vascular density in a rat MI model. IL-10 is delivered from the same hydrogel,
using a degradable microgel carrier that allows decoupling of the hydrogel injectability from IL-10 release
behavior. Delivery of this composite hydrogel with IL-10 to the heart in a rat MI model significantly
reduced the presence of inflammatory cells and improved cardiac function and remodeling when
compared to saline.
Finally, an injectable guest-host hydrogel is utilized to deliver EVs isolated from MSCs that are preconditioned to be pro-vasculogenic. EVs isolated from MSCs treated with different pre-conditioning
regimens have varied protein content, and the delivery of pre-conditioned EVs using an injectable hydrogel
improves EV retention in the heart and increases vascularization in the infarct region after MI. These
findings indicate that a shear-thinning hydrogel can be used to deliver and enhance the retention of cells,
cytokines, and EVs in the heart and enhanced therapeutic retention can result in improved outcomes for
cardiac repair after MI. Overall, this thesis highlights the use of an injectable hydrogel as a therapeutic
delivery vehicle toward translation of these therapeutics for clinical use.
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ABSTRACT

INJECTABLE HYALURONIC ACID HYDROGELS FOR THE DELIVERY OF CELLBASED THERAPEUTICS TO THE HEART
Minna H. Chen
Jason A. Burdick

Cardiovascular disease is a leading cause of death in the United States, and
while mortality rates from acute myocardial infarctions (MI) are declining, many of these
surviving patients will develop heart failure as a result of adverse left ventricular
remodeling initiated by the ischemic attack. Cell therapies have been broadly explored in
the clinic to promote cardiac repair after MI, but low engraftment of delivered cells has
limited their translation and clinical efficacy. Additionally, the positive benefits of cell
therapies may be due to paracrine signals that cells produce rather than the cells
themselves, which has motivated the direct delivery of cell-derived therapies, such as
growth factors, cytokines, and extracellular vesicles (EVs). However, with all of these
therapies, new strategies to improve their engraftment and sustained presentation after
MI are needed.
To address this concern, this dissertation engineers an injectable hydrogel
through the mixing of hyaluronic acid functionalized with either adamantane or bcyclodextrin groups. This supramolecular assembly imparts shear-thinning and selfhealing properties into the hydrogel that allows injection into the myocardium. After a
thorough characterization of the hydrogel properties, select formulations are explored for
the delivery of various cell-based therapeutics, including endothelial progenitor cells
(EPCs), interleukin-10 (IL-1), and mesenchymal stromal cell (MSC)-derived EVs. These
iv

therapeutics are intended to improve outcomes after MI, through alterations in
vascularization and the inflammatory response during remodeling.
Hydrogel delivery of EPCs significantly improves EPC retention when compared
to the direct injection of EPCs in saline. This enhanced cell retention is correlated with
improved cardiac function, reduced scar fraction, and increased vascular density in a rat
MI model. IL-10 is delivered from the same hydrogel, using a degradable microgel
carrier that allows decoupling of the hydrogel injectability from IL-10 release behavior.
Delivery of this composite hydrogel with IL-10 to the heart in a rat MI model significantly
reduced the presence of inflammatory cells and improved cardiac function and
remodeling when compared to saline.
Finally, an injectable guest-host hydrogel is utilized to deliver EVs isolated from
MSCs that are pre-conditioned to be pro-vasculogenic. EVs isolated from MSCs treated
with different pre-conditioning regimens have varied protein content, and the delivery of
pre-conditioned EVs using an injectable hydrogel improves EV retention in the heart and
increases vascularization in the infarct region after MI. These findings indicate that a
shear-thinning hydrogel can be used to deliver and enhance the retention of cells,
cytokines, and EVs in the heart and enhanced therapeutic retention can result in
improved outcomes for cardiac repair after MI. Overall, this thesis highlights the use of
an injectable hydrogel as a therapeutic delivery vehicle toward translation of these
therapeutics for clinical use.
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CHAPTER 1
INTRODUCTION

1.1 SIGNIFICANCE
Cardiovascular disease (CVD) is the leading cause of death globally and in the
United States, where it is responsible for almost 1 in every 3 deaths - more than all types
of cancer combined.1 More than 121.5 million adults in the United States have some
form of CVD, and from 2014-2015 the total costs associated with CVD and stroke were
more than $350 billion, accounting for 14% of total healthcare expenditures and more
than any other major diagnostic group.1 While the etiology of the disease is not certain,
CVD can be preventable by reducing risk factors such as smoking and high body weight
through physical activity and a healthy diet, as well as maintenance of healthy
cholesterol, blood pressure, and blood sugar levels.1
Every 40 seconds an American adult suffers from a heart attack or myocardial
infarction (MI).1 An MI most commonly occurs when a coronary artery becomes
occluded, usually due to the rupture of atherosclerotic plaques and subsequent clot
formation (Figure 1.1).2 If diagnosed and treated quickly, medications and surgical
interventions can restore blood flow and limit heart muscle damage. Thrombolytic
medications such as aspirin, heparin, and antiplatelet drugs can break up the existing
clot and prevent new clots from forming.2 Percutaneous coronary intervention
procedures, where stents are used to open narrow or blocked arteries, as well as
coronary artery bypass surgery can be used to restore blood flow to the heart.2 However,
if blood flow is not restored quickly, the lack of oxygen and nutrients cause muscle
damage and tissue death, which triggers an inflammatory response and a loss of
1

cardiomyocytes, the contractile cell of the heart. Over time, this leads to a remodeling
process that replaces healthy tissue with scar tissue and can result in diminished cardiac
function and potentially heart failure (HF).

Figure 1.1. Blockages in coronary arteries can cause MI. A-B) Cholesterol and fatty
acid deposits (plaques) inside coronary arteries, which can rupture and attract platelets
to form C) a blood clot which occludes the artery. D) Downstream of the blockage, the
heart muscle becomes ischemic due to the lack of oxygen and nutrients, eventually
leading to heart muscle death. Adapted from Cleveland Clinic Foundation.2
The prognosis for patients who develop HF is grim- over 50% will die within 5
years.3,4 About 5.7 million American adults suffer from HF, with 915,000 more diagnosed
each year.3 HF costs Americans an estimated $30.7 billion per year due to
hospitalizations, medications, and lost productivity.3 Current treatments for HF focus on
improving cardiac function and blood flow through the use of medications (angiotensin
converting

enzyme

inhibitors,

angiotensin

II

receptor

blockers,

beta-blockers,

aldosterone antagonists) or surgeries (coronary artery bypass graft surgery, valve repair
or replacements).5 Pacemakers and implantable cardiac defibrillators can be used to
2

regulate cardiac contractions. In advanced HF, ventricular assist devices and heart
transplants may be considered. Besides heart transplantation, which suffers from an
extremely limited donor supply, all other treatments are merely palliative and do not
address the irreversible loss of cardiac muscle tissue that occurs as a result of the
ischemic attack. Thus, there exists a great need to develop therapeutics that can target
this damaged tissue to restore cardiac function and limit adverse cardiac remodeling to
improve outcomes for patients with HF.

1.2 LEFT VENTRICULAR REMODELING AFTER MI
MI can lead to the loss of a billion or more cardiomyocytes6, which leads to a
series of regional and global changes in the myocardium that can eventually result in
HF. These changes to the myocardium are broadly termed cardiac remodeling, whereby
biochemical, cellular, and matrix changes result in modifications to the size, shape, and
function of the heart over time.7 The initial phase of acute inflammation evolves into
granulation tissue formation and eventually scar formation (Figure 1.2).8 The process of
cardiac remodeling starts immediately after infarction and continues for a period of
months and even years. Over time, the replacement of healthy myocardium with scar
tissue reduces cardiac function.
Cardiomyocyte necrosis and apoptosis starts as quickly as an hour after
occlusion of a coronary artery, and leads to a localized inflammatory response that is
prominent during the first 4 days.8 At this time, inflammatory cells such as neutrophils
and monocytes infiltrate the infarct region and clear necrotic cardiomyocytes and other
cellular debris.8,9 Matrix metalloproteinases begin to degrade the extracellular matrix
(ECM) and cytokines and chemokines modulate the inflammatory response.8

3

Following this stage is a proliferative phase. In this stage, which occurs 2-3 days
later and lasts for up to 2 weeks, granulation tissue begins to form and endothelial cells
migrate into the infarct region and create new vasculature.8 Fibroblasts and
myofibroblasts start to produce ECM, and the infarct begins to expand as greater wall
stresses lead to ventricular dilation and wall thinning.10 In this stage, formation of new
vasculature, ECM deposition, and macrophage function are crucial to control infarct
expansion, which ultimately has an adverse effect on ventricular function.11 Infarct
expansion is particularly pronounced if the infarct region is transmural.

Figure 1.2. Local cardiac remodeling after MI. Following cardiomyocyte death, phases
of acute inflammation, granulation tissue formation, and scar formation contribute to the
local remodeling of cardiac tissue after MI. During these phases, macrophage activation,
new vessel formation, and collagen deposition are important determinants of infarct
expansion and subsequent cardiac function. Adapted from Matsui, et al.8
In the next phase, the granulation tissue matures to form scar tissue over a
period of weeks to months. Fibroblasts and myofibroblasts undergo apoptosis and
vascular structures start to regress.11 The remaining cardiomyocytes realign themselves
in the dense, cross-linked collagen matrix of the scar tissue, which often exhibits
4

reduced regional wall motion.10 This promotes greater levels of loading on the viable
myocardium, which leads to further ventricular dilation and cardiac hypertrophy (Figure
1.3).11,12 This ventricular dilation preserves the stroke volume, but does not improve the
ejection fraction, and changes the shape of the ventricle to be more spherical, which is
detrimental to cardiac function and ultimately can lead to HF.7,10

Figure 1.3. Global ventricular remodeling after MI. After MI, changes to the infarct,
border zone, and remote regions of the myocardium result in infarct expansion,
ventricular dilation, and ventricular wall thinning, which decreases cardiac function.
Adapted from Jessup, et al.12
The process of adverse cardiac remodeling after MI lends itself to targets to
potentially modulate the remodeling process and improve cardiac function. Antiinflammatory cytokines can be used to mitigate the initial acute inflammatory response,
as well as the response of immune cells in the proliferative phase. The delivery of cells
and cell-derived therapeutics that can increase vascularization can help to control infarct
expansion. Finally, the use of biomaterials can improve the localization and retention of
delivered therapeutics, as well as bulk the ventricular wall, which can ameliorate the
increased wall stresses by increasing ventricular wall thickness.

5

1.3 CELLULAR AND CELL-DERIVED THERAPEUTICS FOR CARDIAC REPAIR
The delivery of cells for cardiac repair is motivated by two overarching theories.
In the first theory, cardiac regeneration is mediated by the delivered cells, which are
intended to engraft, differentiate, and integrate with existing cardiomyocytes.13 Because
adult cardiomyocytes are both difficult to isolate14–17 and have very little proliferative
capacity18,19, the delivery of alternate cell types has been explored to replace
cardiomyocytes lost as a result of MI. These cell types include skeletal myoblasts,
cardiac stem cells, and induced pluripotent stem cells.
In the second theory, cardiac regeneration is mediated through stimulation of
cells in the existing tissue, and the delivered cells release paracrine signaling factors to
promote endogenous repair.13 These paracrine signaling factors may act on
cardiomyocytes to promote proliferation, but also can target other cells and mechanisms
of cardiac repair, such as increasing vascularization or reducing fibrosis. This theory
gained traction when it was discovered that a very small percentage of delivered cells
engraft to the myocardium and are present at even short timepoints after delivery.20–24
Along these lines, the delivery of cell-derived therapeutics has become popular.
Additionally, instead of delivering cells, the factors that the cells produce can be
delivered instead, such as exosomes, growth factors, and cytokines.

The following

sections will outline the various cellular and cell-derived therapeutics that have been
explored, including mention of clinical trials that have been completed or are under
development.
1.3.1. CELLULAR THERAPIES
A wide variety of cell types have been delivered to the heart to promote cardiac
repair and regeneration. Immediately after MI, cell therapies can help to limit cardiac
deterioration largely through the formation of new vascular structures, which, in the long6

term, allows for restoration of pumping capacity (Figure 1.4). While hundreds of preclinical studies have shown that cell delivery is promising for limiting adverse
remodeling, reducing scar, and promoting cardiac function, in general, clinical trials have
been less encouraging.13,25,26 Overall, clinical trials for cellular therapies have had mixed
results, with some suggesting that cellular therapies can significantly improve global
cardiac function, while others show no significant differences between treatment and
control groups.

Figure 1.4. Goals of cellular therapies. Cellular therapies for cardiac repair after MI
aim to limit cardiac deterioration in the days and weeks following MI and restore
pumping capacity in the long term. Adapted from Mummery, et al.27
Many cellular therapies are still undergoing clinical trials with larger patient
populations. For the majority of these clinical trials, cell suspensions are delivered to the
heart in a saline solution injected either systemically (intravenous), to coronary arteries
(intracoronary), or to the myocardium (intramyocardial) (Figure 1.5).
1.3.1.1. SKELETAL MYOBLASTS
Skeletal myoblasts were the first cell type to be investigated in both pre-clinical
and clinical trials for cardiac repair starting in 2001. Easily isolated from autologous
muscle tissue biopsies, these cells were attractive because of their ease of expansion,
7

myogenic capacity, survival in ischemic conditions, and low tumorigenicity.28 Skeletal
myoblasts were delivered in pre-clinical animal models in mice29, rats30,31, rabbits32,33,
sheep34,35, dogs36,37, and pigs38–40 where they showed differentiation into myotubes,
decreased fibrosis, mitigated adverse left ventricular remodeling, and improved cardiac
function. Phase 2 clinical trials started in 2005 and showed that intramyocardial delivery
of skeletal myoblasts resulted in some improvements in left ventricular ejection fraction,
left ventricular remodeling, regional wall motion, and HF severity, but not compared to
the placebo group.41,42 Safety concerns from an increased number of ventricular
arrhythmias ultimately resulted in the termination of the trials. Contrary to what was
previously believed, skeletal myoblasts were found not to transdifferentiate into
cardiomyocytes or form gap junctions to electromechanically couple with existing
cardiomyocytes.43–45 Another Phase 2/3 clinical trial started in 2007 and is currently
ongoing, but inconsistent efficacy coupled with increased risk of arrhythmias has
diminished interest in this cell type.

Figure 1.5. Delivery methods for cells to the heart. Summary of A) intracoronary and
B) intramyocardial methods for cell delivery practiced in clinical trials. RCA: right
coronary artery, CFX: circumflex artery, LAD: left anterior descending artery, LV: left
ventricle. Adapted from Strauer, et al.46
8

1.3.1.2. BONE MARROW-DERIVED MONONUCLEAR CELLS (BMMNCs)
Bone marrow-derived mononuclear cells (BMMNCs) are the most prolific cell
type investigated for cardiac repair. This cell population consists mostly of cells derived
from hematopoietic stem cells at various differentiation stages, but likely also consists of
hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stromal cells.47
Intracoronary48–55 and intramyocardial56–59 delivery of BMMNCs have been extensively
investigated in numerous randomized, controlled clinical trials and have been shown to
be safe and feasible. However, the efficacy of this therapy is varied and there have been
no consistent short-term or long-term benefits shown for cardiac remodeling, cardiac
function, or HF class, leading to the investigation of more specified cell types.
1.3.1.3. ENDOTHELIAL PROGENITOR CELLS (EPCs)
Endothelial progenitor cells (EPCs) are a sub-population of hematopoietic stem
cells that can be isolated in limited quantities from bone marrow and peripheral blood
and have been shown to promote neovascularization in multiple animal models.60,61
Typically, these cells are characterized by their expression of CD34 and CD133,
although a widely accepted definition of this cell type has yet to be determined.62,63 Both
CD34+ and CD133+ autologous cells have been investigated in clinical trials with mixed
results. Intramyocardial64,65 and intracoronary66–69 delivery of CD34+ cells, as well as
intramyocardial70,71 and intracoronary72 delivery of CD133+ cells have shown trends for
improved left ventricular ejection fraction and increased myocardial perfusion. In general,
while safety and feasibility studies have been positive, there is no consensus regarding
efficacy and most studies have shown no effect on global cardiac function, although
trials are ongoing.73–77
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1.3.1.4. MESENCHYMAL STROMAL CELLS
Bone marrow-derived mesenchymal stromal cells (BMMSCs) are nonhematopoietic stem cells that are multipotent, plastic-adherent, and typically
characterized by their ability to differentiate into osteoblasts, adipocytes, and
chondrocytes.78,79 These cells express CD73, CD105, and CD90 but not CD34, CD45,
CD14, or HLA-DR.79 BMMSCs are widely thought to be immune-privileged and
immunosuppressive, allowing for allogeneic delivery and the development of off-theshelf therapies.80 A recent meta-analysis of 58 pre-clinical studies showed that the
delivery of BMMSCs reduced adverse remodeling and improved cardiac function in
animal models of acute MI and chronic ischemic cardiomyopathy.81 However, clinical
studies of BMMSC efficacy have been inconsistent. While many groups have shown that
BMMSC delivery results in significant improvements in LVEF, others have found that
there is no significant difference in cardiac function between cell delivery and control
groups.26,82,83
A similar cell type, adipose-derived mesenchymal stromal cells have also been
explored for cardiac repair. In preclinical MI models, these cells have been shown to be
pro-angiogenic, increasing perfusion and the formation of new vascular structures in the
infarct region.84,85 In clinical trials, this cell type has generally been found to be safe and
feasible, but its impact on cardiac function is questionable. The PRECISE trial found no
improvements in left ventricular ejection fraction but an alleviation of patient symptoms
and increased exercise tolerance was observed.86 The ATHENA trial similarly found
positive changes in VO2 max, but no difference in LV function or volumes with cell
delivery.87 In another trial, cells were pre-treated with vascular endothelial growth factor
and delivered intramyocardially to patients with refractory angina. This trial also found no
improvements in exercise capacity between patients treated with cells or with a control.88
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1.3.1.5. CARDIAC STEM CELLS
Although the regenerative capacity of cardiomyocytes is limited, recently
researchers have discovered the presence of cardiac stem cells (CSCs) or cardiac
progenitor cells. These cells can be isolated from biopsies of the myocardium either
using antibodies for specific cell surface markers89,90 or by culturing as cardiospheres91.
Reports have suggested that these cells can differentiate into cardiomyocytes as well as
endothelial cells and vascular smooth muscle cells.89–91 In a very promising Phase 1
clinical trial that used intracoronary injections to deliver autologous c-kit+ CSCs to
patients with ischemic cardiomyopathy, a significant increase in LVEF and decrease in
scar size was reported, but these results were later retracted due to concerns over
misrepresentation of the CSC phenotype.92,93 For instance, other groups showed that ckit+ cells cannot generate cardiomyocytes at significant levels, and instead abundantly
generate cardiac endothelial cells.94 Additionally, researchers have observed that c-kit+
cells may only be able to generate cardiomyocytes in neonatal hearts and that their role
in adult hearts is primarily revascularization.95,96 Phase 1 and Phase 2 clinical trials
exploring the intracoronary delivery of autologous cardiosphere-derived cells (CDCs),
which are isolated differently than c-kit+ CSCs, have reported improvements in both
cardiac remodeling and cardiac function with treatment.97,98
1.3.1.6. PLURIPOTENT STEM CELLS
Finally, pluripotent stem cells have been explored for cardiac repair and are
attractive because of their capability to differentiate into cardiomyocytes and hopefully
integrate with existing cells. The first pluripotent cell type explored were embryonic stem
cells (ESCs). The risk of tumorigenicity from delivering an undifferentiated cell99,100 has
led researchers to differentiate ESCs into cardiomyocytes prior to implantation, although
it can be difficult to generate pure and mature cardiomyocytes in large enough
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quantities.101,102 The ESCORT Phase 1 clinical trial explored the epicardial delivery of
human ESC-derived cardiac progenitor cells in a fibrin patch. Although the therapy was
deemed to be safe with no patients developing tumors, arrhythmias, or immune
rejection, no follow-up studies have been conducted largely due to ethical concerns.103
Another pluripotent cell type that has been explored is induced pluripotent stem
cells (iPSCs). Like ESCs, iPSCs can be differentiated into cardiomyocytes104–107, but
similar challenges exist for obtaining genetically-stable, adult cardiomyocytes in large
numbers.108,109 However, there are fewer ethical concerns with iPSCs compared to
ESCs. Interestingly, even though iPSCs can be delivered autologously, genetic
instabilities have been found to lead to immunologic rejection which has led researchers
to modify differentiation techniques.110–112 Currently, there have been no completed
clinical trials with iPSC-derived cardiomyocytes for heart disease.
1.3.1.7. SUMMARY OF CELLULAR THERAPIES FOR CARDIAC REPAIR
Numerous cell types have been explored as therapeutics for cardiac repair after
MI (Figure 1.6). While generally deemed to be safe, there is currently no cell type that
consistently displays significant improvements in remodeling or function compared to a
control therapy. Cell therapies also suffer from manufacturing challenges related to the
isolation, culture, and storage of cells prior to delivery. In addition, cell sourcing
(allogeneic vs autologous) and reproducibility are huge hurdles for regulatory approval.
Other challenges that have been explored but still need further investigation and
standardization for the clinic are cell dosage and timing of delivery after MI.
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Figure 1.6. Clinical trials for cell therapies. Various cell types, ranging from
unselected BMMNCs to specific cell types and cardiac stem cells, have been
investigated in clinical trials for almost two decades. Adapted from Hastings, et al.25
Finally, one of the leading factors for the inconsistency in the efficacy of cell
therapies is the low engraftment of delivered cells. Almost all of the clinical studies
mentioned here deliver cells in a saline solution, which has little to no capacity to retain
cells at the injection site. Cell washout or mechanical ejection due to muscle beating, as
well as cell death due to the ischemic and inflammatory infarct environment, are
particularly prevalent in cell therapies delivered to the heart.25,113 Multiple groups have
reported catastrophically low levels of cell retention, regardless of mode of
delivery.20,22,24,114,115 For instance, it has been reported that after four weeks less than 1%
of delivered cells are retained.116 This strongly supports the hypothesis that paracrine
factors that cells produce are the therapeutic element of cellular delivery rather than
functional integration of delivered cells as cardiomyocytes. In response, this has
triggered the investigation of cell-derived products, such as growth factors, cytokines,
and extracellular vesicles (EVs), as therapeutics instead of the cells themselves.
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1.3.2. CELL-DERIVED THERAPIES
The delivery of cell-derived therapies consists of two major strategies- delivering
the entire cell secretome, such as in the form of isolated EVs or exosomes, or delivering
one or more specific factors that are produced by cells. In both cases, cardiac repair is
mediated through the stimulation of resident cells, which can occur through a number of
mechanisms such as modulating inflammation, reducing apoptosis or promoting cell
cycle re-entry, increasing angiogenesis, or recruiting and activating progenitor cells.
1.3.2.1. EXTRACELLULAR VESICLES
EVs are membrane-bound vesicles released by cells that can transport cargo
such as DNAs, RNAs, proteins, and lipids to other cells as a form of cellular
communication (Figure 1.7).117 There are varying types of EVs, differentiated by their
biogenesis. These include exosomes, microvesicles, apoptotic bodies, and oncosomes.
Microvesicles are about 100-1000 nm in diameter and are formed directly from budding
of the plasma membrane and contain cytoplasmic cargo.118 Apoptotic bodies are formed
by blebbing of the plasma membrane in dying cells and are can be up to 2 µm in
diameter with varied content depending on cell type.119,120 Oncosomes are formed by
plasma membrane protrusions in cancer cells and are generally larger, around 1-10 µm
in diameter.121,122 Common EV isolation methods include ultracentrifugation, density
gradient ultracentrifugation, size-exclusion chromatography, and polymer precipitation.123
These methods rely primarily on size to enrich but not distinctly separate isolation of
these different subpopulations of EVs, and most EV research has focused on exosomes.
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Figure 1.7. EVs produced by cells. A) Exosomes and microvesicles are produced by
normal and diseased cells. Apoptosis triggers the release of apoptotic bodies. Some
cancer cells were reported to generate large EVs, termed oncosomes. B) EVs can be
taken up via different mechanisms, including endocytosis, membrane fusion, or
phagocytosis. Ligand–receptor interactions on the cell surface can also result in
biological effects and help to target vesicles to specific cell types. Adapted from
Zaborowski, et al.117
Exosomes are small vesicles (about 100 nm in diameter) formed from the
invagination of membranes of multivesicular bodies inside the cell (Figure 1.8).124
Exosomes are present in all bodily fluids and their payload is cell-specific, but almost all
cell types produce exosomes. Exosomes are released from cells when these
endosomes fuse with the plasma membrane of the cell, releasing their cargo to affect
neighboring or distant cells. Exosomes can contain miRNAs, mRNAs, and proteins from
inside the cell and are used for intercellular communication and signaling.125 Recently,
exosomes have become popular as they can be easily isolated in large quantities from
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cells, are amenable to freezing and storage, and can be used as therapeutics directly or
altered to encapsulate other cargo.126

Figure 1.8. Exosome biogenesis. Exosomes form from invaginations of multivesicular
bodies within the cell and contain proteins and RNAs (mRNA: messenger RNA, MiRNA:
microRNA, lncRNA: long noncoding RNA). These vesicles are then either secreted from
the cell or degraded by lysosomes within the cell. Adapted from Marbán, et al.124
Exosomes isolated from mesenchymal stromal cells, CSCs, iPSCs, and ESCs
have been investigated as therapeutics for cardiac repair in numerous preclinical studies
which have been previously reviewed.127,128 In 2010, Lai, et al published one of the first
studies utilizing exosomes as a therapeutic for cardiac repair and showed that exosomes
isolated from human ESC-derived mesenchymal stem cells reduced infarct size after
systemic delivery in a mouse model of myocardial ischemia/reperfusion injury.129 Since
then, many groups have investigated the benefits of mesenchymal stromal cell-derived
exosomes, including Teng, et al, who found that the intramyocardial delivery of these
exosomes in a rat model of MI reduced infarct size and improved vascularization.130
Exosomes isolated from human cardiosphere-derived cells have been evaluated in more
clinically relevant large-animal models such as pigs, and intramyocardial delivery of
these exosomes 4 weeks after MI was shown to decrease scarring and improve left
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ventricular ejection fraction.131 In mice, Adamiak, et al found that the intramyocardial
injection of EVs derived from mouse iPSCs 48 hours after MI was able to improve
cardiac function and increase perfusion in the infarct region, even more so than the
delivery of IPSCs.132 In addition, teratomas formed after iPSC delivery while none were
observed with EV delivery, indicating that iPSC-derived EVs may be safer and more
effective than iPSCs.132
Additionally, exosomes can be altered to encapsulate additional cargo or to
facilitate targeting to various tissues in the body. Alvarez-Erviti, et al engineered braintargeted exosomes by transfecting primary dendritic cells with a targeting peptide
expressing plasmid, and then altered the cargo of these isolated exosomes using
electroporation to introduce brain-specific siRNAs.133 After intravenous injection of these
targeted exosomes in mice, they observed a knockdown of the same brain-specific
genes.133 Electroporation was also used to load mesenchymal stromal cell-derived
exosomes with miR-132, which were then delivered after MI through intramyocardial
injections in mice.134 The delivery of these loaded exosomes were shown to increase the
formation of new vasculature structures and improve ejection fraction compared to the
delivery of non-loaded exosomes or miR-132 alone.134 For cardiac targeting, Vandergriff,
et al conjugated cardiac stem cell-derived exosomes with a cardiac homing peptide and
showed that they were able to deliver these exosomes systemically in rats at 1/50 of the
dosage they utilized in a previous paper with similar improvements for cardiac
remodeling and angiogenesis after myocardial ischemia/reperfusion injury.135
Currently, there are 147 clinical trials involving EVs or exosomes reported on
ClinicalTrials.gov taking place around the world, with 49 trials in the United States alone
(Figure 1.9). Not all of these trials involve EVs as a therapeutic; some study the effects
of other drugs or disease states on EV production or EV content. At this time, there are
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no trials investigating EV therapies for cardiac disease, although EVs are being explored
as therapeutics for other indications, such as stroke, diabetes, and cancer.136,137

Figure 1.9. Clinical trials for EV or exosome therapies. As of July 8, 2019, there are
147 clinical trials globally that involve EVs or exosomes, with 49 of these trials taking
place in the United States. Studies with multiple locations are represented in each region
containing these locations. Adapted from ClinicalTrials.gov.
1.3.2.2. GROWTH FACTORS
Exosomes contain varied proteins and RNAs, which can make it challenging to
understanding the influence of specific contents on tissue repair and molecular
pathways. In contrast, a more direct approach is the delivery of one or more factors in a
more targeted method. At stated above, the cardiac remodeling process following MI
lends itself to a wide variety of targets, such as inflammation, angiogenesis, extracellular
matrix remodeling, and cardiomyocyte proliferation. A summary of key growth factors or
cytokines relevant to cardiac regeneration and their targets is shown in the table below
(Table 1.1).
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Table 1.1. Main growth factors applicable to cardiac repair.
Factor*
VEGF
FGF
HGF
SDF-1
IGF-1
PDGF
Erythropoietin
G-CSF
Intermedin
Angiopoietin
Periostin
Neuregulin-1

Mechanisms
Angiogenesis
Angiogenesis
Anti-apoptosis, cardiac stem cell chemotaxis
Hematopoietic stem cell mobilization and homing
Stem and progenitor cell viability, differentiation
Anti-apoptosis
Anti-apoptosis
Anti-apoptosis, hematopoietic stem cell mobilization and homing
Angiogenesis
Angiogenesis, remodeling, and vascular stabilization
Cardiomyocyte proliferation
Cardiomyocyte proliferation

*VEGF: vascular endothelium growth factor isoforms; FGF: fibroblast growth factor; HGF:
Hepatocyte growth factor; SDF-1: stromal cell-derived factor; IGF-1: Insulin-like growth factor 1;
PDGF: platelet-derived growth factor; G-CSF: granulocyte colony stimulating factor. Adapted from
Rebouças, et al.138

Most of these growth factors have been evaluated in numerous preclinical
studies, and, in general, positive preclinical results have not translated into clinical
success. For instance, perhaps the most commonly explored target for growth factor
therapies for cardiac repair is angiogenesis, and clinical trials first started in 1994 with
intramyocardial injection of recombinant FGF-1.139 While neovascularization was
observed at the injection site, there were no measurements of improved cardiac
function. Subsequent studies with FGF and VEGF are summarized in the table below
(Table 1.2).
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Table 1.2. Therapeutic angiogenesis clinical trials.
VEGF
Phase
Phase 1/2
Phase 1/2
Phase 2

Author/trial name (year)
Hendel (2000)
Henry (2001)
VIVA (2003)

Product
VEGF-165
VEGF-165
VEGF-165

Route
i.c.
i.c.
i.c./i.v.

n
14
15
178

Outcome
- (Except: ETT
high-dose only)

FGF
Phase
Phase 1/2
Phase 1/2
Phase 1/2
Phase 1/2
Phase 1/2
Phase 1/2
Phase 1/2
Phase 2

Author/trial name (year)
Schumacher (1998)
Pecher (2000)
Selke (1998)
Ruel (2002)
Laham (2000)
Udelson (2000)
Unger (2000)
FIRST (2002)

Product
FGF-1
FGF-1
FGF-2
FGF-2
FGF-2
FGF-2
FGF-2
FGF-2

Route
i.m.
i.m.
i.m.
i.m.
i.c.
i.c./i.v.
i.c.
i.c.

n
40
40
8
24
52
59
25
337

Outcome
+
+
-

ETT: exercise tolerance test; FGF: fibroblast growth factor; i.c.: intracoronary; i.m.:
intramyocardial; i.v.: intravenous; VEGF: vascular endothelial growth factor; -: negative outcome;
+: positive outcome. Adapted from Rubanyi, et al.140

While some initial Phase 1/2 clinical trials showed promise, larger Phase 2
controlled clinical studies of both VEGF141 and FGF142 delivery showed no clinical
benefit. Simply increasing dosage is not an option, since there are serious off-target
effects of VEGF and FGF delivery related to aberrant angiogenesis, including tumor
growth.143,144 For periostin and neuregulin, off-target effects of cardiomyocyte
proliferation raise concerns for cardiac hypertrophy and ventricular arrhythmias.145 Other
factors, such as SDF-1, are susceptible to degradation by matrix metalloproteinases like
MMP-2, which is upregulated after MI.146
The delivery of growth factors and cytokines for cardiac repair suffers from two
major challenges. First, protein instability can render some therapeutics inactive mere
hours after delivery. Second, because protein therapies are being delivered in saline
solutions even in clinical trials, they are rarely retained in the ischemic myocardium,
leading to off-target effects. Biomaterials can be used to address both of these concerns,
by sequestering protein molecules to both protect and control their release in a targeted
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manner. In summary, the retention of cellular and cell-derived therapeutics at the
delivery site of cardiac tissue is a major concern. Mechanical forces in the heart lead to
the distribution of these therapeutics away from the delivery site. As one approach to
address this concern, biomaterials either applied as patches or injected (intracoronary or
intramyocardial) are being developed to retain these therapeutics at the desired delivery
site.

1.4 INJECTABLE HYDROGELS FOR MI
One class of biomaterials of great interest in treating cardiac tissues are
hydrogels (i.e., water-swollen polymer networks). The use of hydrogels to deliver cells
or cell-derived therapeutics is attractive because hydrogels can be designed to be
injectable through minimally-invasive methods utilizing catheter technologies, which
reduces risks for patients, lowers hospital costs compared to open-heart procedures,
and can potentially be applied at multiple timepoints. For injectability, the hydrogel or
precursor must flow through the syringe or catheter, but then gel with the appropriate
kinetics at the injection site for material retention. This is generally achieved either by
using shear-thinning and rapidly self-healing hydrogels or by hydrogels that crosslink in
situ after injection. For both preclinical and clinical trials, hydrogels are typically delivered
via three methods: intracoronary or intramyocardial, either from the epicardial or
endocardial side.
1.4.1. HYDROGELS ALONE
In addition to the delivery of cellular or cell-derived therapeutics, there are
therapeutic advantages to the delivery hydrogels alone. This is due to their ability to
increase the thickness of the left ventricular wall, thereby reducing wall stress, restoring
ventricular geometry, and preserving cardiac function. LaPlace’s law (T = (P*R)/t) states
21

that tension in the myocardial wall (T) is directly proportional to intraventricular pressure
(P) and radius of curvature (R) and inversely proportional to wall thickness (t). Therefore,
increasing wall thickness through the injection of bulking agents such as hydrogels can
decrease wall stress. Finite element models have shown that multiple hydrogel injections
into the border zone region of the infarct can reduce myofiber stresses, which is further
improved using stiffer materials.147 These results were later confirmed in an ovine model
using hydrogels of 8 kPa and 43 kPa stiffness.148 In addition to increasing hydrogel
stiffness, larger hydrogel injection volumes were also found to be beneficial for
decreasing wall stresses in a finite element model (Figure 1.10)149

Figure 1.10. Left ventricular end-diastolic myofiber stress distribution after
hydrogel injection. 150 μL injections (A-C) and 300 μL injections (D-F) of hydrogels of
stiffness 0.1 kPa (A, D), 25 kPa (B, E), and 100 kPa (C, F) show that myofiber stress
near the injection site decreases with increasing hydrogel stiffness and increasing
hydrogel volumes. Adapted from Wang, et al.149
Numerous natural and synthetic injectable hydrogels have been evaluated in
preclinical models with improvements in cardiac remodeling and function. In 2004, one
of the first studies using injectable hydrogels as bulking agents was conducted by
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Christman et al, who found that a fibrin glue preserved infarct wall thickness and cardiac
function in rats.150,151 Since then, other naturally-derived hydrogels such as collagen152,
alginate153–155, chitosan156, matrix derivatives157,158, and hyaluronic acid159 have been
explored. Synthetic hydrogels based on poly(N-isopropylacrylamide) (PNIPAAm)160,161
and poly(ethylene glycol) (PEG)162–164 have also been tested. These materials have
varied gelation methods, ranging from peptide-self-assembly and self-assembly for fibrin
gels and PEG gels, respectively, to ionic mechanisms for alginate gels and thermal
mechanisms for collagen, chitosan, Matrigel, and PNIPAAm. Hyaluronic acid and PEG
have also been modified with functional groups to allow for covalent crosslinking.
Hydrogels have been injected at different timepoints after MI, ranging from immediately
to 8 weeks later and with varied injection volumes even within similar animal models.165
Data collection timepoints have also varied within animal models; for example, rat MI
models have evaluated outcomes at timepoints ranging from 2 to 16 weeks.165 In
addition to the bulking due to initial material properties, the biological response to
injected materials and changes in local extracellular matrix properties likely has a
positive effect as well.165
Hydrogels have also been evaluated in clinical trials. In 2011, LoneStar Heart
Inc. started the AUGMENT-HF Phase 2/3 clinical trial for Algisyl-LVRTM, an injectable
calcium alginate hydrogel delivered intramyocardially to patients with HF. Evaluations at
6 months166 and 1 year167 after injection showed improvements in exercise capacity and
clinical status for patients who received the alginate hydrogel injections compared to
those who did not. A larger follow-up study, AUGMENT-HFII, is planned but not yet
recruiting.
In 2010, Bellerophon BCM LLC started the PRESERVATION-1 clinical trial for
the intracoronary delivery of IK-5001, an injectable sodium alginate calcium gluconate
23

solution that was delivered to patients 2-5 days after MI.168,169 The study included 303
patients and found that, after 6 months, there was no significant improvement in adverse
left ventricular remodeling, exercise capacity, or heart failure classification for the
alginate injection compared to saline, likely because vascular occlusion prevented the
therapy from perfusing the infarct region.169
In 2014, Ventrix, Inc. commenced enrollment in a Phase 1 clinical trial for
VentriGel, an injectable hydrogel derived from decellularized porcine myocardium.157
VentriGel is currently being evaluated using intramyocardial/transendocardial catheter
delivery to patients 60 days to 3 years after MI and results have not yet been reported.
Challenges still remain for hydrogel therapies to promote cardiac repair after MI
and prevent HF. For instance, even though preclinical studies suggest that stiffer
hydrogels provide more therapeutic benefit, clinical trials for hydrogels either do not
report hydrogel stiffness or utilize notably soft hydrogels. Some studies have
investigated delivery parameters such as hydrogel volume, injection pattern, injection
location, and timing of delivery, but a consensus of these parameters still needs to be
obtained. Also, in most cases hydrogels are not inert materials so further investigation
into the biological mechanisms (and not just the mechanical mechanisms) of hydrogel
delivery should be explored.
1.4.2. HYDROGELS AS DELIVERY VEHICLES
1.4.2.1. CELL DELIVERY WITH HYDROGELS
As delivery vehicles, both natural and synthetic injectable hydrogels have been
used by multiple groups to deliver various cell types to the heart for improved retention
and cardiac repair in preclinical trials. For example, in 2004, Christman, et al delivered
skeletal myoblasts in a rat MI model in an injectable fibrin gel and showed that hydrogel
delivery increased cell survival, decreased infarct size, and increased blood flow to the
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myocardium.150 Since then, many other groups have also used fibrin-based gels to
deliver MSCs170, embryonic stem cell-derived cardiomyocytes171, and endothelial
progenitor

cells.172

Other

naturally-derived

hydrogels

made

from

alginate173,

chitosan174,175, or peptides176 have also been used to deliver MSCs and adipose-derived
stem cells. Synthetic hydrogels or combinations of natural and synthetic hydrogels have
also been tested. Oligo (poly (ethylene glycol) fumarate) was used to encapsulate
mouse embryonic stem cells and delivered in a rat MI model with improved cardiac
outcomes.177 Cai, et al combined a star-shaped peptide-PEG-PNIPAAm copolymer with
an engineered recombinant protein to form a hydrogel with an initial weak, physical
network between peptides that was later stabilized via thermo-responsive crosslinking in
situ, and used this hydrogel to deliver adipose-derived stem cells in mice.178 In addition
to assessing relevant functional or remodeling outcomes, many groups also showed that
the use of biomaterials can improve the retention and localization of delivered cells
compared to saline and, interestingly, these increases in cell retention can become more
pronounced over time (Table 1.3).
Table 1.3. Fold-increase in cell retention over intramyocardial saline delivery
reported with various injectable hydrogels.
Hydrogel
Fibrin150
PEG diacrylate171
Fibrin170
Chitosan/b-glycerol
phosphate/hydroxyethyl
cellulose175

Cell type
Skeletal myoblast
ESC-CM
MSC
ADSC

Time(s) of analysis
5 weeks
48 hours
90 min
24 hours
4 weeks

Fold-increase
~2
~2.5
1.77
1.5
8

PEG: poly(ethylene glycol); ESC-CM: embryonic stem cell-derived cardiomyocyte; MSC:
mesenchymal stromal cell; ADSC: adipose-derived stem cell. Adapted from Hastings, et al.25

Hydrogels can also change the local environment of encapsulated cells,
potentially influencing cell viability, behavior, and differentiation.174 For instance,
hydrogels can shield cells from ischemia and inflammation, and prevent anoikis-related
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cell death.25 Injectable hydrogels can also be protective to cells during syringe
ejection.179,180 Aguado, et al observed that the viability of human umbilical vein
endothelial cells after ejection in an alginate hydrogel (G’=29.6 Pa) was 88.9% ± 5.0%,
compared to 58.7% ± 8.1% after ejection in saline.179 However, hydrogels of higher and
lower stiffness were not as protective, indicating that mechanical and flow properties of
hydrogels should be tuned for high cell viability. Other considerations for translation that
affect cell viability after injection include needle gauge, needle length, and flow rate.
Currently, there are no clinical trials for cell therapy for MI that use injectable hydrogel
carriers.
1.4.2.2. EXTRACELLULAR VESICLE DELIVERY WITH HYDROGELS
Injectable hydrogels have been investigated to some extent in preclinical trials for
their ability to increase the retention and stability of EVs at the delivery site. Human
placenta MSC-derived exosomes were delivered with an injectable chitosan hydrogel in
a mouse model of hindlimb ischemia, and the chitosan hydrogel was shown to increase
the stability of proteins and miRNAs in exosomes, as well as increase exosome retention
in vivo and increase perfusion.181 In another mouse hindlimb ischemia model, human
umbilical cord MSC-derived exosomes were delivered in an injectable silk fibroin
hydrogel and showed increased perfusion after 4 weeks compared to exosomes
delivered in saline.182
In a rat MI model, the delivery of iPSC-derived cardiomyocytes in an implantable
collagen gelfoam mesh was shown to permit the sustained delivery of EVs for at least 1
week in vivo and, after 4 weeks, increased ejection fraction and reduced infarct size.183
For improved EV retention, Han, et al delivered human umbilical cord MSC-derived
exosomes in an injectable peptide hydrogel, since peptide hydrogels can be engineered
to have much smaller mesh sizes than hydrogels made of other naturally-derived
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materials.184 After delivery in a rat MI model, the delivery of exosomes with the peptide
hydrogel showed enhanced exosome retention and improved cardiac function,
remodeling, and vascularization compared to the delivery of exosomes in saline.184 Our
group has also previously investigated the delivery of EPC-derived EVs in a rat MI model
using an injectable hyaluronic acid hydrogel and showed that hydrogel delivery of EVs
can improve outcomes of cardiac repair185, and that the timing of EV delivery may be
important for better cardiac outcomes.186
1.4.2.3. GROWTH FACTOR DELIVERY WITH HYDROGELS
In preclinical animal MI models, injectable hydrogels have also been used to
deliver proteins, growth factors, and cytokines, all of which benefit from hydrogel carriers
because improved retention and sustained delivery of these therapeutics can decrease
the need to deliver supraphysiological doses, which can often have detrimental off-target
effects.143,144 Many different natural and synthetic injectable hydrogels have been used to
deliver a spectrum of growth factors to the heart, and there are recent reviews that
highlight many of these studies.165,187,188
For instance, growth factor delivery can encourage the recruitment of
endogenous cells for cardiac repair. An injectable, hydrolytically degradable, hyaluronic
acid-based hydrogel was used for the delivery of a synthetic analog of chemokine SDF1a called engineered stromal cell-derived factor analog or ESA. In prior studies, ESA
has been shown to be more effective than native SDF-1a for EPC migration.189 In a rat
MI model, delivery of ESA with the injectable hydrogel allowed for the sustained release
of ESA for 4 weeks in vivo, and increased EPC chemotaxis, improved vascularity,
preserved ventricular geometry, and improved cardiac function.190
Growth factors are also commonly delivered for angiogenesis. As one example,
VEGF and HGF were encapsulated in an injectable, protease-degradable, PEG-based
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hydrogel and delivered to the heart after ischemia/reperfusion injury in rats. The delivery
of the combination growth factor therapy with the injectable hydrogel led to significant
improvements in angiogenesis, cardiac progenitor cell recruitment, myocardial fibrosis,
and cardiac function after 3 weeks.191
The delivery of MMP inhibitors can also be useful, especially for MI since the
upregulation of MMPs contributes to adverse ventricular remodeling.192 Purcell, et al
designed an injectable hyaluronic acid-dextran sulfate hydrogel sensitive to MMP
degradation for the delivery of a recombinant tissue inhibitor of MMPs (rTIMP-3), which
is sequestered in the hydrogel through electrostatic interactions.193 In this way, rTIMP-3
is released in response to MMP activity. When delivered to the heart in a porcine model
of MI, there was a significant reduction in MMP activity, preserved ventricular geometry,
and improved cardiac function after 2 weeks.193
The release of these molecules from hydrogel carriers is mediated by the size of
the molecules relative to the hydrogel mesh size (Figure 1.11).194 Molecules that are
small relative to mesh size diffuse freely from the hydrogel, often on the order of hours to
days. When molecule size approaches mesh size, steric hindrance prevents the
molecule from freely diffusing through the material, and slow release can extend
molecule delivery from days to weeks. Molecules that are larger than the hydrogel mesh
size are effectively immobilized within the material, and degradation, swelling, or
mechanical deformation mechanisms can be engineered to control release of the
therapeutic. Hydrogel mesh size can also change over time through material
condensation and reorganization.195 Most proteins are smaller than or near the mesh
size of a typical hydrogel, so combining hydrogel degradation mechanisms with proteinhydrogel interactions can be effective for controlling growth factor release. For instance,
hydrogels can be engineered to be degradable in response to enzymatic activity, pH,
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temperature, or light and common molecule-hydrogel interactions involve covalent
linkages, electrostatic interactions, or hydrophobic interactions that can sequester
molecules within the hydrogel.194

Figure 1.11. Relative hydrogel mesh size to drug size mediates diffusion of
encapsulated therapeutics. Drugs that are small relative to the mesh size diffuse
rapidly through the hydrogel. As drug size approaches hydrogel mesh size, diffusion is
slowed. Drugs that are large relative to the mesh size are immobilized in the hydrogel
and eventually released through degradation, swelling, or deformation mechanisms.
Adapted from Li, et al.194
Also, the use of composite hydrogel systems of micro- or nano-gels within a bulk
hydrogel can be used to create complex release profiles of multiple molecules. For
example, in angiogenesis, VEGF is important for neovessel formation while PDGF-BB is
crucial for blood vessel stabilization, so the sequential delivery of VEGF and PDGF-BB
may be desired.196 Awada, et al developed a composite hydrogel consisting of a heparin29

based coacervate within a fibrin gel and encapsulated VEGF within the fibrin gel and
PDGF-BB in the heparin-based coacervate.197 In vitro studies showed the varied release
profiles for VEGF and PDGF-BB, with most of the VEGF released by day 7 and PDGF
release continuing for at least 3 weeks.197 When delivered to the heart in a rat MI model,
they found that the delivery of both growth factors in their sequential delivery system
significantly increased neovessel formation after 3 weeks compared to the free delivery
of both growth factors but with no delivery system, and they also observed
improvements for wall thickness, fibrosis, and cardiac function.197 To date, there have
been no clinical trials that employ injectable hydrogel carriers to deliver proteins, growth
factors, or cytokines to the heart. Combination therapies with injectable hydrogels, cells,
and growth factors are also possible to leverage the mechanisms of both therapies.198

1.5 CONCLUSIONS
Cardiovascular disease and MI exert a tremendous burden on the American
healthcare system and current available therapies fail to address the physiological
changes that occur in the myocardium that can lead to HF. Clinical trials for cell
therapies and cell-derived therapeutics have largely failed to replicate the improvements
in cardiac function and remodeling observed in preclinical studies. Injectable hydrogels
alone are useful for myocardial bulking, but recently have been explored as delivery
vehicles that can be engineered for a range of payloads. This thesis describes the
development of injectable hydrogel systems to deliver cells and cell-derived therapeutics
for improved retention and efficacy to increase angiogenesis and modulate inflammation
for cardiac repair and preserved cardiac function.
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CHAPTER 2
RESEARCH OVERVIEW

2.1 SPECIFIC AIMS
Heart failure (HF) is a growing cause of morbidity and mortality in the United
States, where it contributes to 1 in 9 deaths.1 Currently, medical and surgical treatments
for HF, except for heart transplantation, are merely palliative and do not attempt to
resolve the underlying disease.2 One cause of HF is ischemic cell death after myocardial
infarction (MI), which can lead to the loss of a billion or more cardiomyocytes3 and
initiates a process of adverse remodeling that lessens the ability of the ventricles to
contract.4
A number of therapeutics (e.g., cells, drugs) have been delivered to cardiac
tissue to improve outcomes after MI. For example, various cell types have been tested
extensively in preclinical studies with positive outcomes for cardiac repair, but benefits of
cellular delivery have not translated in clinical trials.5,6 This is likely due to the low
retention and engraftment of delivered cells which suggests that the benefits of cellular
therapies are not mediated directly by the delivered cells, but instead indirectly by the
paracrine signals that the delivered cells produce that act on cells in the endogenous
tissue to promote regeneration.7,8
The paracrine hypothesis of cellular delivery has led to the exploration of cellderived therapies for cardiac repair, such as growth factors, cytokines, or extracellular
vesicles (e.g., exosomes). These factors can help to promote angiogenesis, reduce
apoptosis, promote cardiomyocyte proliferation, control fibrosis, and modulate
inflammation.9 Growth factors, such as vascular endothelial growth factor, have been
tested in numerous preclinical as well as clinical studies.10 Again, clinical results have
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not recapitulated the positive successes of preclinical models, likely due to the low
retention of therapeutics at the injection site.11 This leads to the delivery of
supraphysiological doses of growth factors, which can have deleterious off-target
effects.12,13 Exosomes are a more recently developed therapeutic, but they have already
been isolated from various cell types and evaluated in preclinical trials for cardiac
repair.14,15 However, the delivery of exosomes to the myocardium presents the same
challenges as cell and growth factor delivery, which is local and sustained delivery at the
injection site.
Injectable hydrogels are evolving to improve upon these therapies for cardiac
repair after MI. They have been used alone as bulking agents to reduce myocardial wall
stresses, which has been shown to limit left ventricular wall thinning and dilation that
leads to decreased cardiac function.16–18 Injectable hydrogels can also be used as
delivery vehicles for cellular and cell-derived therapeutics. Our lab has recently
developed an injectable hyaluronic acid (HA) hydrogel based on the guest-host
interactions

of

b-cyclodextrin

and

adamantane.19

HA

is

a

non-sulfated

glycosaminoglycan found in the extracellular matrix and is involved in many cellular
processes (e.g., proliferation, wound healing).20 Compared to other naturally-derived
materials such as collagen, elastin, or fibrin, HA lends itself to facile modification with
functional groups that can mediate a variety of crosslinking mechanisms, varying from
covalent to supramolecular crosslinks.21 Hydrophobic interactions between these bcyclodextrin and adamantane groups form guest-host, supramolecular interactions that
allow this hydrogel to be both shear-thinning and rapidly self-healing, permitting
injectability as well as rapid solidification at the injection site.19
Our lab has investigated the use of this hydrogel alone in cardiac repair as a
bulking agent22,23, as well as a delivery vehicle for miRNAs24, small molecule drugs25,
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and extracellular vesicles26. This thesis describes the design criteria necessary for
injectable hydrogels, and then applies these design principles to the use of injectable
hydrogels for the delivery of cellular and cell-derived therapies, such as growth factors
and extracellular vesicles. In combination, these aims utilize material design and
characterization to develop novel injectable treatments that will improve the efficacy of
cellular and cell-derived therapies for cardiac repair.

Aim 1: Develop methods to characterize shear-thinning and self-healing hydrogels
and their potential for injectability in biomedical applications.
Hypothesis: Rheological properties, injection forces, and encapsulated cell viability are
dependent on injectable guest-host hydrogel formulation and injection parameters.
Injectable hydrogels when used for therapeutic delivery (e.g., as cell carriers)
increase therapeutic retention in the heart.5 Toward this, it is important to understand the
hydrogel properties that relate to injectability and therapeutic applications. For example,
it has been shown that the viability of cells after ejection using a biomaterial carrier is
mediated by material properties, such as storage modulus.27 Other factors, such as
viscosity and injection force, are also important when evaluating the application of
hydrogels as injectable biomaterials. In this aim, HA is modified separately with bcyclodextrin and adamantane groups to form a shear-thinning, injectable guest-host
hydrogel when mixed. Hydrogel formulations are varied by percent functionalization of
the HA backbone, material concentration, and molar ratio of b-cyclodextrin and
adamantane groups and injection parameters include syringe needle gauge, syringe
needle length, and flow rate. Methods are developed for the quantitative (e.g., rheology,
injection force) assessment of hydrogels for injectability, and cells are encapsulated in
these hydrogels and cell viability after ejection is investigated as a function of hydrogel
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formulation and injection parameters. Techniques for the in vivo delivery of injectable
hydrogels to the heart are also described. Material formulations identified from this aim
that are injectable and result in high cell viability after injection are assessed in
subsequent aims.

Aim 2: Deliver endothelial progenitor cells (EPCs) using an injectable hydrogel to
the heart after MI.
Hypothesis: Injectable hydrogels improve EPC localization and therapeutic efficacy (e.g.,
vascularization, cardiac function, geometry) when delivered after MI.
EPCs are primary, bone marrow-derived cells that can differentiate into mature
endothelial cells and promote new vasculature through paracrine signals.28–30 Although
EPC delivery has been shown to be effective for cardiac repair in preclinical models31,32,
clinical trials have been less encouraging, likely due to the low retention of delivered
EPCs.33,34 Injectable hydrogels can improve the retention of delivered cells.5 Here, EPCs
are isolated from the bone marrow of adult male Wistar rats, cultured, and encapsulated
in an injectable hydrogel formulation found in the previous aim to give high cell viability
after injection. In a rat model of MI, EPCs are delivered with or without the injectable
hydrogel carrier via intramyocardial injections to the border zone of the infarct. After 48
hours, the retention of fluorescently-tagged EPCs is assessed via fluorescent imaging.
After 4 weeks, cardiac function is measured using an aortic flow probe,
echocardiography, and an intraventricular pressure-volume catheter. Masson’s trichrome
staining is utilized to visualize scar tissue, and immunohistochemistry for vascular
markers and fluorescent microscopy is used to assess new vessel formation. This study
evaluates the use of our injectable guest-host hydrogel as a cell delivery vehicle for
EPCs and highlights the benefits of cell delivery to the heart with biomaterial carriers.
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Aim 3: Design and evaluate injectable microgel/hydrogel composites for
interleukin-10 (IL-10) delivery to the heart.
Hypothesis: IL-10 delivery from injectable microgel/hydrogel composites reduces
inflammation

(e.g.,

macrophage

levels)

and

improves

cardiac

repair

(e.g.,

vascularization, cardiac function, geometry) after MI.
The paracrine hypothesis for cell delivery suggests that the signals that cells
produce are important for cardiac repair.7,8 The delivery of these signals, such as growth
factors and cytokines, can benefit from injectable hydrogel carriers to improve
therapeutic retention and reduce the need for supraphysiological doses that can cause
detrimental off-target effects.11–13 However, it may also be advantageous to decouple
hydrogel injectability from the controlled release of encapsulated therapeutics. Toward
this, composites of hydrogels (that govern injectability) and encapsulated microgels (that
control sustained release profiles) are developed. This includes the same injectable
hydrogel studied in Aim 1 and microgels fabricated via microfluidics from norbornenemodified HA, which forms crosslinks with dithiols in the presence of photoinitiator and
UV light. Microgels are formulated with various dithiol crosslinkers, and microgel
degradation and therapeutic cargo release are assessed as a function of crosslinker
degradability. Material properties of composite hydrogels are measured using rheology.
Finally, the composite hydrogel is evaluated in vivo as a delivery system for IL-10, an
anti-inflammatory cytokine, in a rat model of MI. After 7 days, immunohistochemistry is
used to assess the immune response to the therapy. After 4 weeks, cardiac function,
cardiac remodeling, and new vessel formation are evaluated to assess the treatment in
both tissue structure and functional outcomes. This study describes an injectable
microgel/hydrogel composite that can be useful for the targeted and sustained delivery
of growth factors and cytokines to the heart.
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Aim 4: Develop pre-condition protocols for the isolation of extracellular vesicles
(EVs) from mesenchymal stromal cells (MSCs) and deliver to the heart using an
injectable hydrogel.
Hypothesis: EVs isolated from pre-conditioned MSCs (e.g., hypoxia, growth factors) will
have varied protein content and increased vasculogenic potential and EV hydrogel
delivery will increase vasculature after MI.
MSC-derived EVs have been investigated for their potential to improve cardiac
outcomes after MI in preclinical models.35,36 Additionally, MSCs can be pre-conditioned
with growth factors37 or cultured in hypoxic conditions38 to be more pro-vasculogenic. In
this aim, we first pre-condition MSCs by culturing both with angiogenic growth factors
and under hypoxic conditions. Next, we isolate EVs from these pre-conditioned MSCs
using polymer precipitation. EV size and concentration are quantified via nanoparticle
tracking analysis, and EV contents (e.g., proteins) are explored using proteomics. The in
vitro angiogenic potential of EVs is investigated using a Matrigel angiogenesis assay.
Finally, the injectable, guest-host hydrogel described in Aim 1 is used as a carrier for
local, sustained delivery of EVs to the heart in a rat model of MI. The formation of new
vasculature after EV delivery is evaluated compared to controls of EV injection alone or
hydrogel delivery alone. This aim evaluates a method of enhancing the efficacy of
cellular-derived therapeutics, by pre-conditioning cells to direct them to produce desired
signaling factors, such as EVs. Also, while our group has used this hydrogel before to
deliver EPC-derived EVs to the heart39, these studies further explore the use of our
injectable hydrogel as a delivery vehicle for EV therapies.
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2.2 CHAPTER OUTLINE
Chapter 1 provides a detailed description of MI and the adverse remodeling
processes that occur afterward that can lead to HF. Also, clinically-relevant trials for
cellular and cell-derived therapies are reviewed, as well as a description of the clinical
application of injectable hydrogels for cardiac repair and preclinical studies using
injectable hydrogels as delivery vehicles.
Chapter 3 describes the research proposed in Aim 1, which concerns the
development of methods to assess biomaterials for use as injectable hydrogels as well
as the application of those methods to evaluate injectable hydrogels for cell delivery.
Chapter 4 describes the research proposed in Aim 2, which uses the injectable
hydrogel evaluated in Aim 1 to deliver EPCs to the heart in a rat MI model.
Chapter 5 describes the research proposed in Aim 3, which involves developing
injectable hydrogel/microgel composites for local and sustained delivery of IL-10 to the
heart. In this chapter, a microfluidic device is utilized to form microgels, which allow for
hydrogel injectability to be decoupled from the release of therapeutic cargo.
Chapter 6 describes the research proposed in Aim 4, which uses the injectable
hydrogel from Aim 1 to deliver EVs to the heart in a rat MI model. This chapter
showcases a method for improving the therapeutic benefit of cell-derived therapies by
pre-conditioning MSCs prior to EV collection and evaluates our injectable hydrogel for
EV delivery.
Chapter 7 presents a summary of the work presented in this thesis, highlighting
the contributions of each aim toward developing injectable hydrogels for the delivery of
cellular and cell-based therapeutics for cardiac repair. Limitations of these studies are
discussed, as well as possible future directions toward further clinical translation and
eventual commercialization of these therapies.
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CHAPTER 3
METHODS TO CHARACTERIZE INJECTABLE HYDROGELS FOR BIOMEDICAL
APPLICATIONS

Adapted from:
1. Chen, M. H., Wang, L. L., et al. Methods to assess shear-thinning hydrogels for
application as injectable biomaterials. ACS Biomater. Sci. Eng. 3, 3146-3160
(2017).
2. Loebel, C., Rodell, C. B., Chen, M. H., & Burdick, J. A. Shear-thinning and selfhealing hydrogels as injectable therapeutics and for 3D-printing. Nature Protocols
12, 1521-1541 (2017).

3.1 INTRODUCTION
Hydrogels are water-swollen polymer networks with widespread applications in
the biomedical sciences, including drug delivery and tissue regeneration.1,2 Their high
water content and mechanical properties make hydrogels natural mimetics of
extracellular matrices. Acellular hydrogels can be delivered for tissue bulking or as
artificial tissue mimetics.3,4 Hydrogels can also be loaded with cells for therapeutic effect,
and may promote additional infiltration of cells upon implantation.5,6 Therapeutic
molecules can also be encapsulated within hydrogels and released with highly tunable,
controlled profiles in response to erosion, swelling, or external stimuli such as enzymes
or light.7–10
Over the past few decades, injectable hydrogels have become increasingly
popular for their ability to be delivered via minimally invasive approaches.1 In this
context, two major routes for injection have been explored. The first approach is the
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engineering of hydrogels that gel in situ after injection, through chemical or physical
crosslinking mechanisms that occur either during or after injection of the hydrogel
precursors.11 While many hydrogels can be delivered in this fashion, they often require
the use of multi-barrel syringes for mixing during injection or an external trigger to induce
gelation. Gelation is also time sensitive, as crosslinking that occurs too slowly can lead
to rapid material dispersion upon injection and prior to gelation, leading to cargo loss.12
Alternatively, crosslinking that occurs too quickly can clog the needle or syringe before
hydrogel deposition.13
To overcome limitations of in situ crosslinking systems, hydrogels have also been
engineered with shear-thinning properties, which are defined as the ability for a material
to decrease in viscosity with increasing shear. Such hydrogels can be pre-formed into
syringes, which allows them to be extruded upon application of shear, and rapidly reformed upon cessation of mechanical load, a process known as self-healing. The selfhealing nature of these hydrogels allows for improved material retention upon injection
and offers advantages to in situ gelation systems, including minimization of potential
embolization into the systemic circulation. However, these self-healing systems are often
mediated by physical crosslinks and may not confer the mechanical stability of in situ
crosslinking covalent systems. To overcome this, secondary crosslinking techniques
have been explored toward stabilizing physically assembled hydrogels after injection.4,14
Shear-thinning and self-healing hydrogels have been investigated in various
biomedical applications including drug delivery,7,15 tissue regeneration,2,16 mechanical
bulking,3,4,17 and extrusion-based bioprinting.18,19

These systems include hydrogels

crosslinked through peptide assembly,20,21 recombinant protein assembly,22,23 ionic
interactions,24 thermal assembly,25 electrostatic interactions between colloidal systems,26
and supramolecular chemistry.27–31 Dynamic covalent crosslinks have also been
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explored for injection, where their dynamic nature confers shear-thinning during injection
and then slow self-healing after injection.32,33
For translation, the injectability of shear-thinning hydrogels plays a major role in
enabling minimally invasive delivery (i.e., through percutaneous catheters or via
standard surgical minimally invasive or robotic means).34,35 For tissue regeneration, the
encapsulation of cells within hydrogels also requires specific injection parameters that
can influence viability.6,36 For bioprinting applications, injection parameters are also
important in modulating both the resolution and stability of printed structures, as well as
cellular viability.37,38 For these reasons, it is important to engineer and tune hydrogels for
injection and to understand how various design parameters influence these outcomes,
using both quantitative and qualitative techniques. In this methods article, we detail
techniques useful for exploring the mechanical properties that enable shear-thinning and
self-healing, and demonstrate protocols that can be employed to ensure consistent
hydrogel injection and retention.
As a model system, we investigated these properties for hydrogels assembled
through guest-host chemistry, which we have previously described, including in a
detailed protocols paper on the synthesis of these hydrogel components.15,30,39
Specifically, hyaluronic acid (HA) was modified with either b-cyclodextrin (CD, host, 28%
of disaccharide repeats) or adamantane (Ad, guest, 22% of disaccharide repeats) to
form CD-HA and Ad-HA, respectively, and assembled through supramolecular
hydrophobic interactions to form hydrogels that are shear-thinning and self-healing
(Figure 3.1). These materials are only a representative example of the many types of
shear-thinning and injectable hydrogels that are available, and the techniques used for
their characterization can be applied to other injectable hydrogels. We organize this
work into five main methods, including (i) synthesis of hydrogel components, (ii)
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rheological characterization of hydrogels, (iii) measurement of hydrogel injection forces,
(iv) encapsulated cell viability after injection, and (v) injection of hydrogels into cardiac
tissue.

Figure 3.1. Guest-host material synthesis and assembly. (a) Schematic of guest-host
material synthesis through modification of hyaluronic acid with either adamantane (AdHA) or b-cyclodextrin (CD-HA). (b) Graphic showing guest-host assembly of
adamantane and b-cyclodextrin groups and shear-thinning.

3.2 SYNTHESIS OF HYDROGEL COMPONENTS
A step-by-step protocol with characterization of the desired products is provided
for Ad-HA (guest) and CD-HA (host), which are the components of the injectable guesthost hydrogel that will be utilized extensively in the rest of this chapter and in the rest of
this thesis. The synthesis reactions are typically performed for 2.5 g of HA and can be
scaled to a desired size (reactions using 0.5–5 g of HA have been successfully
performed in our laboratory by linear scaling of all reagents).
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For CD-HA, the water-soluble β-cyclodextrin (CD) is aminated via intermediate
tosylation of one of the primary hydroxyl groups to obtain 6-(6-aminohexyl)amino-6deoxy-β-cyclodextrin (CD-HDA). CD-HA is then synthesized by the reaction of CD-HDA
with the TBA salt of HA, with benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium
hexafluorophosphate (BOP) as the coupling reagent in anhydrous DMSO. For Ad-HA,
the

TBA

salt

of

HA

is

reacted

with

1-adamantane

acetic

acid

using

4-

(dimethylamino)pyridine (DMAP) and di-tert-butyl dicarbonate (BOC2O) in DMSO. Both
products are purified by excessive dialysis, lyophilized for storage, and then rehydrated
and used to form hydrogels.
3.2.1. MATERIALS
Reagents
CAUTION: When using the chemicals described in this protocol, always wear suitable
personal protective equipment, including lab coat, gloves, safety goggles and, where
indicated, face shield, respirator and thermo-insulated gloves. Follow the relevant
institutional and governmental safety guidelines and refer to the appropriate material
safety data sheets. All synthesis steps should be performed within a chemical fume
hood.
•

Sodium hyaluronic acid, 66–99 kDa (Lifecore, cat. no. HA-60K; store it under
nitrogen at −20 °C)
o

Other molecular weights of sodium hyaluronic acid can be used for this
protocol. However, this affects the viscosity during synthesis and the
properties of the resulting hydrogels.

•

Methacrylic anhydride (MA; Sigma-Aldrich, cat. no. 276685; store under nitrogen
at 4 °C)
o

CAUTION: Contact with methacrylic anhydride can cause skin irritation,
eye damage and respiratory irritation. Wear a face shield and respirator.
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•

Sodium hydroxide (NaOH; Sigma-Aldrich, cat. no. S8045; store it at room
temperature (RT; 20–25 °C))
o

CAUTION: Sodium hydroxide can cause skin corrosion and serious eye
damage. Avoid any direct contact.

•

Dowex 50W×8 resin (Sigma-Aldrich, cat. no. 217506; store at RT)
o

CAUTION: Dowex is acutely toxic and causes skin and eye irritations and
presents organ toxicity after a single exposure. Wear a respirator.

•

Tetrabutylammonium hydroxide solution, 40% (wt/vol) in water (TBA-OH; SigmaAldrich, cat. no. 178780; store it at RT)
o

CAUTION: Tetrabutylammonium hydroxide can cause skin corrosion and
serious eye damage. Avoid any direct contact and wear face shield and
respirator.

•

1-Adamantane acetic acid (Acros Organics, cat. no. 331560010; store it at RT)
o

CAUTION: 1-adamantane acetic acid causes skin irritation and serious
eye irritation, and may cause respiratory irritation if inhaled.

•

4-(Dimethylamino)pyridine (DMAP; Sigma-Aldrich, cat. no. 29224; store dry at
RT)
o

CAUTION: DMAP can cause severe skin burns and eye damage. Wear a
face shield and respirator.

•

Anhydrous DMSO (Sigma-Aldrich, cat. no. 276855; store at RT)
o

•

CAUTION: Always wear a face shield.

Di-tert-butyl dicarbonate (BOC2O; Sigma-Aldrich, cat. no. 361941; store it under
nitrogen at 4 °C)
o

CAUTION: BOC2O is flammable, causes serious eye damage and is fatal
if inhaled. Always wear a respirator and face shield.

•

Acetone (Fisher Scientific, cat. no. A18-20; store at RT)
o

CAUTION: Acetone is flammable and may cause irritation of the
respiratory tract; vapors may cause dizziness. Keep it away from heat
and hot surfaces.

•

p-Toluenesulfonyl chloride (TCI America, cat. no. T0272; store dry at RT)
o

CAUTION: p-Toluenesulfonyl chloride is highly corrosive and may cause
severe skin burns and eye damage. It should be directly weighed out in
the reaction vessel. Avoid any direct contact and wear a face shield.
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•

Acetonitrile (Sigma-Aldrich, cat. no. 271004; store at RT)
o

CAUTION: Acetonitrile is flammable, irritating to the eyes and may cause
skin and respiratory tract irritation. Wear a face shield and respirator
when handling.

•

Diethyl ether (Sigma-Aldrich, cat. no. 296082; store at RT)
o

CAUTION: Diethyl ether is flammable and may cause respiratory irritation
if inhaled and skin dryness if exposed repeatedly. Wear a respirator and a
face shield.

•

(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium

hexafluorophosphate

(BOP; Sigma-Aldrich, cat. no. 226084; store it under nitrogen at 4 °C)
o

CAUTION: BOP is flammable and acutely toxic, and causes specific
organ toxicity upon a single exposure.

•

β-Cyclodextrin (CD; TCI America, cat. no. C0900; store it under nitrogen at 4 °C)

•

Ammonium chloride (Fisher Scientific, cat. no. A661-500; store it at RT)
o

CAUTION: Ammonium chloride is harmful if swallowed and may cause
skin and respiratory tract irritation.

•

N,N-Dimethylformamide (DMF; Sigma-Aldrich, cat. no. 227056; store it at RT)
o

CAUTION: DMF is flammable and acutely toxic, can cause serious eye
irritation and is harmful if inhaled. Always wear a respirator and a face
shield.

•

Liquid nitrogen (Airgas National Welders, cat. no. 160LT22)
o

CAUTION: Contact with liquid nitrogen may cause serious freezing
injuries. When handling liquid nitrogen, always wear thermo-insulated
gloves, a full-face shield and a laboratory coat.

•

1,6-hexanediamine (HDA; TCI, cat. no. D0095; store it at RT)
o

CAUTION: HDA is harmful on contact with skin and if swallowed, and can
cause severe skin burns and eye damage.

•

Sodium chloride (Sigma-Aldrich, cat. no. S9888; store it at RT)

•

Deuterium oxide (D2O; Sigma-Aldrich, cat. no. 151882; store it at RT in a
desiccator)

•

DMSO-d6 (Sigma-Aldrich, cat. no. 151874; store it at RT in a desiccator)
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Equipment
•

Heated stir plate (e.g., RCT Basic; IKA, cat. no. 0003810001)

•

1-, 2- and 3-neck round-bottom flasks, assorted sizes, with a magnetic stir bar

•

Rubber septa (Sigma-Aldrich, cat. no. Z553980)

•

pH meter (e.g., accumet, Fisher Scientific, cat. no. AB150BCERT)

•

Cannula, 20 gauge (e.g., Chemglass, cat. no. A-0519-08)

•

Glass pipettes with dropper bulbs

•

Beaker with a minimum of 3-liter volume

•

Milli-Q Biocel (Millipore, cat. no. ZMQS60F01)

•

Separatory funnel (e.g., Chemglass, cat. no. CG-1742-04)

•

Dialysis tubing (6,000–8,000 MW cut-off, regenerated cellulose; e.g., Spectra/Por
1, Spectrum Labs, cat. no. 132670) and tubing closures (e.g., Spectrum Labs,
cat. no. 142734)

•

Schlenk line with vacuum line, cold trap and oil pump (Liebig condenser (e.g.,
Chemglass, cat. no. CG-1218-03)

•

Bubbler (e.g., Chemglass, cat. no. AF-0513-20)

•

Lyophilizer (e.g., Labconco FreeZone; Thermo Fisher Scientific, cat. no.
7387020)

•

NMR spectrometer (e.g., Bruker, cat. no. DMX360)

•

Sterile 1.5-, 2-, 15- and 50-ml conical (micro)centrifuge tubes

•

Glass beaker, 200–500 ml

•

Spatula

•

Forceps

•

Micropipettes and tips

•

Disposable Pasteur glass pipettes

•

Pasteur pipette rubber bulbs

•

Sterile syringes and needles

•

Refrigerator set to 4 °C

•

Freezer set to −20 °C

•

Freezer set to −80 °C

•

Standard laboratory bench-top refrigerated centrifuge for 50-ml conical tubes
(e.g., Thermo Fisher Scientific, cat. no. 75004521)
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•

Microcentrifuge (e.g., Eppendorf Refrigerated Microcentrifuge; Eppendorf, model
no. 5417R)

•

Vortex mixer (e.g., Fisher Scientific, cat. no. 02-215-414) and tube holder (e.g.,
Fisher Scientific, cat. no 11-676-363)

3.2.2. PROCEDURE
Overview
•

Step 1: Preparation of tetrabutylammonium salts of HA (HA-TBA)

•

Step 2: Preparation of CD-HA, part 1: synthesis of 6-o-monotosyl-6-deoxy-βcyclodextrin (CD-Tos)

•

Step 3: Preparation of CD-HA, part 2: synthesis of CD-HDA

•

Step 4: Preparation of CD-HA, part 3: synthesis of CD-HA

•

Step 5: Preparation of Ad-HA

Step 1: Preparation of tetrabutylammonium salts of HA (HA-TBA) (2 hours, 3 days
lyophilization)
Dissolve 3.0 g of HA in 150 ml of deionized water in a 250-ml one-neck roundbottom flask equipped with a magnetic stir bar.40 Add 9.0 g of Dowex 50W×8 to the HA
solution and continue stirring for 30 min at RT.
CAUTION: The hydrogen form of Dowex is a strong acid. Avoid any direct
contact; always wear appropriate personal protective equipment, including gloves, safety
goggles and a laboratory coat.
Critical step: The reaction may be scaled by adjusting the amount of HA while
maintaining a 2.0% (wt/vol) solution and a 3:1 weight ratio of Dowex/HA.
Collect the HA from the resin by vacuum filtration using a No. 1 filter paper.
Prepare 1:1 (20% (vol/vol)) and 1:5 (8% (vol/vol)) dilutions of tetrabutylammonium
hydroxide (TBA-OH, 40%) in deionized water. Subsequently titrate the HA solution first
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to pH 5 by adding 40% TBA-OH, then to pH 7 by adding 20% TBA-OH and finally to pH
7.02–7.05 by adding 8% TBA-OH.
Critical step: Add the TBA-OH slowly, as the pH of the solution can change
rapidly near neutral pH values.
Transfer the HA solution to 50-ml tubes, freeze them in a −80 °C freezer
overnight and lyophilize the sample until the polymer is fully dry (3–4 d). To maintain a
barrier, cover the 50-ml conical tubes with gauze and seal them with rubber bands
before lyophilization. Ensure that samples do not thaw when transferred to the
lyophilizer. Once dry, store polymers under nitrogen at −20 °C to avoid absorption of
water and hydrolysis of HA. Lyophilized HA-TBA can be stored for at least 1 year at −20
°C.
Confirm the product and the degree of modification using 1H NMR spectroscopy
and D2O as a solvent. Dissolve 5 mg of HA-TBA in 0.7 ml of D2O with shaking for 30 min
at RT to ensure complete dissolution. Transfer the solution to an NMR tube using a
Pasteur pipette, and seal the tube with a cap. Acquire spectra according to the
manufacturer's instructions.
Step 2: Preparation of CD-HA, part 1: synthesis of 6-o-monotosyl-6-deoxy-βcyclodextrin (CD-Tos) (2 days)
Critical step: Ensure that all glassware and laboratory equipment are clean to
avoid chemical contamination.
The protocol described here is for 50 g of CD and can be scaled accordingly
(reactions from 10 g–100 g of CD have been successfully performed in our laboratory).41
Suspend 50 g (44 mmol) of CD in 300 ml of Milli-Q water in a one-neck roundbottom flask and cool the solution in an ice bath (Figure 3.2). The solution will remain
cloudy white because of limited CD solubility. Dissolve 10.07 g (53 mmol) of p65

toluenesulfonyl chloride in 25 ml of acetonitrile under stirring. Use a cannula to gradually
add the p-toluenesulfonyl chloride solution to the CD solution over 10 min under stirring.
Alternatively, the solution can be added through a needle using a 50-ml glass syringe.
Maintain the CD solution on ice for 2 h and continue stirring vigorously.

Figure 3.2. Synthetic route for preparation of CD-Tos and CD-HDA. Reagents and
conditions are as follows: reaction 1 (CD-Tos): deionized water, p-toluenesulfonyl
chloride, NaOH, 0 °C → room temperature; reaction 2 (CD-HDA): DMF, HDA, 80 °C. (a)
Schematic of chemical reaction and (b) reaction setup for the amination reaction, in
which the dry round-bottom flask containing a stir bar is charged by the tosylated
intermediate and purged by nitrogen, and DMF and HDA are separately added via a
syringe through a rubber septa.
Critical step: To achieve the desired pressure difference for cannulation, place
the flask containing p-toluenesulfonyl chloride under nitrogen pressure, vent the flask of
the CD solution and connect with the cannula (Figure 3.3). Ensure adequate stirring of
the CD solution to avoid precipitation during the reaction.
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Figure 3.3. Reaction setup for synthesis of CD-Tos and CD-HDA. Setup for (a) CDTos and (b) CD-HDA synthesis under anhydrous conditions.
Remove the flask from the ice bath. Dissolve 5.3 g (133 mmol) of sodium
hydroxide in 20 ml of deionized water and add this dropwise to the CD solution over 10
min. Continue stirring at RT for 30 min. The solution will turn slightly yellowish and
become clearer.
Critical step: Use a glass pipette when handling sodium hydroxide, as alkali
solutions may corrode plastic pipette tips.
Add 40 g (748 mmol) of ammonium chloride to the solution to adjust the pH to 9.
Add additional ammonium chloride in 5-g increments until the pH is stable between 8.5
and 9. Flocculation of the CD-Tos should occur.
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Critical step: Ensure adequate stirring and complete dissolution of the
ammonium chloride before adding additional ammonium chloride.
Precipitate the CD-Tos product: Separate the solution into 50-ml conical tubes
and cool on ice for 15 min. Centrifuge the tubes at 3,200g for 2 min at 4 °C and decant
the supernatant. Resuspend the crude product in 40 ml of deionized water (per tube) by
vortexing. Cool the resuspended product on ice for 15 min, centrifuge at 3,200g for 2 min
at 4 °C and decant the supernatant. Repeat this step twice.
Critical step: For best yields, ensure that the solution is completely cooled on
ice before centrifugation. Wash the reaction vessel with deionized water to collect the
entire product.
Wash the CD-Tos product: resuspend the product in 40 ml of ice-cold acetone
(per tube) by vortexing, cool the resuspended product on ice for 15 min, centrifuge at
3,200g for 2 min at 4 °C and decant the supernatant. Repeat this step twice. Resuspend
the product in 40 ml of diethylether (per tube), centrifuge at 3,200g for 2 min at 4 °C and
decant the supernatant. Repeat this step and decant the supernatant. Evaporate organic
residues by vacuum pressure overnight to obtain a dry CD-Tos product.
CAUTION: Wear goggles, thermally insulated gloves and a long-sleeved
laboratory coat to avoid direct contact of liquid nitrogen with eyes and skin.
Critical step: Vacuum drying should be carried out in a fume hood using a cold
trap filled with liquid nitrogen. To maintain a barrier, cover the 50-ml conical tubes with
gauze and seal them with rubber bands.
Confirm the CD-Tos product using 1H NMR spectroscopy and DMSO-d6 as a
solvent. CD-Tos can be stored under nitrogen at −20 °C for at least 6 months.
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Step 3: Preparation of CD-HA, part 2: synthesis of CD-HDA (4 days)
Add 10 g (8.8 mmol) of CD-Tos to a dry three-neck round-bottom flask and
connect the flask to a Liebig condenser in-line with a gas bubbler (Figure 3). Purge by
nitrogen, add 50 ml of DMF using a syringe and stir the mixture at RT until CD-Tos is
fully dissolved.42
Critical step: To ensure that glassware is dry, place the vessels in a drying oven
at 125 °C for 24 h. Remove glassware from oven and stopper immediately.
CAUTION: Be careful when handling hot glass and allow it to cool to RT before
use.
Melt HDA in a 60 °C oil bath and add 40 g (34 ml, 344 mmol) to the CD-Tos
solution using a syringe. The solution will turn yellowish. Allow the reaction to stir for 18
h at 80 °C in an oil bath before cooling to RT.
Critical step: Transfer the HDA solution quickly to ensure that it does not solidify
in the syringe.
Precipitate the CD-HDA product: To 50-ml conical tubes holding 45 ml of ice-cold
acetone (each), add 5 ml of the reaction solution and allow it to precipitate. Centrifuge
the precipitate at 3,200g for 2 min at 4 °C and decant the supernatant. Re-dissolve the
precipitate in 5 ml of DMF (per tube) by vortexing. Precipitate by adding 45 ml of ice-cold
acetone (per tube), centrifuge at 3,200g for 2 min at 4 °C and decant the supernatant.
Repeat this step three times.
Critical step: The crude product will agglomerate as a pellet during
centrifugation, which requires vigorous vortexing to re-dissolve in DMF. Increase the
volume of DMF and acetone if full dissolution cannot be achieved.
Wash the product by resuspending the pellet in 45 ml of cold acetone (per tube),
centrifuge at 3,200g for 2 min at 4 °C and decant the supernatant. Resuspend the pellet
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in 40 ml of ice-cold diethyl ether (per tube), centrifuge at 3,200g for 2 min at 4 °C and
decant the supernatant. Repeat this step two times.
Critical step: To reduce the number of tubes (allowing easier drying and
collection of the final product), combine multiple fractions while washing with diethyl
ether.
Evaporate organic residues by vacuum pressure for 48 h to obtain dry CD-HDA
as a white powder. Confirm the CD-HDA product using 1H NMR spectroscopy and
DMSO-d6 as a solvent. CD-HDA can be stored under nitrogen at −20 °C for at least 6
months.
Step 4: Preparation of CD-HA, part 3: synthesis of CD-HA (11 days)
Allow the HA-TBA to warm to RT. Equip a dry one-neck round-bottom flask with
a magnetic stir bar and stopper.
Critical step: Keep the HA-TBA in a desiccator, as it is hydroscopic and will
remove water from the atmosphere. It is essential to exclude moisture while performing
this reaction, as the presence of water reduces the coupling efficiency of the reaction.
Add 2.5 g (3.43 mmol, 1 equiv.) of HA-TBA and 2.96 g (4.86 mmol, 0.5 equiv.) of
CD-HDA to the flask. Purge with nitrogen before adding 125 ml of anhydrous DMSO (2%
(wt/vol)) via cannulation. Stir the mixture at 350 r.p.m. until it is fully dissolved. Add 1.06
g (4.86 mmol, 0.5 equiv.) of BOP to a separate dried round-bottom flask, purge with
nitrogen and add 20 ml of DMSO via cannulation. Once the BOP is fully dissolved,
transfer the solution to the HA-TBA/CD-HDA solution via cannulation and stir for 3 hours
at RT.
Quench the reaction with 10 ml of cold deionized water and transfer the solution
to dialysis tubing. Dialyze for 5 d at RT and change the water twice daily. During the first
3d, add sodium chloride (NaCl; 1.5 g per liter of dialysate) to force dialysis of the TBA
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salt. Remove insoluble by-products from the BOP coupling reaction by vacuum filtration,
and return to dialysis for an additional 5 d.
Freeze the dialyzed solution at −80 °C and lyophilize. Confirm the product and
the degree of modification using

1

H NMR spectroscopy and D2O as a solvent.

Lyophilized CD-HA samples can be stored under nitrogen for at least 1 year at −20 °C.
Step 5: Preparation of Ad-HA (10–15 days)
Allow the HA-TBA to warm up to RT. Equip a one-neck round-bottom flask with a
magnetic stir bar and stopper. Add 2.5 g (3.5 mmol, 1 equiv.) of HA-TBA, 2.04 g (10.5
mmol, 0.753.0 equiv.) of 1-adamantane acetic acid and 0.32 g (2.63 mmol, 0.75 equiv.)
of DMAP to the flask and purge with nitrogen before adding 125 ml of anhydrous DMSO
(2% (wt/vol)) to the vessel via cannulation. Stir at 350 r.p.m. for 20 min, or until the HATBA is fully dissolved.
Critical step: Secure the stopper with a copper wire to prevent the stopper from
becoming dislodged because of increased pressure when the reaction is heated. It is
essential to exclude moisture while performing this reaction, as the presence of water
reduces the coupling efficiency of the reaction.
Melt BOC2O in a 37 °C water bath and add 0.35 ml (0.41 equiv.) to the reaction
using a plastic syringe. Purge the reaction vessel with nitrogen and stir for 20 h at 45 °C
in an oil bath.
Critical step: The degree of modification can be controlled by adjusting the
amount of BOC2O; modifications of 20–50% have been achieved in our laboratory
(quantity used to afford the desired modification: 20%, 0.41 equiv.; 30%: 0.54 equiv.;
40%, 0.81 equiv. and 50%, 1.15 equiv.)
Let the reaction mixture cool to RT, add 10 ml of cold deionized water to quench
the reaction and transfer the mixture to the dialysis tubing. Dialyze for 3 days at RT and
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change the water twice daily. Precipitation of excess adamantane is expected and
should be removed by vacuum filtration using a No. 1 filter paper. Return the filtrate to
dialysis for an additional 12 d. Change the water twice daily. Freeze the samples in a
−80 °C freezer overnight and lyophilize. Confirm the product and the degree of
modification using 1H NMR spectroscopy and D2O as a solvent. Lyophilized Ad-HA
samples can be stored under nitrogen for at least 1 year at −20 °C.
3.2.3. TROUBLESHOOTING
-

Low yield of CD-Tos (Step 2). Possible reasons for this include the use of poor
quality p-toluenesulfonyl chloride. In this case, use a freshly opened ptoluenesulfonyl chloride. The p-toluenesulfonyl chloride also could have been
added too quickly, so ensure low nitrogen pressure when using a cannula.
Alternatively, add dropwise via a syringe over ∼10 min. Poor precipitation during
water and acetone washes could also lead to low yields. Be certain to keep
water, acetone, and samples on ice between the washing steps and centrifuge at
4 °C.

-

High residual water peak on CD-Tos 1H NMR (Step 2, Figure 3.4). This is
likely due to incomplete drying of CD-Tos. Repeat vacuum drying overnight to
remove residual water and purge sample with nitrogen before storage.
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Figure 3.4. 1H NMR spectrum of CD-Tos in DMSO-d6. The product was not fully dried,
which causes combination of the HOD peak with the hydroxyl groups of the CD ring
(purple shaded), prohibiting reliable integration of the CD necessary to confirm monotosylation.
-

Cloudy acetone supernatant (Step 3). Usually this is the result of poor
precipitation. Make sure to use low amounts of DMF (ca. 5 mL) to dissolve the
pellet during washing steps.

-

Low degree of CD or Ad modification on HA (Steps 4-5). Residual water can
quench the anhydrous reaction. Ensure that the glassware is completely dry and
purged with nitrogen before starting the reaction. Pre-weigh HA-TBA before
storage under nitrogen to avoid long exposure to the atmosphere before starting
CD-HA or AD-HA syntheses. Also, be sure to sufficiently purge by dry nitrogen
before the reaction.
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3.2.4. ANTICIPATED RESULTS
The HA-TBA product should be recovered as a spongy white solid. 1H NMR
spectroscopy (D2O) HA-TBA δ = 0.9–1.04 (t, 12H), 1.33–1.47 (m, 8H), 1.62–1.76 (m,
8H), 2.1 (s, 3H), 3.13–3.3 (m, 8H), 3.30–4.20 (10 H) (Figure 3.5). All products derived
from this intermediate (CD-HA, Ad-HA) should be examined to confirm sufficient dialysis
for elimination of the TBA salt.

Figure 3.5. 1H NMR spectra of HA-TBA in D2O. Modification of HA with TBA salt is
determined by the integration of the TBA methyl-groups (12H, shaded brown) relative to
the N-acetyl group of HA (3H, shaded gray).
The CD-Tos product should be recovered as a white powder, where yields (2.5 g,
21.1%; 20 g, 22.2%; 50 g, 17.8%) and product characterization are consistent
regardless of reaction scale and are consistent with literature reports.41

1

H NMR

spectroscopy (300MHz, DMSO-d6) δ = 2.42 (s, 3H), 3.123.80 (m, overlaps with HOD),
4.124.40 (m, 6H), 4.77 (s, 2H), 4.83 (s, 5H), 5.606.05 (br s, 14H), 7.43 (d, 2H), 7.75 (d,
2H) (Figure 3.6).
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Figure 3.6. 1H NMR spectrum of CD-Tos in DMSO-d6. Tosylation of CD is confirmed
by integration of the methyl (3H, shaded red) and aromatic hydrogens (2H each, shaded
orange), relative to the secondary hydroxyls of CD (14H, shaded gray). Anticipated
minor impurities in the spectra may include trace acetone ( = 2.10), ammonium chloride (
= 6.98, 7.12, 2.27 (s)), ethyl ether ( = 3.42 (q), 1.13 (t, 3H)), and water (see Figure 4).
CD-HDA should resemble a white powder and the overall yield of this step is
74.7± 7.4% (n = 3). 1H NMR spectroscopy (DMSO-d6) δ = 1.141.61 (m, 12H), 3.123.45
(m, overlaps with HOD), 3.483.78 (m, 28H), 4.284.56 (br s, 6H), 4.83 (s, 7H), 5.595.88
(br s, 14H) (Figure 3.7).
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Figure 3.7. 1H NMR spectrum of CD-HDA in DMSO-d6. Modification of CD with HDA is
determined by integration of the hexane linker (12H, shaded red) relative to the
secondary hydroxyls of CD (14H, shaded gray). Anticipated minor impurities in the
spectra may include trace dimethlyformamide ( = 7.98, 2.92, 2.08), acetone ( = 2.10),
and ethyl ether ( = 3.42 (q), 1.13 (t, 3H)).
The CD-HA product should be recovered as a spongy white to off-white solid,
with typical yields of ∼70%. The modification of HA is ∼30% for CD-HA, which is
validated by 1H NMR spectroscopy (D2O) based on the integration of the hexane linker δ
= 1.351.85 (12H) relative to the methyl singlet of HA δ =2.1 (3H) (Figure 3.8).
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Figure 3.8. 1H NMR spectra of CD-HA in D2O. Modification of HA with pendant CD
(30.2%) is determined by integration of the hexane linkers (12H, shaded red) relative to
the N-acetyl singlet of HA (3H, shaded gray).
The Ad-HA product should be recovered as a spongy white solid, with typical
yields of ∼70%. The modification of HA repeat units is 32.5% for Ad-HA as validated by
1

H NMR spectroscopy (D2O) based on integration of the ethyl multiplet of adamantane (δ

= 1.501.85, 12H) relative to the HA backbone (δ = 3.204.20, 10H) (Figure 3.9).
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Figure 3.9. 1H NMR spectra of Ad-HA in D2O. Modification of HA with pendant Ad
(32.5%) is determined by integration of the ethyl multiplet (12H, shaded blue) relative to
the sugar ring of HA (10H, shaded gray).

3.3 RHEOLOGICAL CHARACTERIZATION OF HYDROGELS
Rheology is a tool that can be used to quantitatively measure parameters of
hydrogels such as viscosity and storage and loss modulus, which are important
determinants of hydrogel injectability. Viscosity is a direct measurement of the ability for
a material to resist deformation in response to stress and is a direct measurement of
relative ability for hydrogel formulations to respond to changes in shear stress during
injection. Storage and loss modulus provide information about the elastic and viscous
response behaviors of a hydrogel, respectively, in response to oscillatory shear. In
particular, they measure the extent to which a hydrogel is able to respond to stress and
either absorb energy (storage modulus) or undergo stress relaxation to dissipate energy
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(loss modulus). This information is relevant for injections to better understand the
behavior of hydrogels during injection.
There are certain steps that must be taken in hydrogel sample preparation,
hydrogel loading onto the rheometer, and rheometer data acquisition that are crucial to
precise data collection and analysis. In this section, we describe a method for
rheological analysis of injectable hydrogels that can be used to determine compatibility
of hydrogels for future injection, including in vivo delivery.
3.3.1. MATERIALS
Reagents
•

Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis
described elsewhere with reagents available from sigma (St. Louis, MO)39

•

Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis
described elsewhere with reagents available from Sigma (St. Louis, MO)39

•

Phospho-buffered saline (Life Technologies, Carlsbad, CA, cat no: 15710-064)

•

Deionized water

Equipment
•

Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15)

•

1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 05408-129)

•

Vortex (e.g. Fisher Scientific, Waltham, MA, cat no: 02-215-414) with
microcentrifuge tube holder (e.g. Fisher Scientific, Waltham, MA, cat no: 11-676363)

•

Sonicator (e.g. Branson Ultrasonics, Danbury, CT, model no: CPX5800H)

•

Microcentrifuge (e.g. Eppendorf Refrigerated Microcentrifuge 5417R, Eppendorf,
Hamburg, Germany)

•

Scoopula (made from a cut 1-mL pipette tip)39

•

Rheometer (AR 2000 EX, TA Instruments, New Castle, DE)
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3.3.2. PROCEDURE
Overview
•

Step 1: Hydrogel preparation

•

Step 2: Rheometer set-up and calibration

•

Step 3: Hydrogel loading onto rheometer

•

Step 4: Rheometer data acquisition

•

Step 5: Clean-up and next sample preparation

•

Step 6: Rheometer data analysis

Step 1: Hydrogel preparation (2 hours)
Thaw materials (i.e., Ad-HA, CD-HA) from storage as a dry powder at -20°C until
they reach room temperature. For guest-host hydrogels, the mixing of Ad-HA with CDHA in aqueous solution forms an injectable hydrogel. Weigh materials separately into
two microcentrifuge tubes and dissolve them in PBS at the desired concentration on a
vortex for at least 30 minutes or until dissolved. Pipette the Ad-HA solution into the CDHA solution and mix the components with a pipette until the hydrogel is formed. Vortex
the hydrogel for 30 minutes. Then, sonicate the hydrogel for at least 10 minutes at 50°C
to completely dissolve the hydrogel components. Mix the hydrogel again with a pipette,
and then centrifuge for 2 minutes at 25000 RCF to remove any bubbles. The
components and concentrations can be varied depending on the shear-thinning hydrogel
that is being investigated.
Critical step: For reproducibility between samples, it is important that the
hydrogel components are weighed accurately. It is recommended to prepare solutions of
Ad-HA and CD-HA and aliquot these solutions into microcentrifuge tubes so that each
tube contains the desired polymer mass. Tubes can then be frozen, lyophilized, and
stored under nitrogen until needed. Each aliquot serves as an independent preparation
of hydrogel, and a minimum of three preparations should be tested to achieve statistical
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significance between different hydrogel formulations. Additional preparations or technical
replicates should be used if large variability is observed between formulations. In
addition, both components of the hydrogel must be thoroughly dissolved and mixed
together, without air bubbles. Any inconsistencies in hydrogel preparation will result in
poor reproducibility in subsequent experiments.
Step 2: Rheometer set-up and calibration (15-30 min)
2-1. Rheometer set-up. The following steps are specific to the AR 2000 EX
rheometer. These directions are to be taken in addition to steps provided by the
manufacturer for rheometer set-up and calibration. Close vent and turn on compressor.
The pressure should reach 30 PSI for rheometer operation. Connect the geometry and
the Peltier plate stage to the rheometer. Depending on the application, the Peltier plate
temperature should be set to 25°C or 37°C depending on the property measured. For
our experiments, temperature is set to 25°C as this is the ambient temperature in which
an injection would be performed. Experiments are performed at room temperature
(25°C).
Critical step: Rheometer geometry is important and is determined by sample
viscosity, shear rates and shear stresses desired, as well as sample volumes. For these
studies, a cone and plate geometry was chosen because this geometry normalizes
shear rates across the entire sample, allowing for an accurate determination of true
sample viscosity (as opposed to parallel plate geometries, where shear rates vary
across the sample). Cone angle (0° 59’ 42”) and diameter (20 mm) were chosen based
on shear rates and shear stresses desired and to minimize sample volumes needed.
The truncation height or gap for this geometry is 27 µm. The gap height must be greater
than or equal to ten times the particle size, if particulate-based hydrogels are
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investigated. Rheometer geometry may need to be adjusted depending on hydrogel
properties.
2-2. Calibration. Open the instrument control program on the computer and
calibrate instrument inertia, geometry inertia, and bearing friction. Use rotational
mapping to calibrate the geometry, then zero the geometry gap to prepare for sample
loading.
Critical step: Because the geometry is removed for cleaning after every sample,
all calibrations except for the instrument inertia should be repeated between each
sample.
Step 3: Hydrogel loading onto rheometer (10 min)
Remove the hydrogel from the microcentrifuge tube using a scoopula. Load the
hydrogel onto the Peltier plate, taking care not to introduce air or bubbles into the
hydrogel. Place the hydrogel in the center of the plate. When centered, use the program
to set the height of the cone to the gap height (27 µm). Spin the geometry so that it is
turning while it contacts the hydrogel for more even hydrogel flattening (Figure 3.10a).
Either right before (~5% higher) or when the gap height is reached, trim the edges of the
hydrogel with a pipette tip so that the hydrogel correctly fills the geometry (Figure
3.10b). Place the solvent trap over the geometry and onto the Peltier plate and surround
the outer edges of the solvent trap with water to keep the hydrogel hydrated during data
acquisition.
Critical step: Correct filling of the geometry by the hydrogel is important for
accurate rheological data acquisition. An over-filled sample overestimates mechanical
values, while an under-filled sample underestimates mechanical values. A correctly filled
sample can be difficult to obtain by trimming. Hydrogel loading volume may need to be
optimized based on the geometry used.
82

Figure 3.10. Hydrogel loading onto the rheometer stage. (a) When lowering the
geometry onto the hydrogel, spin the geometry slightly for more even hydrogel loading.
(b) Over-filling and under-filling of the sample results in increased and decreased forces,
respectively. The hydrogel sample must fill the space between the geometry and the
rheometer stage correctly for accurate measurements.
Step 4: Rheometer data acquisition (variable)
Open the procedure desired and start the protocol. Depending on the tests
chosen, the procedure length will vary. For these studies, we used the following protocol:
A. Time sweep (2 min) at 0.2% strain, 10 Hz
Note that % strain is determined using strain sweeps to select a % strain
lower than the yield strain. A consistently non-deforming strain in our
system is <1%. Similarly, the frequency is determined from frequency
sweeps by selecting a frequency greater than the crossover frequency.
B. Frequency sweep from 0.01 to 100 Hz at 0.2% strain with a conditioning time of 3
seconds, a sampling time of 3 seconds, and 10 points per decade
Note that the % strain is the same as for the time sweep.
C. Time sweep (2 min) at 0.2% strain, 10 Hz to recondition the hydrogel
D. Strain sweep from 0.01% to 500% strain at 10 Hz with a conditioning time of 3
seconds, a sampling time of 3 seconds, and 10 points per decade
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Note that the frequency is the same as for the time sweep.
E. Low strain (cyclic strain) time sweep (2 min) at 0.2% strain, 10 Hz
F. High strain (cyclic strain) time sweep (1 min) at 500% strain, 10 Hz
G. Repeat E, F 5 times for cyclic strain test
H. Time sweep (2 min) at 0.2% strain, 10 Hz to recondition hydrogel
I.

Continuous ramp from shear rates of 0 s-1 to 50 s-1 over 2 min 30 seconds with
20 points per decade

J. Continuous ramp from shear rates of 50 s-1 to 0 s-1 over 2 min 30 seconds with
20 points per decade
Step 5: Clean-up and next sample preparation (10 min)
Raise the geometry using controls on the machine. Remove the hydrogel from
the stage and clean up any excess water around the solvent trap. Remove the geometry
carefully from the bearing and wipe dry. Repeat steps starting at rheometer calibration
for all remaining samples.
Critical step: Be sure to clean the stage and complete all calibration steps fully
between each sample.
Step 6: Rheometer data analysis (variable)
Export data as text files from the computer program. Import files into graphing
software and create plots based on tests completed.
Critical step: TA Instruments includes a data analysis program, but this program
does not allow you to fully manipulate graphs and graph settings.
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3.3.3. TROUBLESHOOTING
-

Air bubbles within hydrogel prior to loading onto rheometer. After the
hydrogel is mixed, spin down the hydrogel at 25000 RCF for 2 minutes to remove
any bubbles accumulated during mixing. Note that centrifugation speeds for
hydrogels with encapsulated therapeutics should be determined empirically, as
small molecules or cells may settle in the hydrogel during centrifugation.

-

Difficulties in hydrogel loading or hydrogel trimming on the rheometer
stage. Change the volume of hydrogel prepared to match the amount of hydrogel
that is needed for the specific geometry chosen to limit the need to trim the
hydrogel. Take care to load the hydrogel onto the center of the plate and make
sure the geometry is slightly spinning when it touches the hydrogel.

-

Hydrogel dries out during testing. Make sure to add water to the top of
geometry and use the solvent trap. Surround the edges of the solvent trap with
water to provide a humidified environment for the hydrogel during testing.
Lowering the temperature of the Peltier stage may also be helpful for longer
studies, as long as the temperature change does not affect the mechanical
properties of the hydrogel.

3.3.4. ANTICIPATED RESULTS
For demonstration, we prepared guest-host hydrogels of varying material
concentrations for rheological analysis. Using the materials previously described, we
formed hydrogels with a total (Ad-HA and CD-HA) polymer content of 5 wt% or 7.5 wt%.
Following hydrogel preparation, we loaded these hydrogels onto the rheometer and ran
the tests outlined above. The results from these tests are shown in Figure 2. Frequency
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sweeps (Figure 3.11a), strain sweeps (Figure 3.11b), continuous flow experiments
(Figure 3.11c), and cyclic strain time sweeps (Figure 3.11d) are highlighted here.

Figure 3.11. Rheological characterization of guest-host hydrogels. Results of (a)
frequency sweep, (b) strain sweep, (c) continuous flow, and (d) cyclic strain time sweep
rheology experiments for hydrogels of 5 wt% and 7.5 wt% material concentration, using
the described method and rheological parameters. For cyclic strain, shaded regions are
high strain (500%) and unshaded regions are low strain (0.2%).
The frequency sweep indicates that both hydrogels transition from a primarily
liquid to a primarily solid state with increasing frequencies, and that the relaxation time
for the 5 wt% hydrogel is shorter than that of the 7.5 wt% hydrogel (Figure 3.11a).
Frequency sweeps provide a relative ranking of elastic and viscous properties under
constant strain. Increasing frequencies decrease relaxation times and favor elastic
properties (G’, storage modulus) over viscous properties (G’’, loss modulus) as there is
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minimal time for energy to dissipate or for hydrogels to flow during testing. These results
indicate that the 5 wt% hydrogel flows more readily than the 7.5 wt% hydrogel. From the
strain sweep, we observe that both hydrogels experience a steep drop in storage and
loss modulus after a certain yield strain, indicating material yielding (Figure 3.11b). This
yield strain is lower for the 5 wt% hydrogel, indicating that the 5 wt% hydrogel may be
easier to inject than the 7.5 wt% hydrogel.
An important factor for injectability from the rheology data is whether the hydrogel
is shear-thinning. Shear-thinning hydrogels experience decreases in viscosity upon
application of shear, which are enabled by reversible crosslinking mechanisms. From the
continuous flow experiments, we observe that the viscosity decreases as shear rate
increases for both the 5 wt% and 7.5 wt% hydrogels, indicating that both hydrogels are
shear-thinning (Figure 3.11c). Similarly, the cyclic strain sweeps show that at high
strains, both of these hydrogels yield and show sharp decreases in storage and loss
modulus, which are recovered instantly at low strains upon cessation of shear (Figure
3.11d, Figure 3.12b-c). This displays the ability for hydrogels to transition from a
predominantly elastic material to a predominantly viscous one, and demonstrates the
rapidly self-healing properties of this hydrogel. From the continuous flow experiments,
we can also observe that the 5 wt% hydrogel displays shear banding, or a precipitous
drop in shear stress for certain shear rates (Figure 3.12a).43 This also indicates
injectability.
Hydrogels with a lower viscosity and a lower storage and loss modulus are
typically easier to inject than hydrogels of a high viscosity and a high storage and loss
modulus. The viscosity of the 5 wt% hydrogel is lower than that of the 7.5 wt% hydrogel,
indicating that the 5 wt% hydrogel would be easier to inject (Figure 3.11c). From the
cyclic strain time sweeps, we observe that the storage modulus of both hydrogels
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change with strain and that the 5 wt% hydrogel has a lower storage modulus than the
7.5 wt% hydrogel, indicating that the 5 wt% hydrogel may be easier to inject (Figure
3.11d). Cyclic strain time sweeps showing both storage and loss modulus for 5 wt% and
7.5 wt% hydrogels can be found in Figure 3.12b-c.
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Figure 3.12. Additional rheological characterization of guest-host hydrogels. (a)
Continuous flow experiments of shear stress by shear rate that show shear banding for 5
wt% hydrogels, but not 7.5 wt% hydrogels. (b-c) Cyclic strain time sweep experiments at
10 Hz for 5 wt% (b) and 7.5 wt% (c) hydrogels show storage (G’) and loss (G”) moduli
over time. Shaded regions represent high strain (500%) and unshaded regions represent
low strain (0.2%).

3.4 MEASUREMENT OF HYDROGEL INJECTION FORCES
While material properties such as viscosity, storage, and loss modulus are
important for determining injectability, injection force determines whether or not a
material is clinically relevant for injection. Controlled methods to measure injection force,
such as a force sensor or a material testing machine, allow us to compare quantitatively
the injectability of various hydrogels of differing material formulations. In this section, we
describe a protocol for determining injection force using both a versatile, inexpensive
force sensor and using an established material testing machine. We also describe
factors that influence injection force, such as flow rate, needle gauge, and needle length.
Injection force is not only relevant as a physical property, but also has effects on
hydrogel contents, such as cells.
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3.4.1. MATERIALS
Reagents
Reagents for hydrogel formation
•

Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis
described elsewhere with reagents available from sigma (St. Louis, MO)39

•

Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis
described elsewhere with reagents available from Sigma (St. Louis, MO)39

•

Phospho-buffered saline (Life Technologies, Carlsbad, CA, cat no: 15710-064)

Equipment
•

Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15)

•

1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 05408-129)

•

Vortex (e.g. Fisher Scientific, Waltham, MA, cat no: 02-215-414) with
microcentrifuge tube holder (e.g. Fisher Scientific, Waltham, MA, cat no: 11-676363)

•

Sonicator (e.g. Branson Ultrasonics, Danbury, CT, model no: CPX5800H)

•

Microcentrifuge (e.g. Eppendorf Refrigerated Microcentrifuge 5417R, Eppendorf,
Hamburg, Germany)

•

Scoopula (made from a cut 1-mL pipette tip)39

•

Various syringes and needles for gel preparation or testing
o

1 mL syringe (BD, Franklin Lakes, NJ, cat no: 309628)

o

½ mL, 27G x ½” tuberculin syringe (BD, Franklin Lakes, NJ, cat no:
305620)

o

18G x ¼” needle (McMaster-Carr, Elmhurst, IL, cat no: 75165A121)

o

25G x ¼” needle (McMaster-Carr, Elmhurst, IL, cat no: 75165A127)

o

27G x ¼” needle (McMaster-Carr, Elmhurst, IL, cat no: 75165A128)

o

25G x 1 ½” needle (BD, Franklin Lakes, NJ, cat no: 305127)

•

Force Sensor (Tekscan, Boston, MA, FlexiForce Quickstart Board)

•

myDAQ Data Acquisition Device (National Instruments, Austin, TX)

•

Syringe pump (e.g. New Era Pump Systems Inc, Farmingdale, NY, model no:
NE-300)

•

Mechanical testing machine (Instron, Norwood, MA, model no: 5848)
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3.4.2. PROCEDURE
Overview
•

Step 1: Hydrogel preparation

•

Step 2: Hydrogel loading into syringe for testing

•

Step 3: Force testing by force sensor or mechanical testing machine

Step 1: Hydrogel preparation (2 hours)
Hydrogels are prepared the same way as described for Method 1. Briefly, weigh
Ad-HA and CD-HA materials into separate microcentrifuge tubes and dissolve in PBS on
a vortex. Mix Ad-HA and CD-HA components together using a pipette. Vortex the
hydrogel for 30 minutes, then sonicate at 50°C for 10 minutes. Mix the hydrogel again
with a pipette and centrifuge at 25000 RCF for 2 minutes to remove entrapped air. Refer
to Step 1 of Method 1 for more details and critical steps.
Step 2: Hydrogel loading into syringe for testing (20 min + overnight incubation)
Cut the needle off of a ½ mL, 27G x ½” tuberculin syringe. Remove the hydrogel
from the microcentrifuge tube using a scoopula and load it onto the cut end of the
syringe. Pull back on the plunger to load the hydrogel into the syringe. After the hydrogel
is loaded, paraffin the open end of the syringe and cut the excess plunger using wire
cutters. Centrifuge at 1000 RCF for 3 minutes to remove bubbles. Then, using the cut
portion of the plunger, depress the plunger to load the hydrogel into a 1 mL syringe for
testing. We use a 1 mL Luer lock syringe that can be connected to a wide variety of
needles with different gauges and lengths. After loading the syringe and attaching the
desired needle, wrap the needle with a hydrated wipe and cover with aluminum foil to
prevent the hydrogel from drying. Store at 4°C overnight to allow any remaining bubbles
to rise to the top of the syringe barrel.
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Critical step: Any imperfections in hydrogel loading and hydrogel preparation
(bubbles, dust, etc) will affect injection force so take care to load the hydrogel into the
testing syringe homogeneously. The overnight incubation time is crucial for removing
any air taken in during the hydrogel loading process.
Step 3: Force testing (variable by sample number)
By force sensor (Figure 3.13a). For best results, use a syringe pump to
standardize the application of force to the syringe. Connect the force sensor to myDAQ
for data acquisition. Create a standard curve by placing weights that correspond to the
injection forces that will be measured onto the sensor. Record voltages and adjust
sensitivity of the force sensor if the voltages are out of range. Prime syringes, then place
samples onto the syringe pump, and place the force sensor between the plunger of the
syringe and the syringe pump. Start the syringe pump and record voltages for 1-2
minutes. Convert the voltage to force using the standard curve and plot the force over
time.

Figure 3.13. Injection force using a force sensor. (a) Schematic of the set-up for
measuring injection force using a force sensor. (b) Plot of injection force over time for
hydrogels with varying material concentrations (5 wt%, 7.5 wt%) and different flow rates
(2 mL/hr, 8 mL/hr).
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By mechanical testing machine (Figure 3.14a). The use of a mechanical
testing machine negates the use of a syringe pump, since the load cell will apply even
forces. Prime the syringe and place into the stage of the mechanical testing machine.
We used the base test frame as a stage with no accompaniments. Zero the force from
the load cell and then maneuver the load cell so that it is just touching the syringe, which
can be detected by an increase in force. Using the tensile extension mode, set the linear
rate to match a flow rate desired for testing. Start applying displacement and record the
force over time for 1-2 minutes. Extract data and plot force over time.
Critical step: For most accurate results, run each trial with the same starting
volume of hydrogel. The distance traveled by the plunger will affect the forces applied.

Figure 3.14. Injection force using a mechanical testing machine. (a) Schematic of
the set-up for measuring injection force with a mechanical testing machine. (b) Plot
showing injection force over time for hydrogels injected from a 1 mL syringe with ¼”
needles of 18G, 25G, and 27G. (c) Injection force over time for hydrogels injected from a
1 mL syringe with a 25G needle of ¼” and 1 ½” lengths. All measurements were taken at
a flow rate of 2 mL/hr.
3.4.3. TROUBLESHOOTING
-

Force changes over time. Over time, injection force should plateau for most
hydrogel samples. If the force continues to rise, let the test run for a longer period
of time. If the force declines unexpectedly and then increases, there may be
imperfections in hydrogel loading. Ensure that the hydrogel is adequately mixed
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and that there are no bubbles in the testing syringe for the most accurate
measurements.
-

Needle detaches from syringe. Because of the nature of Luer-Lock needles,
they can become detached from the syringe upon the application of extreme
forces. In these cases, the hydrogel requires a high amount of force for injection.
While this may not be practical for eventual clinical application, to measure this
force, use a needle and syringe combination that is not detachable, such as an
insulin syringe, to obtain measurements. Note that differences in syringes include
barrel diameter, needle gauge, and/or needle length, all of which are variables
which can affect injection force and that need to be controlled between samples
for comparison.

3.4.4. ANTICIPATED RESULTS
We tested the injection force necessary to eject both 5 wt% and 7.5 wt% guesthost hydrogels from 1 mL plastic syringes at different flow rates and with differing needle
gauges and needle lengths, using both a force sensor and a mechanical testing
machine. We observed that, at a flow rate of 2 mL/hr, the injection force required for a 5
wt% hydrogel was close to 5N. At the same flow rate, the injection force required for a
7.5 wt% hydrogel was close to 15N (Figure 3.13b). From rheology we know that the 7.5
wt% hydrogel has a higher viscosity and a higher storage and loss modulus than the 5
wt% hydrogel, both of which contribute to its higher injection force.
Higher flow rates also lead to higher injection forces, and this effect was
dependent on weight percent. For the 5 wt% hydrogels, increasing flow rate from 2 to 8
mL/hr minimally increased injection force. For the 7.5 wt% hydrogels, increasing the flow
rate from 2 to 8 mL/hr increased injection force. Other factors that affect injection force
include needle gauge and needle length. Increasing needle gauge, and thereby reducing
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needle diameter, increased injection force. For a 5 wt% hydrogel with a flow rate of 2
mL/hr, reducing the needle diameter from 18G (0.84 mm) to 25G (0.26 mm) to 27G
(0.21 mm) increased the injection force from 0.4N to 4N to 7N, respectively (Figure
3.14b). We also found that increasing the needle length from ¼” to 1 ½” drastically
increased injection force for a 5 wt% hydrogel at 2 mL/hr from 4N to 13N (Figure 3.14c).
Blips in the force profile as it builds up can be attributed to heterogeneity in hydrogel
preparations or improper loading. Care should be taken to ensure hydrogels are
adequately mixed prior to testing, and that the syringe is properly loaded to ensure even
contact between the load cell and syringe barrel. New syringes and needles should also
be used for each independent hydrogel preparation. Single blips may be caused by one
of the above issues, but multiple blips within the same profile may indicate problems
such as phase separation.

3.5 ENCAPSULATED CELL VIABILITY AFTER INJECTION
Injection force is not only an important mechanical measure of hydrogel
injectability but can also affect the ability of the hydrogel to carry certain types of cargo
that are sensitive to force, such as cells. Material properties of hydrogels, such as
storage modulus, can also affect the cell-protective capacity of injectable hydrogels.36
Standardized techniques for encapsulating cells in hydrogels, especially two-component
hydrogels such as the guest-host hydrogels described here, are important for
reproducibility since variations in mixing techniques can alter cell responses and
ultimately therapeutic efficacy. In this section, we describe a method for encapsulating
cells within injectable hydrogels, culturing injectable hydrogels in vitro, and assessing
encapsulated cell viability after injection.
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3.5.1. MATERIALS
Reagents
•

Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis
described elsewhere with reagents available from sigma (St. Louis, MO)44

•

Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis
described elsewhere with reagents available from Sigma (St. Louis, MO)44

•

Mouse 3T3 fibroblasts (e.g., ATCC, cat. no. CRL-1658; store in liquid nitrogen
and routinely check to ensure that they are not contaminated with mycoplasma)

•

DMEM, high glucose, with GlutaMAXTM (Thermo Fisher Scientific, cat. no.
10566016; store it at 4 °C)

•

FBS (Thermo Fisher Scientific, cat. no. 1437028; store it at −20 °C)

•

Penicillin–streptomycin, 10.000 U/ml (Life Technologies, cat. no. 15140-122;
store it at −20 °C)

•

PBS (Life Technologies, cat. no. 10010023; store it at 4 °C)

•

Trypsin–EDTA (Life Technologies, cat. no. 15090-054; store at 4 °C)

•

Acrylonitrile–butadiene–styrene spool (MakerBot 1.75 mm/1.8 mm filament; ABS;
store it at RT)

•

Agarose (Sigma-Aldrich, cat. no. A9539; store it at RT)

•

Live/Dead Viability/Cytotoxicity Kit for mammalian cells (e.g., Thermo Fisher
Scientific, cat. no. L3224; store it at −20 °C)

Equipment
•

Tissue culture hood (e.g., Thermo Fisher Scientific 1300 Series Class II, Type A2
biological safety cabinet)

•

CO2 cell culture incubator set to 5% CO2 and 37 °C (e.g., Heracell VIOS;
Thermo Fisher Scientific)

•

Microwave

•

Confocal microscope (e.g., Leica, model no. TCS SP5)

•

Hemocytometer (e.g., Hausser Scientific, cat. no. 0630010)

•

Water bath set to 37 °C

•

Scoopula (made from a cut 1-mL pipette tip)44

•

Sterile 100 cm2 tissue culture dishes (e.g., Sigma-Aldrich, cat. no. Z707694)
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•

Sterile 24-well plates for 3D cell culture (e.g., Corning Costar; Sigma-Aldrich, cat.
no. CLS3527)

•

3D printer (e.g., Makerbot Replicator 2)

•

ImageJ (https://imagej.nih.gov/ij/) or CellProfiler (http://cellprofiler.org/releases/)
software

•

1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 05408-129)

•

Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15)

•

Micropipettes and tips

•

Sterile syringes and needles

•

Refrigerator set to 4 °C

•

Freezer set to −20 °C

•

Freezer set to −80 °C

•

Microcentrifuge (e.g., Eppendorf Refrigerated Microcentrifuge; Eppendorf, model
no. 5417R)

•

Vortex mixer (e.g., Fisher Scientific, cat. no. 02-215-414) and tube holder (e.g.,
Fisher Scientific, cat. no 11-676-363)

3.5.2. PROCEDURE
Reagent set-up
•

Mouse 3T3 fibroblast medium: prepare DMEM supplemented with 9% FBS
and 1% penicillin–streptomycin. This medium can be stored for 1 week at 4 °C.

•

ABS molds: using a 3D-printer, prepare plastic molds designed to fit into a 24well plate with inserts of 8-mm length and 5-mm diameter44

•

Solution for live/dead staining: add 0.5 μL of calcein AM (2 μM) and 2 μL (4
μM) of ethidium homodimer-1 (from Live/Dead Viability/Cytotoxicity Kit) to 1 ml of
serum-free DMEM and allow the solution to warm to 37 °C. Protect the vial from
light. Live/Dead staining solution should be freshly prepared at the time of the
assay and kept at RT. Prepare at least 300 μL per sample, adjusting the volume
according to the number of samples to be assayed.
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Overview
•

Step 1: Prepare materials

•

Step 2: Prepare agarose molds

•

Step 3: Encapsulate cells in hydrogel and inject

•

Step 4: Assess cell morphology and viability

Step 1: Prepare materials (2 hours)
Prepare sterile polymer stock solutions: Sterilize the desired amounts of dry AdHA and CD-HA components by placing them beneath a germicidal UV lamp for 60 min in
a class II biological safety cabinet. Dissolve the components individually in sterile PBS at
the desired concentration and shake the polymer solutions overnight to ensure complete
dissolution of the polymer.
Critical step: For cell culture applications, work in a class II biological safety
hood and use sterile instruments. Clean all working surfaces with 70% (vol/vol) ethanol
before use. 20% of the final hydrogel volume should be reserved for resuspending the
cell pellet, to yield the desired final concentration.
Step 2: Prepare agarose molds (2-3 hours)
For in vitro experiments, we recommend the use of a well-in-well culture system
to ensure facile media changes without disruption of the GH hydrogel construct. We
designed a mold made of acrylonitrile–butadiene–styrene (ABS), which fits into a 24-well
plate and can be used to fabricate agarose well-in-well molds (Figure 3.15a). Agarose
represents an ideal material for preparing such molds, as cells do not adhere to the
agarose surface; therefore, cells do not undergo excessive aggregation or proliferation
at the gel–gel interface.
Sterilize the customized plastic mold (Figure 3.15a) by spraying it with 70%
(vol/vol) ethanol in a class II biological safety cabinet. Dissolve 1.5 g of agarose in 50 mL
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of PBS by microwaving the agarose solution for 1 min at 600 W. Pipette 2 mL of agarose
into each well of a sterile 24-well plate, avoiding introduction of air bubbles. Cover the
24-well plate with the customized plastic mold (Figure 3.15b) and secure with rubber
bands. Let it cool to RT for at least 60 min to ensure that the agarose is fully solidified.
Gently remove the plastic mold from the 24-well plate and rinse the agarose-containing
wells twice with 1 mL of sterile PBS per well (Figure 3.15c). Add 0.5 mL of sterile PBS
to each well and transfer to a cell culture incubator at 37 °C while preparing the hydrogel
and processing the cells.
Critical step: After spraying ABS mold with ethanol, ensure that the plastic mold
has fully dried before proceeding. Caution: wear thermo-insulated gloves when handling
the agarose-containing glassware.

Figure 3.15. Agarose molds. (a) Customized plastic mold made of acrylonitrilebutadiene-styrene (ABS). (b) The mold is designed to fit into a 24-well plate with inserts
of 8 mm length and 5 mm diameter. (c) After solidification of 2 mL agarose, molds can
be used to contain injected guest-host hydrogels for culture.
Step 3: Encapsulate cells in hydrogel and inject (3 hours)
Expand cells of choice (e.g., mouse 3T3 fibroblasts) in tissue culture dishes (e.g.,
100 cm2) using the appropriate cell culture medium. Wash cells with 10 mL of sterile
98

PBS, add 3 mL of sterile trypsin–EDTA and incubate for 5 min in a cell culture incubator
at 37 °C. Add 10 mL of sterile mouse 3T3 fibroblast medium and transfer the cell
suspension to a sterile 50-mL conical tube. Pellet the cells by centrifuging at 500g for 5
min at RT. Remove the supernatant and resuspend the cell pellet in a suitable volume of
medium (e.g., 5 mL) to determine the cell concentration using a hemocytometer.
Calculate the cell suspension volume for the desired cell number and transfer to a sterile
1.5 mL microcentrifuge tube. Pellet the cells by centrifuging at 500g for 5 min at RT.
Critical step: The cell concentration depends on the cell type and its application.
A typical cell density for the encapsulation of mouse 3T3s is 5 × 106 per mL.
Aspirate the medium from the cell pellet, resuspend in 20% of the final gel
volume and separate into the Ad-HA and CD-HA stock solutions. Ensure homogeneous
cell dispersion by mixing gently with a pipette. Combine the two component solutions by
gentle mixing in a 1.5-mL tube (Figure 3.16a), briefly centrifuge at 500g for 30s at RT
and transfer to the syringe barrel using an adequate scoopula. Alternatively, components
may be combined directly in a 1-mL syringe barrel (Figure 3.16b). Depress the plunger
slowly and inject the gel (e.g. 30 µL) into the agarose wells. Add 0.5 mL of mouse 3T3
fibroblast medium and incubate in a culture incubator at 37 °C.
Critical step: The CD-HA solution can be viscous, depending on the polymer
concentration. Alternatively, use a positive-displacement pipette for mixing the cell
suspension. Be very gentle when handling the cell–polymer solutions to ensure low
shear stress during mixing. We recommend mixing the GH components in the back of a
syringe to reduce unnecessary shear forces that may be experienced by the cells during
hydrogel transfer to the syringe.
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Figure 3.16. Techniques for mixing guest-host hydrogels. (a) Prepare CD-HA and
Ad-HA solutions in stoichiometric equivalence in PBS and portion the therapeutic cargo
between the two stock solutions. Mix the two components in a 1.5-mL tube, briefly
centrifuge to remove entrapped air and transfer the preformed hydrogel to the back of a
syringe. (b) For cell encapsulation, portion the cell suspension between the two stock
solutions. To load the syringe with the GH gel, first add the CD-HA solution to the back
of the syringe, then add the Ad-HA while continuously mixing the two components;
continue to mix gently until a homogeneous gel is formed.
Step 4: Assess cell morphology and viability (3 hours)
After a desired culture period, remove the medium from the wells and add 300 μL
of Live/Dead staining solution per sample in a 24-well plate. Incubate for 30 min in a
culture incubator at 37 °C. Aspirate the staining solution and replace with 0.5 mL of
serum-free medium. Image the samples with a confocal laser scanning microscope with
a 10/20× objective. Quantify cell viability by counting cells that stain positive for live and
dead stains using ImageJ or CellProfiler.
Critical step: Protect samples from light before imaging.
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3.5.3. TROUBLESHOOTING
-

Low cell viability. Avoid air bubbles inside the sample prior to injection. Make
sure to centrifuge the preformed hydrogel and avoid rupture of the sample when
transferring. Alternatively, mix guest-host components in the back of a syringe.

3.5.4. ANTICIPATED RESULTS
When we encapsulated cells within hydrogels using the established protocol, we
observed that the viability of cells delivered using a 5 wt% hydrogel was significantly
higher than that of cells delivered using a 7.5 wt% hydrogel (Figure 3.17a-b).39 We
determined cell viability after injection using a live/dead assay and CellProfiler to quantify
cell counts, as previously described.39 However, not all increases in injection force have
a deleterious effect on cargo. When we assessed cell viability after injection at 2 mL/hr
or 40 mL/hr, we observed that cell viability was not significantly different at the two flow
rates, even though injection force increased with flow rate (Figure 3.18a-c).
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Figure 3.17. Cell viability depends on material concentration. Cell viability
immediately after injection at 2 mL/hr or without injection for mouse 3T3 fibroblasts
encapsulated in guest-host hydrogels of 5 wt% and 7.5 wt%. (a) Live cells (calcein AM)
are green and dead cells (ethidium homodimer-1) are red. Scale bar is 100 µm. (b) Cell
viability was significantly lower for the 7.5 wt% hydrogels compared to the 5 wt%
hydrogels after injection. Data displayed is mean ± SE with p<0.05.

Figure 3.18. Effect of increasing flow rate on injection force and cell viability. (a)
For a 5 wt% hydrogel, increasing the flow rate from 2 mL/hr to 40 mL/hr increases
injection force from 5N to 7.5N. (b) Images of mouse 3T3 fibroblast cells immediately
after injection at varying flow rates. Scale bar is 100 µm. (c) Quantified cell viability
shows no significant differences in cell viability after injection at either 2 or 40 mL/hr.
Data displayed as mean ± SE with p<0.05.
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Many factors, such as flow rate, needle gauge, and needle length can affect
injection force for the same hydrogel in the same syringe. Using a force sensor or
mechanical testing machine to measure injection force can allow for quantifiable
measures of injectability that, when other variables are controlled, can be used to
compare ease of injection between different hydrogels. While these tests were done
injecting into air, injections into liquids or tissues would more accurately mimic in vivo
conditions. Clinically relevant injection forces typically are <20N45,46 but actual
injectability can depend not only on force but also on the ergonomics of the syringe,
which can affect the force applied. The methods described here for characterizing
injectable hydrogels using rheology and measurements of injection force can also be
utilized for applications other than in vivo delivery that include ejection of hydrogels, such
as 3D printing.

3.6 INJECTION OF HYDROGELS IN RAT MI MODELS
Injectable hydrogels have been widely investigated for cardiac repair and have
been used for mechanical bulking,3,4,35 modulating remodeling,7,17 or therapeutic delivery
(cells, small molecules, RNAs) after MI.6,15,47 Some hydrogel formulations have
undergone testing in clinical trials.48–52 Especially for the heart, injectable hydrogels are
advantageous because of their potential for minimally invasive delivery such as through
a catheter.34,35 Toward their assessment in vivo, hydrogels have been used in small and
large animal models in which they are injected intramyocardially into the infarct site or
the border zone region around the infarct. Although delivery through catheters has been
investigated in larger animal models, most current models of hydrogel injections are still
through minimally invasive thoracotomy and myocardial injection, which is an open-heart
surgery and will be the focus of this section.
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Common small animal cardiac models are mouse and rat. While the mouse has
been the model organism for studying heart disease in humans and ease in testing
biocompatibility, it is also the farthest from translatability to humans due to its small size.
Rats are larger than mice and enable easier hemodynamic modalities (such as
pressure-volume catheterization) to assess cardiovascular function, and surgical
techniques are often technically easier than in mice, leading to decreased noise and
variability in studies. Rat studies also enable greater quantities of myocardial tissue for
post-mortem histological analyses.53 However, costs associated with rat models may be
higher and favorable results may not always be reproducible in clinical studies.
Moreover, while transgenic rat models exist, a high cost is associated with generating
and maintaining these colonies and there are appreciably fewer models in rats than in
mice.54–57
Here, we outline the steps necessary for injection of hydrogels into a rat model of
MI, which is widely utilized in the rest of this thesis. This protocol focuses on the injection
of hydrogels, and additional protocols regarding the surgeries themselves (anesthesia,
intubation, thoracotomy, closure, and post-operative care) can complement these
methods.58 We have found that the steps listed below lead to reproducible and reliable
hydrogel injection models. However, these steps should be used as guidelines for other
hydrogel injections and can be adapted as necessary on a case-by-case basis, where
variations in the method (e.g., location, number, volume, or timing of injections) are
desired. We note that investigators should obtain IACUC or similar approval and training
prior to animal testing.
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3.6.1. MATERIALS
Reagents
•

Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis
described elsewhere with reagents available from Sigma (St. Louis, MO)39

•

Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis
described elsewhere with reagents available from Sigma (St. Louis, MO)39

•

Phospho-buffered saline (Life Technologies, Carlsbad, CA, cat no: 15710-064)

•

Analgesics as listed below or a comparable and approved pain control regimen
o

Meloxicam (Norbrook Laboratories, Newry, United Kingdom, 5 mg/mL
solution for injection)

o

Buprenorphine (ZooPharm, Windsor, CO, 1 mg/mL)

o

Bupivacaine (Hospira, Inc, Lake Forest, IL, 0.25%, 2.5 mg/mL)

•

Betadine solution swab stick (Purdue Pharma LP, Stamford, CT)

•

Isoflurane (Piramal Enterprises Ltd, Mumbai, India, 250 mL)

Equipment
•

Hydrogel preparation
o

Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15)

o

1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no:
05-408-129)

o

Vortex (e.g. Fisher Scientific, Waltham, MA, cat no: 02-215-414) with
microcentrifuge tube holder (e.g. Fisher Scientific, Waltham, MA, cat no:
11-676-363)

o

Sonicator (e.g. Branson Ultrasonics, Danbury, CT, model no: CPX5800H)

o

Microcentrifuge (e.g. Eppendorf Refrigerated Microcentrifuge 5417R,
Eppendorf, Hamburg, Germany)

o

Scoopula (made from a cut 1-mL pipette tip)39

o

½ mL, 27G x ½” tuberculin syringe (e.g. BD, Franklin Lakes, NJ, cat no:
305620)

o

½ mL, 28G x ½” insulin syringe (e.g. BD, Franklin Lakes, NJ, cat no:
329420)
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•

In vivo rat surgery set-up58,59
o

Rat ventilator with isoflurane (Isoflurane VIP 3000 Vaporizer, Midmark
Co, Dayton, OH; Anesthesia workstation, Halowell EMC, Pittsfield, MA,
cat no: 000A5653)

o

Endotracheal tube: 16G x 2” IV catheter (Terumo, Tokyo, Japan, Surflo IV
Catheter)

o

Electrical clippers/shaver (Wahl Clipper Co, Sterling, IL)

o

45° Angled Potts scissors (Teleflex, Wayne, PA, Pilling 35-2166 N22)

o

Blunt-tip scissors (Integra Miltex, York, PA, cat no: 5-SC-16)

o

Blunt-tip forceps (Integra Miltex, York, PA, cat no: 6-30)

o

Weitlaner retractor (Fine Science Tools, Foster City, CA, cat no: 1701211)

o

Sutures (Medtronic, Fridley, MN, ligation: SurgiProTM II 7-0 VPF-702-X,
closing: SurgiProTM II 4-0 VP-583-X)

o

Sterile gauze (Fisher Scientific, Waltham, MA, cat no: 22-362-178)

3.6.2. PROCEDURE
Overview
•

Step 1: Hydrogel preparation and syringe loading

•

Step 2: Anesthesia

•

Step 3: Infarct induction

•

Step 4: Syringe inspection

•

Step 5: Syringe priming

•

Step 6: Stay suture placement

•

Step 7: Needle insertion

•

Step 8: Hydrogel extrusion

•

Step 9: Needle withdrawal

Step 1. Hydrogel preparation and syringe loading (2 hours)
Polymers should be sterilized under germicidal UV irradiation for at minimum 30
minutes and subsequently dissolved in sterile PBS solution and loaded into syringes as
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previously described.39 Cells or therapeutics that are to be encapsulated should be
included at this step. Hydrogels should be kept on ice if biologics are included.
Depending on the hydrogel properties, 50-100µL can be injected in 20µL increments
(Figure 3.19a). Hydrogels are usually prepared for a single rat in a ½ mL, ½”, 27G or
28G insulin or tuberculin syringe. Separate hydrogels should be made for each animal
due to concerns for sterility and cross-contamination.

Figure 3.19. Intramyocardial hydrogel injections in rat MI models. (a) Schematic of
ligation and injection sites rat MI models. A representative rat model uses 5 x 20 µL
injections circumferentially around the infarct. (b) Technique for localizing gel to infarct
border zone, where needle is angled and inserted into the infarct as parallel as possible
to the tissue. With the bevel pointing upward toward the epicardium, the hydrogel
remains in constant view of the operator. (c) Schematic of injection sites and direction of
arrow insertion in a radial pattern for targeting of the border zone in a rat infarct model.
(d) Injection of HA hydrogel into a rat heart, demonstrating needle angling, stay suture
placement, heart elevation from the thoracic cavity, and hydrogel localization.
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Step 2. Anesthesia (5 minutes)
A method of anesthesia should be selected in accordance with animal health and
safety protocols. In our animal models, rats are anesthetized under 1-3% isoflurane,
intubated with an endotracheal tube, and maintained under 1-3% isoflurane and positive
pressure ventilation.
Step 3. Infarct induction (5 minutes)
The animal should be placed in right lateral recumbency. Shave the left anterior
and lateral thorax and disinfect with iodine. Incise the skin and subcutaneous tissues
with heavy scissors to expose the ribcage. The thoracic cavity should be entered
between the 4th and 5th ribs in the 4th intercostal space. Using the forceps to grab the 4th
rib, elevate the ribcage to provide room between the chest wall and underlying heart and
lungs and carefully insert one blade of the Potts scissor, taking care not to injure the
intrathoracic structures. Extend your incision to provide adequate exposure to the heart.
Place your retractors between the cut ribs and spread carefully to achieve visualization
of the target organ. Using blunt forceps, lift the pericardium off the surface of the heart
and cut a generous window into the tissue using blunt-tip scissors.58 Using anatomic
landmarks, identify the artery of interest and perform a suture ligation of a major arterial
branch in as consistent a manner as possible to ensure relatively reproducible regions of
infarction. This is traditionally done through ligation of the left anterior descending artery,
1-2mm below the level of the left atrial appendage (Figure 3.19a).59
Step 4. Syringe inspection (<1 minute)
Inspect the syringe for damage and air bubbles and ensure that adequate
volumes have been prepared for injection.
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Critical Step: Air bubbles in the hydrogel have the potential to cause
embolization. Thus, routine inspection of syringes for air bubbles and subsequent
centrifugation is necessary.
Step 5. Syringe priming (<1 minute)
Prime the syringe by manually applying pressure until the hydrogel begins to
extrude from the needle. It is important to be familiar with the forces required prior to the
cardiac injection.
Step 6. Stay suture placement (5 minutes)
Using a stay suture or the ligation suture, manually orient the heart so that the
injection site is in clear view of the operator. This may require externalizing the heart
from within the chest cavity, especially for posterior injections that would otherwise be
inaccessible. Use gentle and controlled movements to prevent tearing of the
myocardium and bleeding.
Step 7. Needle insertion (<1 minute)
While stabilizing the heart in the desired position, insert the needle tip either
parallel or as close to parallel to the injection site as possible, avoiding any visible
surface vessels. It may be necessary to introduce a gentle bend in the needle to achieve
the appropriate angle for insertion (0-45 degrees). This step ensures that any
penetration by the needle does not lead to ventricular puncture (Figure 3.19b).
Critical step: Throughout the duration of needle insertion, the needle tip should
remain superficial enough to be visible to the operator through the overlying
myocardium. The bevel should always be inserted face up in clear view of the operator
so that it is apparent when the hydrogel begins to extrude. During the hydrogel injection,
a visible wheal should form at the needle tip. If not visible, the needle has been inserted
too deep and should be repositioned.
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Critical step: To target the border zone, the needle should be inserted into the
infarct and directed radially into the border zone. This improves targeting as the infarct is
akinetic, allowing for easier insertion. This also minimizes any potential damage from the
needle to non-infarcted myocardium (Figure 3.19c).
Step 8. Hydrogel extrusion (<1 minute)
After ensuring that the entire length of the bevel is buried within tissue, inject
slowly with controlled, manual pressure until adequate volumes have been injected. We
recommend one hand be used to stabilize the needle in the heart while the other is used
to inject material. (Figure 3.19d).
Step 9. Needle withdrawal (<1 minute)
After the injection is complete, wait for 1-2 seconds before withdrawing the
needle so that the hydrogel can disperse into the tissue. Withdraw the needle slowly to
prevent material leakage. Manual pressure can be applied after injection also to limit
material leakage.
3.6.3. TROUBLESHOOTING
-

Hydrogel cannot be visualized during injection. The needle is inserted too far
into the tissue, which increases likelihood of ventricular puncture and
embolization. Remove the syringe and re-insert as needed. If bleeding occurs,
apply manual pressure with gauze until bleeding stops.

-

Hydrogel causes excessive bleeding or damage. This is an unlikely scenario
where there has likely been damage to the ventricle caused by needle movement
during placement or injection. To prevent this, it is important that the hand
controlling the syringe be rested on a solid immobile surface to prevent small
movements during needle insertion and injection. A controlled injection using two
hands, one to stabilize the syringe in the heart and one to apply pressure, may
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be necessary for some operators. If this occurs, gentle compression with a dry
gauze will most often achieve hemostasis.
-

Hydrogel leaking from injection sites. This can occur when needles are too
quickly removed following injection or if the hydrogel used has slow healing
properties. To prevent this, slowly withdraw the needle from the injection site 1-2
seconds after the injection is complete. Manual pressure can be applied over the
hydrogel as the needle is withdrawn. Occasionally, this is due to the bevel not
being fully inserted into the tissue during the injection. In this case, re-insert the
needle and ensure that the bevel is fully buried within the tissue. Leaked
hydrogel can be easily wiped away with a gauze pad.

3.6.4. TISSUE PROCESSING AFTER HYDROGEL INJECTION
In addition to assessing functional outcomes of cardiac remodeling after MI, most
studies involve investigating tissue outcomes of cardiac remodeling. These outcomes
are often measured through stains, such as Masson’s Trichrome, to assess collagen
content and scar fraction, as well as immunohistochemistry. All of these outcomes
involve a tissue preservation step, followed by sectioning, and then a staining process.
Due to the weak mechanics and hydrophilicity of hydrogels described in these methods,
typical processing can be challenging. Guest-host hydrogel was injected into ex vivo
porcine cardiac tissue and then, for preservation, was embedded into OCT either via
snap-freezing (Figure 3.20a-c) or via freezing after sucrose infiltration (Figure 3.20d-f).
Tissue was also embedded in paraffin (Figure 3.20g-i). Next, to compare hydrogel and
tissue morphology after tissue preservation, hemotoxylin and eosin (H&E), Masson’s
Trichrome, and Alcian blue stains were performed.
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Figure 3.20. Hydrogel and tissue preservation after embedding, sectioning, and
staining. Ex vivo tissue after being snap-frozen in OCT (a-c), frozen in OCT following
sucrose infiltration (d-f), or embedded in paraffin (g-i). H&E (a, d, g), Masson’s Trichrome
(b, e, h), and Alcian Blue (c, f, i) staining was done to visualize the hydrogel within the
tissue. Scale bar: 200 µm.
Tissue preservation was poorest in snap-frozen OCT samples, and improved in
sucrose infiltration samples. Sucrose infiltration prevents tissue expansion during
freezing, which can help reduce tissue artifacts. However, tissue morphology was most
preserved in paraffin-embedded samples. The same trends followed for hydrogel
morphology. Hydrogel was not observed at all in the snap-frozen OCT samples or
sucrose infiltration samples and was only visible in the paraffin-embedded samples.
Alcian blue was used to confirm the presence of glycosaminoglycans, such as the
hyaluronic acid we would expect from our hydrogel, on our slides.
Since paraffin embedding completely dehydrates the tissue and the hydrogel, it
decreases the likelihood that the hydrogel will be washed away in subsequent staining
steps, even if it is preserved after sectioning. Placing paraffin slides into a 37°C oven for
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15 minutes prior to staining can help completely remove any remaining water beneath
the tissue and the slide, effectively securing the tissue to the slide. However, paraffin
embedding is much more tedious than the other methods. Snap-freezing is the fastest
(only a few hours), followed by sucrose infiltration (3 days), and then paraffin embedding
(4-6 days, depending on tissue size). For paraffin embedding, it is crucial to allow each
of the many solutions to fully diffuse within the tissue, which can take days. Still, we
recommend paraffin-embedding tissue when it is preferred to preserve the hydrogel
within the tissue sections.

3.7 SUMMARY
Injectable hydrogels are useful delivery vehicles and have been used in many
clinical applications to improve cargo retention at the injection site. Using rheology and
injection force measurements to characterize these hydrogels can be helpful to
determine which material formulation is best suited for an application, as long as
considerations are taken to carefully prepare hydrogel samples for accuracy and
reproducibility. However, it can be difficult to definitively establish minimum or maximum
values for viscosity or storage and loss modulus, for example, that will render the
hydrogel to be injectable, since those values will vary depending on the shear forces
applied. While it may be easier to define clinically relevant limits for injection force, every
clinician will handle these hydrogels differently and the maximum amount of force a
clinician can apply will depend also on the ergonomics of the syringe.
The effects of hydrogel material formulation and flow properties on therapeutic
cargo, such as cells, is also important to consider and techniques described here can be
used to engineer hydrogels for high cell viability after injection. In our case, a low
material concentration (5 wt%) guest-host hydrogel was most protective to cells after
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injection, and this material formulation will be used in subsequent aims to deliver cells
and other cell-derived factors.
For delivery in vivo, special care must be taken both to avoid damage to healthy
native tissue during injection and to retain the hydrogel in the delivery site. These
considerations are especially important for cardiac delivery, where mechanical forces
can make it difficult to control injection and to localize the hydrogel where desired. We
describe techniques here that can be used for cardiac delivery in rat animal models, as
well as considerations for tissue post-processing if hydrogel visualization is desired.
Paraffin embedding of tissues, although time-intensive, best preserves hydrogel
morphology by removing water which can make the hydrogel susceptible to washing
during staining.
In conclusion, we describe here quantitative in vitro techniques for characterizing
injectable hydrogels. These techniques can be valuable for exploring the capabilities of
an injectable hydrogel or comparing formulations of the same hydrogel prior to in vivo
studies. We also describe here technical methods for in vivo delivery to the heart in rats.
The techniques described in this paper can also be applied to the delivery of injectable
hydrogels in other clinical applications, as well as for the evaluation of injectable
hydrogels as printing bioinks.
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CHAPTER 4
INJECTABLE HYDROGELS FOR ENDOTHELIAL PROGENITOR CELL DELIVERY
TO THE HEART

Adapted from:
1. Gaffey, A. C., Chen, M. H., et al. Injectable shear-thinning hydrogels used to
deliver endothelial progenitor cells, enhance cell engraftment, and improve
ischemic myocardium. Journal of Thoracic and Cardiovascular Surgery 150,
1268-1276 (2015).
2. Gaffey, A. C., Chen, M. H., Delivery of progenitor cells with injectable shearthinning hydrogel maintains geometry and normalizes strain to stabilize cardiac
function after ischemia. Journal of Thoracic and Cardiovascular Surgery 157,
1479-1490 (2019).

4.1 INTRODUCTION
Ischemic heart failure is a major global health concern. Within the United States,
a myocardial infarction (MI) occurs every 34 seconds1, and current therapies for heart
failure, including both medical and surgical treatments, are merely palliative and only
result in slight improvements in length and quality of life. Overall, there has been a
reduction in mortality from acute MI, but treatment strategies for those patients who
develop ventricular dysfunction are still lacking. As a result, the number of patients who
progress to heart failure has not improved, and both the incidence and prevalence of
heart failure have increased.2–5
Cell-based therapies for treating ischemic myocardium are emerging as a
treatment option for this ever-growing public health challenge. To date, numerous cell
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types have been used in experimental models, including fetal myocytes, embryonic stem
cell–derived myocytes, skeletal myoblasts, endothelial progenitor cells (EPCs), and
mesenchymal stem cells.6–9 Our lab and others have demonstrated that EPCs are easily
expanded in vitro and have the ability to engraft, improve cardiac function, and
attenuate ventricular remodeling when delivered after MI.10–14
Therapy with EPCs involves postnatal vasculogenesis that can be used to
revascularize the ischemic myocardium. EPCs are pluripotent, bone marrow–derived
stem cells with the ability to differentiate into de novo vasculature.15 Initial work was
focused on cytokine therapies to locally recruit EPCs to the ischemic myocardium,
because EPCs are known to promote vasculogenesis.12 Unfortunately, translatable
outcomes were marginal at best. Further studies were focused on directly delivering
syngeneic EPCs locally to the infarcted myocardium.6,16,17 Both small and large animal
studies showed significant vasculogenic responses in ischemic myocardium. However,
the benefit has not been translatable to a sustainable clinical model.
One of the major challenges for the therapeutic application of EPCs has been
optimizing cell delivery, dispersal, and engraftment. After direct cell injection into
the myocardium, <1% of cells are retained, as shown by cell-tracking studies.18–
21

Numerous factors contribute to the poor cell retention, including exposure of the cells

to ischemia and inflammation, mechanical washout of cells from the beating myocardium
and coronary vasculature, and leaking of the cell suspension from the targeted injection
site.22–24 Overall, most cell death occurs within the first few days of cell delivery.
Consequently, a delivery and stabilization mechanism is likely to promote longer cell
retention and engraftment.24
One possible approach involves the use of biomaterials to provide a
surrogate extracellular matrix to localize cells at the delivery site. Hydrogels in particular
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may provide an environment for protection from the insults of inflammation
and ischemia to reduce immediate cell death upon exposure.12,25 Hydrogels are
biocompatible materials that have gained increasing interest, owing to their ability to
enhance cell and biomolecule delivery.26–30
In this chapter, we utilize the injectable guest-host hydrogel described in Chapter
3 of this thesis to deliver EPCs to the ischemic myocardium. This hydrogel was designed
to be shear-thinning to allow for flow through a syringe upon the application of force and
also rapidly self-healing to quickly reassemble at the injection site.30 Hydrogel properties
were tuned for high cell viability after injection31,32 and cell release through gel
degradation.31 This injectable hydrogel is based on hyaluronic acid (HA) and assembles
by the guest-host interactions of adamantane-modified HA (guest-macromer; Ad-HA)
and β-cyclodextrin–modified HA (host-macromer; CD-HA).30
As a biomaterial, HA is particularly attractive because it is found abundantly in
tissues and used in biomedical applications.31 For EPC delivery and cardiac repair, HA
has been shown to interact with EPCs via membrane protein CD4433–35 and to stimulate
angiogenesis in vivo in necrotic tissue.36 Furthermore, derivatives of adamantane are
used in pharmaceuticals, and cyclodextrans are recognized by the US Food and Drug
Administration as safe and approved for use in pharmaceuticals, cosmetic products, and
food products.30 We have chosen to use EPCs for this study because they are readily
available, highly vasculogenic, and have demonstrated clinical potential. We hypothesize
that, compared to the delivery of EPCs in saline, the delivery of EPCs with injectable
hydrogel will increase cell retention within the ischemic myocardium and lead to
robust vasculogenesis, minimization of adverse ventricular remodeling, and improved
ventricular function after MI.
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4.2 METHODS
4.2.1. ANIMAL CARE AND BIOSAFETY
Adult male Wistar rats (250-300 g) were obtained from Charles River
Laboratories, Inc. Food and water were provided ad libitum. This investigation adheres
to the National Institutes of Health guidelines on animal care and use, conforms to
institutional ethical review, and has been approved by the University of Pennsylvania
Institutional Animal Care and Use Committee (Protocol 803394). All measurements were
performed by 2 independent investigators blinded to animal treatment conditions.
4.2.2. ENDOTHELIAL PROGENITOR CELLS
EPCs were isolated from the long bones of syngeneic adult male Wistar rats by
density-gradient centrifugation (Histopaque-1083; Sigma-Aldrich). After isolation, EPCs
were seeded on vitronectin-coated plates and cultured in endothelial cell basal medium
supplemented with fetal bovine serum, human epidermal growth factor, vascular
endothelial growth factor, human fibroblast growth factor-B, R3-insulin-like growth factor,
ascorbic acid, gentamicin, and amphotericin-B for 6 days (Lonza). The EPC phenotype
(DiLDL+VEGFR2+CD34+) was previously confirmed by our group.10,37
4.2.3. HYDROGEL FORMATION AND CELL ENCAPSULATION
All chemicals were purchased from Sigma-Aldrich unless otherwise noted.
Protocols for hydrogel formation (Chapter 3.2) and cell encapsulation (Chapter 3.5) are
described in detail in earlier chapters of this thesis. Briefly, sodium hyaluronate (HA, 90
kDa) was purchased from Lifecore Biomedical LLC and dissolved in deionized water at 2
wt%,

exchanged

against

Dowex-100

resin,

neutralized

by tetrabutylammonium hydroxide (TBA), frozen, and lyophilized to form HA-TBA.
Adamantane-modified HA (Ad-HA) was prepared by coupling 1-adamantane acetic
acid to HA-TBA via esterification.30 b-cyclodextrin (CD) was first reacted to add
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a hexane diamine linker to form β-CD-hexane diamine, which was coupled via amidation
to HA-TBA to form β-cyclodextrin–modified HA (CD-HA) (Figure 4.1).

Figure 4.1. Overview of hydrogel composition. Illustration of hydrogel containing
EPCs (left) and schematic of hydrogel formation (right), utilizing guest-host complex of βcyclodextrin (CD, host) and adamantane (Ad, guest) for initial self-assembly, as well as
subsequent injection and self-healing in situ. EPC: endothelial progenitor cell.
Percent modification of the HA backbone by adamantane (26%) or β-CD (21%)
was confirmed by NMR. Hydrogels of 4 wt% total polymer concentration were
subsequently prepared from stock solutions of Ad-HA and CD-HA in phosphate buffered
saline. This hydrogel fomulation was tested in a pilot study of the native heart to ensure
optimal gel dose and tensile properties. To ensure a guest-host assembly mechanism,
the two component solutions were combined and mixed manually by stirring to ensure a
homogeneous structure, which was briefly vortexed to remove entrapped air. For
incorporation of EPCs, the cells were trypsinized and counted before being mixed into
the hydrogel at a cell density of 700,000 cells per 100 μL of hydrogel. This cellular
density has been previously used by our group and has demonstrated improvements in
vasculogenesis.12
For EPC viability after hydrogel encapsulation, the gel + EPC construct was
cultured in vitro in agarose wells to allow for ease in handling. Immediately after EPC
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encapsulation, Live/Dead staining (calcein AM/ethidium homodimer-1, Thermo Fisher
Scientific) was used to visualize EPC viability. Samples were imaged using confocal
microscopy and cell viability was quantified using CellProfiler.
4.2.4. RAT MI MODEL
The animal model used here was described in Chapter 3.6 of this thesis. Briefly,
adult male Wistar rats (∼300 g) were anesthetized with 3% isoflurane in an induction
chamber (Vetequip, Inc), endotracheally intubated, and mechanically ventilated (Harvard
Apparatus Regenerative Technology) with 1% isoflurane. A left lateral thoracotomy in
the fourth intercostal space was performed. The proximal left anterior descending (LAD)
coronary artery was identified approximately 2 mm below the left atrial appendage, and
a 7-0 polypropylene (Prolene; Ethicon, Inc) suture was placed around the artery and the
surrounding myocardium. Regional left ventricular ischemia was induced and confirmed
by discoloration of the myocardium and by changes in cardiac rhythm. The ligation
induced a consistent and reproducible anterolateral infarction of 35% to 40% of the left
ventricle.10,38–41 The mortality rate after infarct induction was 18%.
After infarct induction, animals were randomized to 1 of 4 treatment groups:
saline (100 μL of phosphate buffered saline), EPC (700,000 EPCs in 100 μL of
phosphate buffered saline), gel (100 μl of injectable hydrogel), or gel + EPC (700,000
EPCs in 100 μl of injectable hydrogel). All treatment groups were injected using a
straight 27G needle intramyocardially in 5 x 20 μL injections along the anterior and
posterior left ventricular wall in the border zone of the infarct. After injection, the exposed
heart was monitored for 2 to 5 minutes for stability and return to sinus rhythm. The chest
was closed in 3 layers with a 3-0 polypropylene suture and the animals were allowed to
recover. Four weeks after MI, hemodynamic analysis was conducted, and the animals
were sacrificed for histologic analysis.
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4.2.4.1. CELL ENGRAFTMENT AND RETENTION
For fluorescent EPC tracking, EPCs were transduced with enhanced green
fluorescent protein from Baculovirus vector (enhanced green fluorescent protein+
CellLight Reagents BacMam 2.0, Life Technologies). The BacMam 2.0 reagent was
added directly to the cells, with approximately 90% transduction efficiency at 24 hours.
Transduced EPCs were delivered either in saline or encapsulated in the injectable
hydrogel and injected into the ischemic myocardium after MI. At specified timepoints, the
hearts were explanted, flushed with phosphate buffered saline, and distended with
optimal cutting temperature embedding compound (Electron Microscopy Sciences).
Hearts were sectioned along the short axis of the myocardium using a cryostat. Nuclei
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc).
Samples were imaged at 20x on a Leica DM IL LED fluorescent microscope and
analyzed using LAS AF 3.2 (Leica Microsystems Inc). Quantitative analysis was
performed in the peri-infarct border zone, which was defined as 1 microscopic field from
the infarct.
For ex vivo imaging, EPCs were labeled with CellVue NIR815 (LI-COR), which is
an aliphatic near-infrared dye that stably incorporates into the cell membrane lipid bilayer
without disrupting cell viability or function. EPCs were labeled immediately before
injection using an iso-osmotic aqueous diluent with 2 µM CellVue NIR815 dye. A trypan
blue viability test of cells post-labeling confirmed the non-toxic properties of the dye.
Labeled EPCs were delivered either in saline or encapsulated in the injectable hydrogel
and injected into the ischemic myocardium after MI, then visualized at indicated
timepoints using the LI-COR Pearl Small Animal Imaging System.
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4.2.4.2. ANALYSIS OF GLOBAL VENTRICULAR FUNCTION
After

4

weeks, transthoracic

echocardiography was

performed

to

assess myocardial function via ejection fraction (Sonos 5500 revD system with S12
probe, 12 mHz, 2 cm penetration depth, Philips Healthcare). Technicians were blinded to
study conditions. Ventricular measurements were performed according to the American
Society of Echocardiography leading-edge method. Then, a pressure-volume catheter
(Millar Instruments, Inc.) was inserted into the left ventricle in a retrograde fashion via
the right common carotid artery for analysis of ventricular function. In addition to steadystate hemodynamic parameters (maximum pressure, dP/dt max), contractility was
determined from pressure-volume relationships obtained by reducing preload via
occlusion of the inferior vena cava. Finally, a sternotomy was performed and a 2.5-mm
ascending aortic flow probe (Transonic Systems, Inc) was placed for Doppler analysis of
cardiac output.
4.2.4.3. ANALYSIS OF MYOCARDIAL FIBROSIS
At 4 weeks after analysis of global ventricular function, hearts were explanted,
flushed with phosphate buffered saline, and distended with optimal cutting temperature
embedding compound (OCT, Tissue-Tek, Sakura Finetek USA, Inc). Hearts were frozen
in OCT at −80°C. Sections (10 μm thick) were prepared from each heart using a cryostat
to section along the short axis of the myocardium. Sections at the mid-papillary level
were stained with Masson's trichrome (Accustain Trichrome Stains Kit) according to
manufacturer instructions. Sections were imaged and analyzed with ImageJ (NIH) to
assess scar fraction.
4.2.4.4. QUANTIFICATION OF MYOCARDIAL VASCULOGENESIS
Sections at the mid-papillary level were washed 3 times in phosphate buffered
saline, fixed in 4% paraformaldehyde for 10 minutes at room temperature, and blocked
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with 10% fetal bovine serum (Gibco BRL, Life Technologies, Inc) for 1 hour at 37°C.
Primary antibodies were diluted at a ratio of 1:150 in phosphate buffered saline and
incubated for 2 hours at 37°C. Secondary antibodies were diluted at a ratio of 1:200 in
phosphate buffered saline and incubated for 2 hours at 37°C. Primary antibodies
included sheep anti–von Willebrand factor conjugated to fluorescein isothiocyanate and
rabbit anti–smooth muscle actin (ab8822 and ab5694, respectively; Abcam). Donkey
anti-rabbit conjugated to Alexa Fluor 594 (ab150068, Abcam) was used as a secondary
antibody. Nuclei were stained with DAPI. Samples were imaged at 20x on a Leica DM IL
LED fluorescent microscope and analyzed using ImageJ (NIH). Vascularization was
quantified in the peri-infarct border zone, which was defined as 1 microscopic field from
the infarct.
4.2.5. STATISTICAL ANALYSIS
Quantitative data are expressed as mean ± standard deviation (SD) unless
otherwise noted. Statistical significance was evaluated using either an unpaired twosample Student’s t-test with unequal variance or a one-way ANOVA with Bonferroni
correction for multiple comparisons. All analyses were performed using Stata 13.1 (Stata
Corporation).

4.3 RESULTS
4.3.1. CELL VIABILITY AFTER HYDROGEL ENCAPSULATION
The injectable hydrogel formulation used in this study was previously
investigated for high cell viability after encapsulation and injection and these studies
were described in Chapter 3.5 of this thesis. As confirmation, confocal microscopy of
EPCs in injectable hydrogel stained with Live/Dead showed high viability (98.6%) of
EPCs immediately after encapsulation, which confirms that EPCs were viable prior to
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delivery with the injectable hydrogel (Figure 4.2), which validates the use of this
injectable hydrogel as a delivery vehicle for EPCs.

Figure 4.2. EPC viability after injectable hydrogel encapsulation. Confocal
microscopy of EPCs (live: calcein, green and dead: ethidium, red staining) confirmed
high viability (98.6%) after injectable hydrogel encapsulation. Scale bar: 200 μm.
Adapted from Loebel, et al.42
4.3.2. ENDOTHELIAL PROGENITOR CELL ENGRAFTMENT
The engraftment of eGFP-transduced EPCs in the myocardium after MI was
evaluated using immunofluorescence microscopy. EPCs were delivered either in saline
or with injectable hydrogel. After 48 hours, the number of EPCs detected was
significantly greater after delivery with injectable hydrogel (11.3 ± 4.1 cells per HPF,
n = 4) compared to delivery in saline (3.2 ± 1.8 cells per HPF, n=4; P < .0001) (Figure
4.3) and it was noted during sectioning that the injectable hydrogel was still visible in the
myocardium. After 1 week, there was still a significantly larger number of EPCs detected
after delivery with injectable hydrogel (17.2 ± 0.8 cells per HPF, n=4) than after delivery
in saline (3.5 cells ± 1.3 cells per HPF, n=4; P = .0002), although the injectable hydrogel
was no longer easily visible in sectioned tissue. Overall, this demonstrates a significant
increase in EPC retention when delivered with injectable hydrogel compared with direct
cell injections in saline.
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Figure 4.3. EPC engraftment after 48 hours. Fluorescence imaging of eGFPtransduced EPCs (green) after delivery (a) with saline or (b) with injectable hydrogel.
Sections were stained for nuclei (DAPI, blue). EPC: endothelial progenitor cell; scale
bar: 50 µm.
4.3.3. BIOLUMINESCENT TRACKING OF DELIVERED EPCS
The retention of NIR815–labeled EPCs was investigated after injection at the
heart apex after MI either alone (EPC) or when encapsulated in the hydrogel (Gel +
EPC) (Figure 4.4). After 24 hours, cells are observed within the targeted myocardium for
both groups. However, after 14 days, cells injected alone were sparse, whereas cells
delivered with the injectable hydrogel remained within the myocardium. Generally, there
was a reduction of cells within 24 hours after injection alone and lower cell numbers at
all observed time points when compared to injection with hydrogel.

Figure 4.4. EPC tracking over time. Fluorescently NIR815 tagged EPCs apical view
(border zone and ischemic myocardium) from day of surgery to 14 days after MI
comparing gel + EPC delivery with EPC alone delivery. EPC: endothelial progenitor cell;
scale bar: 1 cm.
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4.3.4. IMPROVEMENT OF MYOCARDIAL FUNCTION
After 4 weeks, hemodynamic analysis demonstrated a statistically significant
improvement in left ventricular ejection fraction, cardiac output, maximum pressure,
dP/dt max, and contractility generated pressure for the Gel + EPC group compared with
the EPC group (Figure 4.5, Table 4.1), indicating that the delivery of EPCs with
injectable hydrogel was able to significantly improve cardiac function compared to the
delivery of EPCs alone in saline. The improvement in ejection fraction was statistically
significant for all treatment groups (EPC, Gel, and Gel + EPC), compared with the saline
control, but the greatest improvement was noted in Gel + EPC group. There was no
significant difference in ejection fraction between the EPC and Gel groups, but the Gel +
EPC group had a significantly higher ejection fraction than the Gel group. While the Gel
+ EPC group had the most improved cardiac function compared to the saline control,
there were improvements to cardiac function observed for the EPC and Gel groups also.
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Figure 4.5. Ejection fraction. Plot and table of left ventricular ejection fraction (EF) as
measured by echocardiography after delivery of saline, EPC, gel, or gel + EPC to the
heart after MI. Mean ± SD; EPC: endothelial progenitor cell.
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Table 4.1. Left ventricular function.
Group

Saline

EPC

Gel

Gel + EPC

(n = 8)

(n = 10)

(n = 13)

(n = 10)

Cardiac output (mL/min)

16.3 ± 4.1

28.3 ± 5.2

24.8 ± 2.1
(P = .005)

46.8 ± 7.0
(P < .00001)

Maximum pressure
(mmHg)

50.8 ± 6.7

74.3 ± 5.6

96.2 ± 7.7
(P < .00001)

98.7 ± 17.0
(P < .00001)

dP/dt max (mmHg/s)

2037 ± 89.2

2496 ± 65.6 2547.3 ± 248.1 5812.1 ± 237.3
(P = .52)
(P < .00001)

Contractility (μL/mmHg)

1.2 ± 0.2

1.5 ± 0.08

2.2 ± 0.1
(P = .003)

2.8 ± 0.1
(P = .004)

Mean ± SD; P values are in relation to EPC treatment; EPC: endothelial progenitor cell.

4.3.5. MINIMIZATION OF MYOCARDIAL FIBROSIS
After 4 weeks, a significant reduction of myocardial fibrosis and ventricular scar
fraction was observed for the Gel + EPC treatment group compared to all other
treatment groups (Figure 4.6a-b), indicating that the delivery of EPCs with injectable
hydrogel significantly improves ventricular remodeling compared to the delivery of EPCs
or gel alone. There was also a significantly lower scar fraction for the EPC group
compared to the saline control. However, the delivery of injectable hydrogel alone
without EPCs did not significantly reduce the scar fraction compared to the delivery of
EPCs or the saline control.
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Figure 4.6. Cardiac remodeling. a) Representative myocardial cross-sectional images
after trichrome staining to delineate scar (blue) and healthy myocardium (red). Scale bar:
5 mm. b) Quantification of scar fraction for each treatment group with significant
differences (p<0.05) in bold. EPC: endothelial progenitor cell.
4.3.6. ENHANCEMENT OF MYOCARDIAL VASCULOGENESIS
After 4 weeks, the presence of vascular structures in the border zone of the
infarct was assessed using histological staining for all treatment groups (Figure 4.7a-h).
Quantification of vascular density demonstrates a statistically significant increase in
vascular structures within the border zone of the ischemic myocardium for the Gel +
EPC group compared to all other treatment groups (Figure 4.7i). Interestingly, there was
no significant improvement in vascular density for the EPC group compared to the saline
group, indicating that enhanced cell retention may be important for the formation of
vascular structures.
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Figure
4.7.
Formation
of
new
vascular
structures.
Representative
immunofluorescence images of vascular structures in the border zone region after
delivery of (a-b) saline, (c-d) EPC, (e-f) gel, or (g-h) gel + EPC and i) quantification of
vascular density. Mean ± SD; ***p<0.001; EPC: endothelial progenitor cell, DAPI: 4′,6diamidino-2-phenylindole; vWF: von Willebrand factor; αSMA: α-smooth muscle actin;
scale bar: 100 μm.

4.4 DISCUSSION
Poor cellular retention is implicated in the failure of cell-based therapies for MI
models. The lack of sustained delivery limits the achievement of clinically significant and
translatable treatment methods.43,44 Much research over the past decade has focused on
bioengineered, chemically modified materials to improve delivery of treatment modalities
(biochemical and cellular) to ultimately preserve left ventricular function.6,45–47
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In the present study, the delivery of EPCs in an injectable hydrogel addresses
the issue of mechanical dispersion of cells delivered to the heart. We have shown high
EPC viability after encapsulation in the injectable hydrogel, and a significant increase in
EPC retention with injectable hydrogel delivery compared with direct EPC injection in
saline using both fluorescent EPC tracking and histological techniques and ex vivo
imaging. Our results are consistent with previous findings that biomaterial delivery
vehicles can enhance cellular retention.25,48–52 Specifically, Liu and colleagues51 reported
a 1.5-fold increase in acute cell retention of adipose-derived mesenchymal stem
cells encapsulated in chitosan/β- glycerophosphate-hydroxyethyl cellulose 24 hours
post-administration compared with cells delivered in saline.51 The use of biomaterials
may improve cell retention at the injection site by reducing cell washout due to
mechanical forces, and the injectable hydrogel used in this study allows for the targeted
delivery of a high concentration of cells to ensure adequate engraftment.
The improved retention of cells led us to assess the implications of increased
retention on ventricular remodeling and function as noted in prior studies.25,51,53–56 Our
in vivo studies demonstrated that the Gel + EPC therapy significantly improved
ventricular function, reduced scar fraction, and increased vascular density compared to
the EPC therapy, showcasing the benefits of improved retention on cardiac repair. The
delivery of EPCs in saline still led to significant improvements in ejection fraction and
scar fraction compared to the saline control, but no change in vascular density, further
highlighting the importance of cell retention for the formation of vascular structures. In
this study, the delivery of gel alone did not lead to significant changes in cardiac
remodeling or vasculature but did significantly increase ejection fraction compared to the
delivery of saline. Prior studies have shown that the delivery of materials alone can help
to maintain left ventricular geometry and preserve cardiac function by limiting adverse
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the myocardium46,47, which could explain the benefits of gel delivery alone.
While EPCs were utilized in this study to improve vasculogenesis, other cell
types or even cell-derived therapies could also be useful for cardiac repair. For instance,
Korf-Klingebiel and colleagues have shown that mesenchymal stem cells release
cytokines, growth factors, and chemokines that are beneficial after MI.57 Future work
could also incorporate a myogenic therapy, or a combination of angiogenic and
myogenic therapies.6,58 In addition to the direct cellular effects of EPCs on the
myocardium, a paracrine influence from the delivery of cells may occur, suggesting that
transplanted cells release soluble factors that help regenerate the heart.57,59,60 This
hypothesis is supported by Gnecchi and colleagues, who demonstrated the ability to
recreate the effects of cell therapy with conditioned media.59 Proposed mechanisms for
paracrine signals include modulation of inflammatory responses, up-regulation of
vasculogenesis, and protection of cardiac cell cycle re-entry.61 Injectable hydrogels could
also be used for the local and sustained delivery of these factors.
Compared with our prior work with a fibrin gel patch12, as well as work by Roche
and colleagues25, one of the benefits of the injectable hydrogel was its ability to target
multiple small infarct areas. While this study still utilized direct intramyocardial injections
and therefore required invasive thoracotomies for delivery, injectable hydrogels could be
designed to be delivered via catheters using a percutaneous approach. In addition, the
injectable hydrogel utilized in this study could be further tuned by adjusting macromer
concentrations, percent modifications, or molar ratios of guest and host groups for
desired material properties, while maintaining injectability and retention at the target
site.30,62 For the delivery of cells or other cargo, rates of gel degradation could also be
designed for a variety of applications and tissue targets. Further studies could also
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investigate the use of hydrogels to alter the hypoxic/ischemic environment of the infarct
to improve cell viability after delivery.

4.5 CONCLUSION
An injectable guest-host HA hydrogel was used as a delivery vehicle for EPCs to
improve EPC retention after delivery to the heart for cardiac repair after MI. The delivery
of EPCs using an injectable hydrogel enhanced cell retention in the border zone of the
ischemic myocardium compared to the delivery of EPCs in saline. In a rat model of MI,
the delivery of EPCs with injectable hydrogel significantly improved cardiac function,
decreased scar fraction, and increased vascular density in the myocardium after 4
weeks compared to the delivery of EPCs in saline, emphasizing the benefits of
enhanced cell retention for cardiac repair. The use of injectable hydrogels as cell
delivery vehicles can help to improve the efficacy of cell therapies for MI for more
effective clinical translation.
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CHAPTER 5
INJECTABLE SUPRAMOLECULAR HYDROGEL/MICROGEL COMPOSITES FOR
THERAPEUTIC DELIVERY

Adapted from:
1. Chen, M. H., et al. Injectable supramolecular hydrogel/microgel composites for
therapeutic delivery. Macromolecular Bioscience. 19 (1), (2018).

5.1 INTRODUCTION
Hydrogels are being developed for a wide range of biomedical applications, due
to the diverse properties that are possible with hydrogel design1. Supramolecular
hydrogels represent a specific class of hydrogels with reversible, non-covalent crosslinks
that permit injectability2–4. Examples of supramolecular chemistry include molecular selfassembly5–8,

host-guest

complexes9–11,

and

mechanically-interlocked

molecular

structures12. Supramolecular hydrogels have been used in a variety of biomedical
applications, including but not limited to imaging13,14, tissue engineering6,15,16, and
therapeutic delivery17,18. The injectable nature of supramolecular hydrogels makes them
particularly attractive for clinical translation since they can be delivered using minimally
invasive approaches.
Strategies for therapeutic delivery from supramolecular hydrogels include the
direct encapsulation of growth factors or cells19–21, which may contain enzymatically or
hydrolytically degradable crosslinks to control release22. Interactions between small
molecules and components of the supramolecular complex can also be used to
sequester cargo and control molecule release23. Additionally, nanoparticles can be
assembled into networks through interactions with polymers to deliver therapeutics24. In
144

this way, molecule release can be controlled through nanoparticle design, allowing for
extended release over direct encapsulation in a hydrogel.
Injectable hydrogels are of particular interest in the treatment of tissue after
myocardial infarction (MI)25,26. Almost 800,000 Americans each year suffer from a heart
attack or MI, which occurs when an occlusion in a coronary artery causes inadequate
blood flow to the heart27. Depending on the severity of MI, adverse remodeling can lead
to significant decreases in cardiovascular function and heart failure (HF)28. HF affects
almost 5.7 million Americans and has a 50% mortality rate within 5 years29. Current
medical and surgical treatments aim to improve the quality and length of life for patients
with HF, but are primarily targeted to the tissue after remodeling. Thus, a clinical need
exists to develop a therapy for ischemic MI that can attenuate remodeling and resulting
tissue damage.
Numerous hydrogel therapies have been developed that can improve tissue
properties after infarction30,31. In some cases, the hydrogel is used to directly thicken the
ventricle wall in approaches that have been evaluated in preclinical studies and in US
clinical trials32,33. According to the Law of Laplace, wall thickness is inversely
proportional to wall stress, so thickening the left ventricle wall leads to reduced wall
stress, preventing further wall thinning and ventricular dilation which can lead to
decreased cardiac function34,35.

In other approaches, hydrogels are used to deliver

therapeutics (e.g. cells, drugs) to the tissue for a local and sustained response, with
targets that include improved vascularization20,36,37 and cardiomyocyte proliferation38.
Specifically, shear-thinning hydrogels have been introduced alone and for therapeutic
delivery to the heart, through direct injections from syringes to percutaneous delivery
from catheters26,35,39.
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To utilize the benefits of supramolecular hydrogels for injectability and retention
and to decouple the delivery of encapsulated therapeutics from the supramolecular
hydrogel design, we demonstrate here the development and application of an injectable
supramolecular hydrogel/microgel composite for localized and sustained therapeutic
delivery.

The supramolecular hydrogel is based on our previous work in which

hyaluronic acid (HA) is modified separately with adamantane (guest) and ß-cyclodextrin
(host) to form an injectable supramolecular hydrogel upon mixing11 and the microgels
are fabricated from covalently-crosslinked HA hydrogels using a high-throughput
microfluidic device40. As a model therapeutic, we chose to deliver interleukin-10 (IL-10),
an anti-inflammatory cytokine41,42 to address excessive inflammation that can cause
extensive damage to the myocardium after MI42. Although shown here to treat MI, such a
composite hydrogel/microgel system could be used for the delivery of a wide range of
therapeutics to treat numerous clinical indications.

5.2 EXPERIMENTAL SECTION
5.2.1. MATERIALS
All chemicals were purchased from Sigma-Aldrich unless otherwise noted.
5.2.2. MATERIAL SYNTHESIS
5.2.2.1. HA-TBA, AdHA, and CDHA
HA-TBA, adamantane-modified HA (AdHA), and ß-cyclodextrin-modified HA
(CDHA) were synthesized as previously described11. For HA-TBA, sodium hyaluronic
acid (HA, 74 kDa, Lifecore) was dissolved at 2% w/v in DI water and exchanged with
Dowex 50W x 200 resin (3 g resin/1 g HA) for 2 hours at room temperature. The resin
was filtered and then the solution was titrated to pH 7 with tetrabutylammonium
hydroxide, frozen, and lyophilized.
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For AdHA synthesis, HA-TBA was coupled to 1-adamantane acetic acid (Acros
Organics) in the presence of di-tert-butyl dicarbonate and 4-methylaminopyridine in
anhydrous dimethyl sulfoxide (DMSO) under nitrogen for 20 hours at 45°C. Reaction
products were dialyzed for 2 weeks in DI water, filtered, frozen, and lyophilized.
Functionalization of HA by adamantane was approximately 20% as quantified via 1H
NMR (Figure 5.1A).

Figure 5.1. NMR Spectra. 1H-NMR of A) Ad20HA, B) CD20HA, and C) Nor30HA.
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For fluorescent labeling, a standard solid phase peptide synthesizer (PS3, Gyros
Protein Technologies) with glycinol 2-chlorotrityl resin was used to synthesize
fluorescent peptides GCDDD-rhodamine B (for gel labeling) or GCDDD-5(6)carboxyfluorescein (for microgel labeling). Peptides were cleaved from the resin using a
solution of 95% trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% water, precipitated
twice in cold diethyl ether, dissolved in water, frozen, and lyophilized before use. Peptide
synthesis was confirmed using MALDI-TOF mass spectrometry. For gel visualization,
AdHA was methacrylated (15% modification) via esterification with methacrylic
anhydride (1 mL/1 g AdHA) at pH 8.5 for 3 hours, dialyzed for 3 days in DI water,
filtered, frozen, and lyophilized to form AdMeHA. AdMeHA was dissolved at 2 mg/mL in
triethanolamine buffer (0.2 M in PBS, pH 10) and reacted with fluorescent peptide
(GCDDD-rhodamine B, 0.015 mol eq) for 2 hours at 4°C. Reaction products were
dialyzed for 4 days at 4°C, frozen, and lyophilized to form AdMeHA-Rho.
For CDHA synthesis, ß-cyclodextrin (ß-CD) was conjugated with a hexane
diamine linker to form ß-CD-HDA as previously described11. HA-TBA was coupled with
ß-CD-HDA in the presence of benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium
hexafluorophosphate (BOP) in anhydrous DMSO under nitrogen for 3 hours at room
temperature. The reaction was quenched with cold DI water, dialyzed in the presence of
NaCl for 3 days, dialyzed in DI water for 5 days, filtered, frozen, and lyophilized.
Functionalization of HA by ß-cyclodextrin was approximately 20% as quantified via 1H
NMR (Figure 5.1B).
5.2.2.2. NorHA
Norbornene-modified HA (NorHA) was synthesized as previously described43.
Briefly, HA-TBA was coupled with 5-norbornene-2-methylamine (TCI Chemicals) in the
presence of BOP in anhydrous DMSO under nitrogen for 2 hours at room temperature.
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The reaction was quenched with cold DI water, dialyzed in the presence of NaCl for 3
days, dialyzed in DI water for 5-7 days, filtered, frozen, and lyophilized. Functionalization
of HA by norbornene was approximately 30% as quantified via 1H NMR (Figure 5.1C).
5.2.2.3. HepSH
Thiolated heparin (HepSH) was synthesized based on previously described
reports44,45. Briefly, heparin (5 mg/mL) was dissolved in DI water and reacted with
cystamine-dihydrochloride (30 mol/mol heparin) in the presence of 1-ethyl-3-(3dimethylaminopropyl)carbodiimide-HCl

(EDC,

20

mol/mol

heparin)

and

1-

hydroxybenzotriazole hydrate (HOBt, 20 mol/mol heparin) at pH 6.8 for 5 hours at room
temperature. Reaction products were purified by dialysis for 3 days, frozen, and
lyophilized, then re-reacted with tris (2-carboxyeethyl) phosphine-HCl (TCEP, 10
mol/mol heparin) to reduce oxidized disulfide groups at pH 7.5 for 3 hours at room
temperature. After 3 hours, the pH was adjusted to 5.0 with 1.0 N HCl and the solution
was dialyzed against dilute HCl (pH 3-3.5) with 100 mM NaCl for 3 days at 4ºC and then
without NaCl for an additional 4 days at 4ºC. Reaction solution was aliquoted into 1.5 mL
tubes, frozen, and lyophilized overnight. Percent conjugation of thiol groups to heparin
was determined to be approximately 45% via Ellman assay.
5.2.3. MICROGEL FORMATION AND CHARACTERIZATION
5.2.3.1. Microgel Formation
Microgels were formed via water-in-oil emulsion using a microfluidic device with
parallel flow-focusing particle generators as previously described40,46. The aqueous
phase (1 mL) consisted of NorHA (30 mg, 3% w/v), thiol crosslinker (pentaerythritol
tetrakis(mercaptoacetate), PETMA, TCI Chemicals or 1,4-dithiothreitol (DTT)) at 0.95
mol thiol per 1 mol norbornene, Irgacure-2959 (I2959, 0.05% w/v), HepSH (0.05 mol
thiol per 1 mol norbornene), and (if indicated) rat IL-10 (R&D Systems, 12 µg) and was
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attached to an in-line 0.22 µm filter with a flow rate of 0.6 mL/hr. For visualization
purposes, if indicated, fluorescein isothiocyanate-dextran (FITC-dextran, 2 MDa, 1 mg)
or fluorescent peptide (GCDDD-5(6)-carboxyfluorescein, 0.05 mol thiol per 1 mol
norbornene) was incorporated in the aqueous solution. The oil phase consisted of 2%
w/w Span 80 in mineral oil and was filtered using a 0.45 µm filter prior to use at a flow
rate of 3.5 mL/hr. Microgels were crosslinked via UV light (OmniCure Series 1500,
Excelitas, 320-390 nm, 20 mW/cm2) as they flowed out of the device and into a
collection vial. Microgels were washed with water and then isopropanol to remove oil,
dried overnight on vacuum, and stored at -20ºC.
5.2.3.2. IL-10 Encapsulation Efficiency and Zeta Potential
Microgels loaded with IL-10 and crosslinked with PETMA were formed either with
(n=3) or without HepSH (n=3) to determine the effect of heparin on IL-10 sequestration.
Heparin has a high negative charge density that can attract positively charged cytokines
such as IL-10. Following microgel formation, microgels were rehydrated at 1 mg
microgel/1 mL release buffer with hyaluronidase (1 mg/mL). After microgels were fully
degraded at 48 hours, IL-10 content was quantified via ELISA (DuoSet kit, R&D
Systems) and encapsulation efficiency was determined as the ratio of the detected
amount of IL-10 to the expected amount of IL-10.
For zeta potential measurements, solutions of NorHA (1 mg/mL in filtered water,
pH 8) and NorHA with HepSH (0.05 mol thiol per 1 mol norbornene, pH 8) were
prepared and the zeta potential of these microgel precursor solutions was measured
using a Zetasizer Nano ZS90 (Malvern Panalytical) at 25°C.
5.2.3.3. Characterization of Microgel Size, Degradation, and IL-10 Release
To characterize size, microgels were rehydrated in PBS and imaged at 10x using
brightfield microscopy. The straight line tool in ImageJ (NIH) was used to measure
150

microgel diameters (n=22).

For degradation and release quantification, microgels

loaded with IL-10 and crosslinked with either a stable (DTT, n=3) or degradable
(PETMA, n=3) crosslinker were rehydrated in release buffer (1% bovine serum albumin
in PBS) at 1 mg microgel/1 mL release buffer and washed via centrifugation at 1200 x g
for 15 minutes. Release buffer was replaced and collected every other day and stored at
-20ºC. After 2 weeks, microgel samples were fully degraded in hyaluronidase (1 mg/mL).
HA release was determined using an uronic acid assay and IL-10 release was quantified
via ELISA (DuoSet kit, R&D Systems).
5.2.4. COMPOSITE HYDROGEL FORMATION AND CHARACTERIZATION
5.2.4.1. Composite Hydrogel Formation
Bulk guest-host hydrogel (4% w/w, 1 mol Ad: 1 mol CD) and degradable
microgels (low concentration: 6.7 mg/mL bulk hydrogel or high concentration: 13.3
mg/mL bulk hydrogel) were combined to form a composite hydrogel. Guest-host
hydrogel materials (AdHA and CDHA) and microgels were weighed and CDHA was
combined with microgels in the same microcentrifuge tube. Following sterilization with a
germicidal lamp (40 minutes; turn materials at 20 minutes), hydrogel components were
dissolved in sterile PBS. To mix, the AdHA solution was added to the CDHA/microgel
solution with a pipette. For rheology samples, hydrogels were further sonicated at 60ºC
for 10 minutes, vortexed, and centrifuged to promote more homogeneous mixing and to
remove air bubbles. Using a scoopula, the composite hydrogel was loaded either onto
the rheometer or into 27G x ½” insulin syringes (BD) for animal studies.
5.2.4.2. Volume Fraction of Microgels in Composite Hydrogel
Composite hydrogels were prepared as described above using rhodaminelabeled bulk guest-host hydrogel components (AdMeHA-Rho) and fluorescein-labeled
microgels at both low (6.7 mg/mL bulk hydrogel) and high (13.3 mg/mL bulk hydrogel)
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concentrations. Confocal microscopy was used to image the composite hydrogel and the
3D Viewer plugin (ImageJ, NIH) was utilized to create a 3D projection of the composite
hydrogel. For each composite hydrogel image stack, regions of interest were selected
and smoothed and a binary mask was created for each stack using an appropriate
thresholding method in ImageJ. The 3D Objects Counter plugin (ImageJ, NIH) was used
to determine the volume of objects in each image stack, and these volumes were
combined to determine the volume fraction of microgels in the composite hydrogel.
5.2.4.3. Rheological Characterization
Oscillatory shear rheometry was used to characterize the material properties of
the bulk hydrogel alone and of the composite hydrogels with low and high microgel
concentrations. Hydrogels were prepared as described above, and rheometer
experiments were conducted as previously described47 with a flat plate geometry and a
gap size of 600 µm (10 times average microgel diameter). Briefly, time sweep (0.2%
strain, 10 Hz), frequency sweep (0.01 to 100 Hz, 0.2% strain), strain sweep (0.01% to
500% strain, 10 Hz), continuous flow (shear rates from 0 s-1 to 50 s-1 over 2 min 30 sec),
and cyclic strain (low: 0.2% strain, high: 500% strain, 10 Hz) experiments were
completed for all samples (300 µL) at 25°C.
5.2.4.4. IL-10 Release
Composite hydrogels were formed with a high concentration of degradable
microgels (50 µL bulk gel, n=3) and release buffer (1% bovine serum albumin in PBS)
was added at 50 µL bulk gel/1 mL release buffer. Every other day, release buffer was
collected via centrifugation at 1200 x g for 15 minutes, replaced, and stored at -20ºC.
After 2 weeks, composite hydrogels were fully degraded in hyaluronidase (1 mg/mL) and
IL-10 release was quantified via ELISA (DuoSet kit, R&D Systems).

152

5.2.5. RAT MI MODEL
5.2.5.1. Infarct Induction and Hydrogel Injection
Using a previously established protocol, a left lateral thoracotomy in the fourth
intercostal space was performed to allow for ligation of the left anterior descending artery
to induce an infarct of approximately 30% of the left ventricle in a rat20,47. Animals were
randomly assigned to one of three treatment groups: PBS (saline control), without IL-10
(composite hydrogel with high concentration of microgels without IL-10), and with IL-10
(composite hydrogel with high concentration of microgels with IL-10). PBS and
composite hydrogels were loaded into 27G x ½” insulin syringes (BD) and delivered to
the infarct in the border zone region in approximately 5 x 20 µL equally spaced
injections. Animals were recovered and evaluated at either 1 week or 4 week timepoints.
Prior to explant at 4 weeks, cardiac function was assessed using a 12-mm pressurevolume loop catheter (Millar). Following explant at 1 or 4 weeks, hearts were washed in
PBS, and frozen in O.C.T. Compound (Tissue-Tek) at -80ºC. From the apex to above
the papillary muscles, tissue sections of 10 µm thickness were obtained using a cryostat.
Animal procedures were approved by the University of Pennsylvania Institutional Animal
Care and Use Committee.
5.2.5.2. Immune Response
After 1 week, immune response was assessed via immunohistochemical staining
of tissue sections at the mid-papillary level for CD68 (MCA341GA, Bio-Rad, 1:500) with
goat anti-mouse AF647 secondary (ab150115, Abcam, 1:300) and DAPI (D1306,
ThermoFisher Scientific, 1:1000). Images were acquired on a Leica DM5000b
fluorescent microscope using a DFC350 FX monochrome camera. At least 4 images of
the border zone of the infarct, defined as one high-powered field away from the infarct,
were quantified and averaged per animal for one biological replicate.
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CD68 positive area fraction was quantified using ImageJ (NIH). A region of interest was
selected for each image that included the tissue area only and excluded the composite
hydrogel if applicable to assess immune response only in the surrounding tissue.
Composite hydrogel areas were defined by large regions of sparse DAPI staining. A
binary mask was created using the default thresholding method and then the area
fraction of CD68+ staining was measured for each image.
5.2.5.3. Tissue Remodeling
After 4 weeks, tissue remodeling was evaluated by staining tissue sections at the
mid-papillary level with Masson’s Trichrome Stain Kit using manufacturer provided
instructions. Scar fraction was quantified using the freehand line tool in ImageJ (NIH) to
measure the endocardial circumference of the left ventricle, the epicardial circumference
of the left ventricle, the length of the endocardial infarct, and the length of the epicardial
infarct, with “infarct” defined by portions of the left ventricular wall in which at least 50%
of the thickness of the wall is scar. The scar fraction was calculated as follows:
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For scar thickness, the same tool was used to measure the width of 5 evenly spaced
points of the infarct and averaged. At least 2 images were quantified and averaged per
animal for one biological replicate.
5.2.5.4. Vascular Structures
After 4 weeks, vascular structure density and size were assessed via
immunohistochemical staining of tissue sections at the mid-papillary level for von
Willebrand factor (vWF-FITC, ab8822, Abcam, 1:400) and

-smooth muscle actin ( -

SMA-AF594, ab202368, Abcam, 1:400) with wheat germ agglutinin (WGA-AF647,
W32466, ThermoFisher Scientific, 1:300) and DAPI (D1306, ThermoFisher Scientific,
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1:1000). Images were acquired on a Leica DM5000b fluorescent microscope using a
DFC350 FX monochrome camera. At least four images of the border zone of the infarct,
defined as one high-powered field away from WGA-bright scar, were quantified and
averaged per animal to represent one biological replicate.
vWF+ area and vWF+a-SMA+ structure size was determined using ImageJ (NIH).
For vWF+ structures and a-SMA+ structures, a binary mask was created via
thresholding. Thresholded images were processed with the Dilate and Erode functions to
improve connectivity. Particles greater than or equal to 3.5 µm2 in area were counted
and measured. The Otsu auto-thresholding method was used unless 1) the area fraction
of particles counted was greater than 10% or 2) the number of structures counted was
over 200 for vWF+ or 75 for a-SMA+. These cases were empirically determined to be
indications that the Otsu auto-thresholding method was unsatisfactory; in these cases,
the Triangle auto-thresholding method was used instead. For the number and size of
vWF+a-SMA+ structures, the result of using the AND operator in the Image Calculator
function on the binary masks of the vWF and a-SMA channels was counted and
measured using the parameters described above.
5.2.6. STATISTICS
All graphs and statistical analyses were completed using GraphPad Prism 7
software. Outliers were removed using the ROUT test with Q=5% and statistical
significance was determined using a two-tailed Student’s T-test or a one-way ANOVA
with post-hoc Tukey’s multiple comparisons test.

155

5.3 RESULTS AND DISCUSSION
5.3.1. MATERIAL SYNTHESIS AND MICROGEL FABRICATION
A supramolecular hydrogel was first fabricated using guest-host interactions of
modified HA. Separately, HA was modified with adamantane (guest, ~20% modification)
to form AdHA and ß-cyclodextrin (host, ~20% modification) to form CDHA (Figure 5.2A).
AdHA and CDHA components, upon mixing, have been previously shown to assemble
due to hydrophobic interactions to form supramolecular, host-guest complexes that
disassemble upon the application of shear but also rapidly re-assemble to form a stable
hydrogel after injection (Figure 5.2B-C)48. The injectable properties of this hydrogel have
been previously explored47 as injectable hydrogels are particularly attractive for clinical
translation because they can improve the retention of delivered therapeutics and be
delivered using minimally invasive approaches like catheters35. Variations of this bulk
guest-host hydrogel have been previously investigated in our lab to deliver cells20,
exosomes49, small molecules23, growth factors19,21, and RNAs38,50.
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Figure 5.2. Material synthesis. A) Reaction schematics for the synthesis of
adamantane-modified HA (AdHA, ~20% modification), cyclodextrin-modified HA (CDHA,
~20% modification), and norbornene-modified HA (NorHA, ~30% modification). B) AdHA
and CDHA assemble into a hydrogel through guest-host complexes upon mixing that
disassemble upon the application of shear, resulting in an C) injectable guest-host
hydrogel (dyed blue) that can be extruded from a syringe and rapidly self-heals after
injection. D) NorHA crosslinks through a thiol-ene reaction in the presence of a di-thiol
crosslinker, photoinitiator, and UV light and can be processed into E) covalentlycrosslinked NorHA microgels (visualized with encapsulated FITC-dextran).
To form microgels, HA was modified with norbornene groups (~30% modification)
to form NorHA (Figure 5.2A). Norbornenes react to form covalent bonds via thiol-ene
reactions with thiols in the presence of UV light and a photoinitiator (Figure 5.2D)51,
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which can be used to form microgels (Figure 5.2E). There are numerous techniques that
can be used to fabricate covalently-crosslinked microgels, primarily through water-in-oil
emulsion techniques52,53. Here, microgels were fabricated using a recently developed
microfluidic device40 to generate particles that were crosslinked with UV light as they
flowed out of the device and into a collection vial (Figure 5.3A-C). Microgels were
spherical and generally uniform in size with a diameter of 59 ± 7 μm (Figure 5.3D-E).

Figure 5.3. Microgel formation. A) Schematic of high-throughput microfluidic device for
water-in-oil droplet formation and screenshots (scale bars = 100 µm) of droplets B) being
formed and C) flowing through the device. After crosslinking with UV light, microgels
were washed from the oil, dehydrated for storage, and then rehydrated to form relatively
uniform spherical microgels as D) visualized with light microscopy and E) quantified as a
histogram with an average microgel diameter of 59 ± 7 μm (mean ± SD).
To encapsulate a therapeutic, such as IL-10, the therapeutic was simply added to
the aqueous phase during microgel processing. Thiolated heparin, which has a high
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density of negative charge, was also incorporated into the microgels to sequester
positively-charged IL-10 prior to release. When we compared the encapsulation
efficiency, or the ratio of the amount of IL-10 detected to the amount of IL-10 expected,
we found that the encapsulation efficiency of microgels formulated with HepSH (17.3% ±
7.2) was significantly higher than that of microgels formulated without HepSH (2.6% ±
0.3) (Figure 5.4A). The remaining IL-10 could have been lost during the microgel
formation process or during ELISA analysis. The zeta potential of microgel precursor
solutions of NorHA with HepSH (-21.5 ± 1.2 mV) was significantly more negative than
the zeta potential of solutions of NorHA alone (-10.0 ± 1.6 mV) (Figure 5.4B). Thus,
HepSH was deemed important for IL-10 encapsulation and was used in all subsequent
studies.

Figure 5.4. Effect of HepSH. A) Thiolated heparin (HepSH) significantly improves IL-10
retention during microgel formation. The percentage of expected IL-10 detected was
measured via ELISA. The remaining IL-10 not detected was lost either during the
microgel formation process or during the ELISA. B) HepSH significantly reduces the zeta
potential of microgel precursor solutions. (mean ± SD; *p<0.05, **p<0.01, ***p<0.001).
Microgels crosslinked with either a stable (DTT) or hydrolytically degradable
(PETMA) crosslinker were fabricated and assessed for degradation and IL-10 release
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over 2 weeks (Figure 5.5A). The degradable microgels were fully degraded after 2
weeks, while stable microgels were still largely intact (Figure 5.5B). Similar trends were
observed for IL-10 release (Figure 5.5C), with IL-10 completely released within 2 weeks
from the degradable microgels, whereas stable microgels still retained much of their IL10 content. Thus, we observed that microgel stability and the rate of therapeutic delivery
can be tailored by changing the stability of the thiol crosslinker within the microgels. For
more complex growth factor cocktails and delivery profiles, microgels of varying stability
could be combined. For IL-10 delivery in our study, we desired the steady release of IL10 from microgels over a few weeks to match doses from previous IL-10 delivery studies
and to correspond to detected expression patterns of IL-10 in various animal MI models;
thus, for animal studies we selected degradable microgels 54–56.

Figure 5.5. Microgel degradation and IL-10 release. A) Schematic for microgel
degradation and release studies. Microgels were fabricated with either stable (DTT as
crosslinker) or hydrolytically degradable (PETMA as crosslinker) crosslinks, washed, and
incubated in release buffer for up to 14 days. At each sample point, microgels were
centrifuged at 1200 x g for 15 minutes and then releasate was collected for analysis of
HA degradation products and IL-10 release. After 14 days, the microgels were fully
degraded in hyaluronidase for analysis of any remaining uronic acid or IL-10. B) Uronic
acid and C) IL-10 cumulative release over 14 days (mean ± SD).
5.3.2. COMPOSITE FABRICATION AND CHARACTERIZATION
To combine the benefits of injectability from the bulk guest-host hydrogel and the
controlled release of microgels, they were combined to fabricate composites (Figure
5.6A). With this approach, microgels can be designed with differing levels of stability
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and added at different loading amounts and even with mixed compositions to control
release, independent of the design of the bulk guest-host hydrogel. Others have
previously explored the use of nano-scale particles (<1 µm) for drug delivery from
composites24,57; here, we use micro-scale particles and investigate the material
properties of these composite hydrogels to learn more about the network interactions
between the bulk guest-host hydrogel and covalently-crosslinked microgels.
Microgels were combined with the bulk guest-host hydrogel to form a composite
hydrogel at low (6.7 mg microgels/mL bulk hydrogel) or high (13.3 mg microgels/mL bulk
hydrogel) concentrations and characterized through confocal microscopy to visualize
fluorescently labeled microgels (Figure 5.6B). The volume fraction of microgels within
the bulk hydrogel for the low concentration was 0.08 ± 0.02 and for the high
concentration was significantly higher at 0.29 ± 0.05 (Figure 5.6C). This illustrates our
ability to alter the loading of microgels and encapsulated therapeutics. Although there is
no specific interaction intended between the bulk guest-host hydrogel and the
covalently-crosslinked microgels, entanglement of the bulk hydrogel within the covalent
network during encapsulation or non-specific interactions between the b-cyclodextrin
and norbornene groups are possible.

Figure 5.6. Composite hydrogels. A) Schematic of supramolecular hydrogel/microgel
composite, consisting of bulk guest-host hydrogel (purple) with encapsulated microgels
(green). B) 3D projections of microgels (green) in bulk guest-host hydrogels (red) at low
(left, 6.7 mg/mL bulk hydrogel) or high (right, 13.3 mg/mL bulk hydrogel) concentrations.
C) Volume fraction of microgels in the bulk guest-host hydrogel at low and high
concentrations (mean ± SD, n=3, *p<0.05, **p<0.01).
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The material properties of the bulk guest-host hydrogel, the low microgel
composite hydrogel, and the high microgel composite hydrogel were evaluated using
oscillatory shear rheometry. All groups behaved as hydrogels (G’ > G”) (Figure 5.7A)
that were viscoelastic, as indicated by changes in the moduli with variations in frequency
(Figure 5.7B). The high microgel composite hydrogel had the lowest crossover
frequency (~0.1 Hz) and therefore the longest relaxation time, indicating that this
hydrogel flows less than the low microgel composite hydrogel or the bulk guest-host
hydrogel, which had similar crossover frequencies (~2 Hz for bulk hydrogel, ~ 1 Hz for
the low microgel composite hydrogel). The granular nature of the composite hydrogels
and the covalent-crosslinking of the microgels likely contributes to the longer relaxation
times.
All groups behaved rheologically as shear-thinning injectable materials. The
strain sweeps indicated material yielding, or a decline in storage and loss moduli at
particular strains (Figure 5.7C). Interestingly, the composites yielded at lower strains
than the bulk hydrogel, likely due to failure at interfaces between the supramolecular
hydrogel and covalently-crosslinked microgels.

Continuous flow experiments also

showed a decrease in viscosity for all groups with increasing shear rate, indicative of
shear-thinning (Figure 5.7D). Both composite hydrogels showed evidence of shear
banding, a phenomenon in which portions of the hydrogel undergo shear and are
liquidized while other portions of the hydrogel remain solid, allowing the same shear
stress to be achieved at 2 or more shear rates58 (Figure 5.7E). At high strains, the
storage and loss moduli for all groups decreased, but then recovered upon the cessation
of strain, indicative of self-healing (Figure 5.7F).
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Figure 5.7. Rheology of composite hydrogels. Bulk guest-host hydrogels alone (Gel)
or as microgel composites at a low (6.7 mg/mL bulk hydrogel) or high (13.3 mg/mL bulk
hydrogel) microgel concentration characterized using oscillatory shear rheometry,
including: storage (G’, closed symbols) and loss (G’’, open symbols) moduli A) over time
at 0.2% strain and 10 Hz, B) across a range of frequencies at 0.2% strain, C) across a
range of % strains at 10 Hz, D) viscosity with increasing shear rate, E) shear stress with
increasing shear rate, and F) cyclic strains over time (low = 0.2% strain at 10 Hz, high
(shaded) = 500% strain at 10 Hz).
Hydrogels with lower storage and loss moduli (at high strains relevant for
injection), lower yield strain, and lower viscosity are typically easier to inject than
hydrogels with higher storage and loss moduli, higher yield strain, and higher viscosity.
Based on these criteria and observations during handling, the composite hydrogels are
easier to inject than then the bulk guest-host hydrogel. The granular nature of these
composite hydrogels potentially makes them more prone to shear banding59,60, which
also improves injectability. To balance injectability and therapeutic dosage, the high
microgel composite hydrogels were used in animal studies to assess them for use in the
delivery of IL-10.

163

Additionally, we investigated the release of IL-10 from these high microgel
composite hydrogels compared to microgels alone (Figure 5.8). After 2 weeks, only
~15% of the encapsulated IL-10 was released in the composite hydrogels, whereas the
microgels alone were fully degraded at the end of 2 weeks with 100% of the
encapsulated IL-10 released. This suggests that the bulk gel can further modulate IL-10
release, and can be engineered to further tune the release profile of encapsulated
therapeutics. Encapsulation of microgels within the bulk gel also eliminated burst release
effects. However, in vivo and in vitro release kinetics may differ due to the contractile
nature of the heart. For example, in previous studies we have observed that the bulk
hydrogel is 90% eroded at the end of 1 week in vivo, but persists for over 3 weeks in
vitro38. Ultimately, it is necessary to entrap microgels within the bulk hydrogel to improve
localization of the therapy to the injection site and prevent the dispersion of microgels if
delivered alone57.

Figure 5.8. IL-10 release from composite hydrogels. Release of IL-10 from composite
hydrogels with a high concentration of degradable microgels compared to the release of
IL-10 from degradable microgels alone.
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5.3.3. RAT MI MODEL
Following MI, PBS, composites without IL-10, or composites with IL-10 were
injected into the border zone region of the infarct (Figure 5.9A-B). IL-10 is produced by
activated T cells and monocytes after MI41 and reduces inflammation by both mediating
the transition of macrophages from a pro-inflammatory M1 phenotype to an antiinflammatory M2 phenotype61,62 and by downregulating the production of inflammatory
cytokines such as IL-1α, IL-1β, TNF-α, IL-6, IL-8, and IL-12 by monocytes and
macrophages via the STAT3 pathway41,42,63. To better understand the influence of
exogenous IL-10 delivery on treating MI, the immune response was evaluated with
CD68 staining for macrophages after 1 week and remodeling, cardiac function, and
vasculature outcomes were assessed after 4 weeks (Figure 5.9C).

Figure 5.9. Rat MI model. Schematic of the analysis of composite hydrogels in a rat MI
model, including A) injection sites in border zone of MI after LAD ligation, B) treatment
groups of saline control (PBS), composites without IL-10, and composites with IL-10, C)
experimental design timeline showing injection at day 0 and outcome measures after 7
and 28 days.
Representative images of immunohistochemistry for CD68 after 1 week are
shown (Figure 5.10A-F). CD68 is a marker commonly expressed by activated or
inflammatory macrophages, which play a critical role in the acute inflammatory response
after MI, but excess activity can lead to increased tissue damage41,64. CD68 staining
showed the presence of macrophages in the border zone region of the infarct for all
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treatment groups. When quantified, CD68+ area fraction showed that delivery of
composites with IL-10 significantly decreased the presence of CD68+ macrophages
when compared to saline delivery, which indicates that IL-10 delivery can mitigate
inflammation near the injection site (Figure 5.10G). There was a non-statistically
significant decrease in CD68+ staining with the composite releasing IL-10 when
compared to the composite without IL-10.

Figure 5.10. Inflammatory response. A-F) Immunohistochemistry for CD68+ cells (red)
in the border zone and G) quantification of area fraction of cardiac tissue outside of the
composite hydrogel that is CD68+ after delivery of (A, D) PBS (n=4), (B, E) composites
without IL-10 (n=4), or (C, F) composites with IL-10 (n=5). (mean ± SD; *p<0.05).
After 4 weeks, Masson’s trichrome staining was used to visualize scar tissue
after the delivery of saline, composites without IL-10, or composites with IL-10 (Figure
5.11A-C). Notably, HA composite hydrogel/microgel structures were still visible (Figure
5.11D-E), which was confirmed to be glycosaminoglycans (i.e., HA) through Alcian blue
staining (Figure 5.12A-D). Quantification of scar fraction showed no difference among
groups (Figure 5.12E); however, there was increased scar thickness with the delivery of
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composites, and this improvement was significant for the delivery of composites with IL10 compared to saline delivery (Figure 11F).

Figure 5.11. Cardiac remodeling. A-E) Masson’s trichrome staining of cardiac tissue
28 days after delivery of PBS (n=11), composites without IL-10 (n=8), or composites with
IL-10 (n=10) to rat MI. F) Quantification of scar thickness of these same treatment
groups (mean ± SD; *p<0.05).

Figure 5.12. Composite hydrogel in cardiac tissue. A-B) Masson’s trichrome and CD) Alcian blue staining of cardiac tissue 28 days after delivery of composites without IL10 (n=8) or composites with IL-10 (n=10) to rat MI. Quantification of E) scar fraction of
these same treatment groups with PBS control (n=11) (mean ± SD).
Scar thickening in the presence of the composite hydrogels is likely due to them
acting as bulking agents. Previous work by our group has shown that the bulk guest-host
hydrogel by itself is not intact and almost completely eroded after 4 weeks38,65; however,
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the microgels likely remain longer in the tissue. Microparticles have been introduced via
biomaterials into infarcted tissue previously and have improved functional outcomes
through a bulking response, likely through altering the inflammatory response66,67. In
addition to a response of the microgels alone, IL-10 has been found to have inhibitory
effects on matrix metalloproteinases and increase production of tissue inhibitor matrix
metalloproteinases by human macrophages in cell culture models, indicating the role of
IL-10 in limiting the adverse remodeling of native tissues68. Combined, the effect of the
composite hydrogel as a bulking agent with the therapeutic delivery of anti-inflammatory
IL-10 showed significant improvements in scar thickness over the saline control, which
may correspond to improvements in cardiac function.
After 4 weeks, pressure-volume catheterization was used to assess cardiac
function by measuring hemodynamics after the delivery of saline, composites without IL10, or composites with IL-10 (Figure 5.13A-D). The delivery of composites without IL-10
showed significant improvements in ejection fraction and dP/dtmax, a measure of cardiac
contractility, compared to saline delivery. The delivery of composites with IL-10 showed
significant improvements in ejection fraction, cardiac output, dP/dtmax, and preload
recruitable stroke work (PRSW; another index of myocardial contractility) compared to
saline and in PRSW when compared to the composites without IL-10. For ejection
fraction, cardiac output, dP/dtmax, and PRSW, the delivery of composites with or without
IL-10 also improved the value of these outcomes to healthy baseline levels.
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Figure 5.13. Cardiac function. A) Ejection fraction, B) cardiac output, C) dP/dTmax, and
D) preload recruitable stroke work (PRSW) 28 days after delivery of PBS (n=15),
composites without IL-10 (n=8), or composites with IL-10 (n=10) to rat MI and measured
via pressure-volume catheterization (mean ± SD; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001; healthy range in shaded boxes).
The improvement of cardiac function with the delivery of composites without IL10 indicates that the material itself has a positive effect, likely due to its ability to act as a
bulking agent and thicken the left ventricular wall. According to the Laplace’s law, wall
thickness is inversely proportional to wall stress, so thickening of the left ventricular wall
can decrease wall stress and prevent further ventricular dilation that can lead to poor
cardiac function34,35. The additional improvements in cardiac function exhibited by the
delivery of composites with IL-10 indicate that the anti-inflammatory effect of IL-10 may
help to mitigate the tissue damage that can be caused by excessive inflammation and
initiate the healing process42,69.
After 4 weeks, immunohistochemistry was used to assess the density and size of
vascular structures after the delivery of saline, composites without IL-10, or composites
with IL-10 and representative images are shown (Figure 5.14A-C). Von Willebrand
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factor, or vWF, is a glycoprotein produced by endothelial cells and is present in the
lumen of vascular structures of all sizes, from capillaries to arterioles70,71, whereas alphasmooth muscle actin (a-SMA) is expressed by smooth muscle cells and is only present
in more mature vasculature71. Both vWF+ and vWF+a-SMA+ vascular structures
contribute to enhancing perfusion in the border zone region after MI. Quantification of
vWF+ area showed that the delivery of composites without or with IL-10 significantly
increased vWF+ area compared to the delivery of saline (Figure 5.14D). Quantification
of vWF+a-SMA+ structure sizes showed that the delivery of composites without or with
IL-10 increased structure size but only the delivery of composites with IL-10 significantly
increased structure size compared to the delivery of saline (Figure 5.14E).

Figure 5.14. Formation of new vascular structures. Immunohistochemistry for
vascular markers 28 days after delivery of A) PBS, (n=9), B) composites without IL-10
(n=8), or C) composites with IL-10 (n=10) to rat MI. Quantification of D) vWF+ area and
E) size of vWF+a-SMA+ structures for these same groups (mean ± SD; *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001).
These results indicate that the composite hydrogel alone has a positive effect on
vascular density, and that the effects of the composite hydrogel and IL-10 can combine
to have an even greater result. Larger vessel diameters are often correlated with more
mature vessels that are more constructive for improved remodeling and functional
outcomes, which makes the influence of IL-10 delivery on vessel size important72.
Systemic IL-10 has also been shown to increase the number of vascular structures after
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delivery of endothelial progenitor cells (EPCs) in MI compared to the delivery of EPCs
without IL-10, further emphasizing the role of IL-10 in vascularization73. HA has also
been shown to improve vascularization, largely due to the role of HA in cell migration
and proliferation74–76.

5.4 CONCLUSIONS
An injectable bulk guest-host hydrogel was combined with covalently-crosslinked
microgels to create a composite hydrogel/microgel for therapeutic delivery, combining
the beneficial properties of both systems. By encapsulating therapeutics within
microgels, the release of therapeutics from this composite hydrogel was decoupled from
the degradation of the bulk hydrogel. The composite hydrogel was shear-thinning, selfhealing, and injectable. As a model therapeutic, IL-10 was delivered using this
composite hydrogel after MI. The delivery of composites with IL-10 significantly
decreased the presence of macrophages after 1 week and increased scar thickness,
improved cardiac function, and enhanced vascular density after 4 weeks compared to
saline delivery. The composite hydrogel/microgel system described here could be tuned
for the delivery of multiple therapeutics with complex release profiles for broad
applications.
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CHAPTER 6
INJECTABLE HYDROGEL DELIVERY OF EXTRACELLULAR VESICLES ISOLATED
FROM PRE-CONDITIONED MSCS TO THE HEART

6.1 INTRODUCTION
Recently, there has been increased interest in the application of extracellular
vesicles (EVs) produced by cells, to treat damaged and diseased tissues, particularly as
a cell-free therapeutic.1–4 There are different types of EVs (e.g., exosomes,
microvesicles, apoptotic bodies) that are characterized by their biogenesis and size.5
Exosomes are a subset of EVs that are approximately 100 nm in diameter and have
membranes that originate from the plasma membrane but are formed from invaginations
of multivesicular bodies.5,6 EVs can carry cargo such as proteins, RNA, and lipids to
other cells, and are therefore an important component of the paracrine signaling
mechanisms that cells use to communicate with each other.5
Mesenchymal stromal cells (MSCs) have been explored in several pre-clinical
and clinical studies and were found to be beneficial for cardiac repair after myocardial
infarction (MI).7,8 However, low rates of cell engraftment and retention after cell delivery
suggest that the paracrine signals that MSCs produce, rather than their direct
integration, are responsible for their positive therapeutic effects.8,9 An important
component of these paracrine signals are EVs. In 2010, Lai, et al. showed that
exosomes isolated from human embryonic stem cell-derived MSCs reduced infarct size
in a mouse model of MI.10 Since then, other groups have also shown that MSC-derived
EVs can improve cardiac repair after MI by enhancing angiogenesis11,12, reducing
inflammation12, and limiting cardiomyocyte apoptosis13, and several reviews have been
published outlining the benefits of MSC-derived EVs as cell-free therapies for MI and
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other indications.14–17 In the majority of these studies, EVs are directly injected into the
myocardium after MI.
Since EVs are cell-derived, altering cell culture conditions has been explored as
a method to both boost EV production levels18 and to produce EVs with desired
therapeutic properties. For instance, both hypoxia and pro-angiogenic growth factors
have been explored as methods for MSC pre-conditioning to enhance the proangiogenic phenotype of MSCs. Human MSCs cultured in hypoxic (1% O2) conditions
have been shown to release pro-angiogenic factors such as vascular endothelial growth
factor (VEGF), fibroblast growth factor 2 (FGF-2, also known as basic fibroblast growth
factor or bFGF), insulin-like growth factor 1 (IGF-1), and hepatocyte growth factor
(HGF).19 Besides secreted factors, Bian et al found that EVs isolated from human MSCs
cultured in serum-free growth media under hypoxic (1% O2) conditions for 72 hours had
significantly higher protein content than EVs isolated from MSCs cultured under
normoxic (21% O2) conditions.11 Also, EVs isolated from hypoxic MSCs significantly
improved formation of new vascular structures in vitro and in vivo after MI in a rat when
compared to saline controls.11 Hypoxia has long been shown to be involved in the
regulation of angiogenesis, primarily through pathways mediated by hypoxia-inducible
factors (HIFs).20
Pro-angiogenic factors, such as epidermal growth factor (EGF)21, bFGF22, IGF23,
VEGF22, and ascorbic acid24 are positive regulators of angiogenesis that are implicated
in endothelial cell (EC) proliferation, differentiation, and migration or the stabilization of
nascent blood vessels. At certain concentrations, heparin22 and hydrocortisone25 have
also been shown to increase angiogenesis. All of these factors are found in a variant of
endothelial cell growth medium, commercially available as EGM-2 from suppliers such
as Lonza and PromoCell. Priming MSCs with EGM-2 for 72 hours was shown to
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decrease the basal cell death rate, and the delivery of primed MSCs via intraperitoneal
injection was shown to significantly increase microvascular density in skeletal muscle in
rats when compared to the delivery of non-primed MSCs.26 Other groups have shown
that the treatment of adipose-derived MSCs with the same factors increased the release
of angiogenic factors secreted by cells after one week in culture.27 MSCs cultured in the
presence of VEGF have also been observed to differentiate into endothelial-like cells.28
This suggests that culturing MSCs with pro-angiogenic growth factors can alter cell
behaviors and potentially enhance the pro-angiogenic potential of EVs that these cells
produce.
As reported in this chapter, rat MSCs were pre-conditioned with one of four
treatment conditions involving combinations of culture in hypoxic and normoxic
environments with and without pro-angiogenic growth factors. EVs were isolated from
pre-conditioned MSCs and the effect of treatment conditions on EV production and in
vitro angiogenesis was investigated. Our hypothesis is that priming MSCs with both proangiogenic growth factors and culture in hypoxic conditions, which has not been done
previously, will alter EV contents and that these EVs will promote angiogenesis in vitro
and in vivo. For targeted and sustained EV delivery in vivo, EVs were encapsulated in an
injectable hydrogel and delivered in a rat MI model that was described in Chapter 3 of
this thesis. Previously, our group has shown that the delivery of endothelial progenitor
cell-derived EVs in an injectable hydrogel to the heart improves cardiac function and
remodeling outcomes compared to the delivery of EVs in saline.29 The move toward
MSC-derived EVs is likely to improve the clinical potential and sourcing of EVs for
potential therapies. Through pre-conditioning MSCs to increase their pro-angiogenic
potential and then delivering isolated EVs using an injectable hydrogel, we aim to
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develop a local and sustained cell-free EV therapy for improved cardiac remodeling
through increased vascularization after MI.

6.2 METHODS
6.2.1. INJECTABLE HYDROGEL
An injectable, guest-host, hyaluronic acid-based hydrogel formed by the
supramolecular interactions between adamantane (Ad, guest) and b-cyclodextrin (CD,
host) functional groups was utilized in this chapter for EV delivery. Synthesis of this
hydrogel was described extensively in Chapter 3 of this thesis. Briefly, sodium hyaluronic
acid (HA, 74 kDa, Lifecore) was converted to the tetrabutylammonium salt of HA (HATBA). HA-TBA was modified separately with Ad to form AdHA through the coupling of 1adamantane acetic acid (Acros Organics) in the presence of di-tert-butyl dicarbonate
and 4-methylaminopyridine or with CD to form CDHA through the coupling of b-CD-HDA
in

the

presence

of

benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium

hexafluorophosphate. Approximately 20-25% of HA repeat units were functionalized by
Ad (for AdHA) as quantified by 1H NMR and approximately 20-25% of HA repeat units
were functionalized by b-CD-HDA (for CDHA) as quantified by 1H NMR. All chemicals
were purchased from Sigma-Aldrich unless otherwise noted.
For subsequent studies, the hydrogel used had a total material concentration of
4.5 wt% (AdHA and CDHA components combined) with an equal molar ratio of Ad to CD
groups. For hydrogel assembly, AdHA and CDHA were dissolved separately in equal
volumes of PBS (or in PBS with EVs when noted) and then mixed to form the injectable
hydrogel. Prior to being dissolved in solution, AdHA and CDHA components were
sterilized with UV light for in vivo applications.
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6.2.2. MSC PRE-CONDITIONING
Wistar rat mesenchymal stem cells (rMSCs, Cyagen, batch no: 130730H31)
were subcultured to passage 6 on tissue culture plastic in MSC growth media (a-MEM
with 16.7% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine)
and media was changed every other day until rMSCs reached 80% confluence. Cells
were rinsed twice with phosphate-buffered saline (PBS) and, for pre-conditioning, rMSCs
were either cultured in hypoxic (1% O2) or normoxic (21% O2) environments and with
either serum-free MSC growth media (a-MEM with 1% penicillin-streptomycin and 1% Lglutamine) or serum-free pro-angiogenic growth factor-supplemented media (PromoCell;
EBM-2 with 5 ng/mL recombinant human epidermal growth factor (EGF), 10 ng/mL
recombinant human basic fibroblast growth factor (FGF), 20 ng/mL insulin-like growth
factor (R3 IGF-1), 0.5 ng/mL recombinant human vascular endothelial growth factor 165
(VEGF), 1 µg/mL ascorbic acid, 22.5 µg/mL heparin, and 0.2 µg/mL hydrocortisone).
Serum-free media was used to avoid contamination with serum-derived EVs.
The pre-conditioning treatment conditions were as follows: standard (normoxia
with serum-free MSC growth media), hypoxia (hypoxia with serum-free MSC growth
media), growth factor (GF, normoxia with serum-free pro-angiogenic growth factorsupplemented media), or growth factor + hypoxia (GF+hypoxia, hypoxia with serum-free
pro-angiogenic growth factor-supplemented media) (Figure 6.1). Treatment conditions
were applied for 72 hours during the EV collection time period. Following, conditioned
media was collected from cells and centrifuged at 2000 x g for 30 minutes at 4°C and
clarified using a 0.22 µm PVDF filter to remove dead cells and cellular debris.
Conditioned media containing EVs was frozen and stored at -80°C until EV isolation.
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EV release into media

Image cells;
collect media for
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Figure 6.1. rMSC pre-conditioning regimen. Passage 6 (p6) rat mesenchymal stromal
cells (rMSCs) were grown to 80% confluence and then cultured in one of four conditions
(A-D). After 72 hours, conditioned media was collected for extracellular vesicle (EV)
isolation. rMSCs were imaged before and after pre-conditioning. GF: growth factor.
Before and after the 72 hour pre-conditioning and EV collection period, cell
images were taken using a brightfield light microscope at 10x magnification. Using
ImageJ (NIH), binary masks were created using default intensity-based thresholding
methods for each image to count the number of cells per area and to calculate cell
spread area, cell shape index, and cell aspect ratio. Cell shape index is calculated as
(4pA)/P2, where A is the area of the cell and P is the perimeter of the cell. Using this
formula, a line has a cell shape index of 0 and a circle has a cell shape index of 1. Cell
aspect ratio is calculated by taking the length of the longest side of the bounding
rectangle encompassing the cell and dividing it by the length of the shortest side of the
bounding rectangle encompassing the cell.
6.2.3. EV ISOLATION AND CHARACTERIZATION
6.2.3.1. EV ISOLATION
EVs were isolated using a previously described polyethylene glycol (PEG)-based
polymer precipitation method.30 For the PEG isolation reagent, a solution of 36% 6 kDa
PEG and 1.5 M NaCl was made in water, filtered with a 0.22 µm filter, and stored at 4°C
until use. Frozen conditioned media was thawed at 37°C and vortexed. PEG isolation
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reagent was added to conditioned media at a 1:2 ratio to achieve a working
concentration of 12% PEG, 0.5 M NaCl. Samples were thoroughly mixed and then
incubated for 12-24 hours overnight at 4°C. The following day, samples were centrifuged
at 10,000 x g at 4°C for 2 hours at low brake to collect EVs. EVs were washed and
resuspended with PBS and then stored at -80°C until use.
6.2.3.2. EV SIZE, CONCENTRATION, AND PROTEIN CONTENT
EVs suspended in PBS were analyzed via nanoparticle tracking analysis (NTA)
to determine EV size, size distribution, and concentration using a NanoSight NS500 (532
nm laser; Malvern Instruments) by the Nanomedicines Characterization Core Facility at
The University of North Carolina at Chapel Hill. Samples were diluted and then injected
manually. Data acquisition was performed at room temperature and data was analyzed
using NTA 3.0 software (Malvern Panalytical). EV protein content was quantified using a
Micro BCA Protein Assay Kit (ThermoFisher Scientific) per manufacturer instructions.
6.2.3.3. MATRIGEL ANGIOGENESIS ASSAY
EV angiogenic potential was quantified in vitro using a Matrigel angiogenesis
assay. 10 µL of Matrigel (Corning) was plated into each 0.125 cm2 inner well of a µ-slide
for angiogenesis (Ibidi). Human umbilical vein endothelial cells (hUVECs, passage 4,
grown to 100% confluence) resuspended in EBM-2 with 1% FBS were seeded onto
Matrigel at a density of 10,000 cells/well (51,000 cells/cm2). EVs isolated from MSCs
pre-conditioned with all four treatment groups were suspended in PBS and were added
to each well at a concentration of 80 µg protein/mL, with EV protein content quantified as
described above (e.g., for 50 µL volume/well, 4 µg EV were added to each well). EV
samples with varying protein concentrations were diluted such that the volume of PBS
added to each well was the same. For a negative control, the same total volume of PBS
without EVs was added to wells. Samples were incubated for 14 hours and imaged at 4x
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using brightfield microscopy. Images were analyzed using the Angiogenesis Analyzer
plug-in (Gilles Carpentier) and ImageJ (NIH).
6.2.3.4. PROTEOMICS
Sample preparation
EVs isolated from MSCs pre-conditioned with standard (n=4) and GF+hypoxia
(n=5) treatments were evaluated for protein content using mass spectrometry. Biological
replicates were defined as separate EV isolations, and each sample consisted of 400 µg
of EVs by protein content. Further sample preparation, mass spectrometry analysis, and
sequence database search and statistical analysis were completed in collaboration with
The Proteomics Core Facility at The Children’s Hospital of Philadelphia.
EV samples were run on a polyacrylamide gel for 0.8 cm and stained with
Coomassie blue. Each gel band was then excised and further cut into 1 mm cubes,
which were destained with 50% methanol/1.25% acetic acid, reduced with 5 mM
dithiothreitol, and alkylated with 20 mM iodoacetamide. Gel pieces were washed with 20
mM ammonium bicarbonate, dehydrated with acetonitrile, and digested with trypsin
(Promega, 5 ng/mL in 20 mM ammonium bicarbonate) overnight at 37ºC. Peptides were
extracted with 0.3% trifluoroacetic acid and 50% acetonitrile. Extracts were combined
and the volume was reduced by vacuum centrifugation.
Mass spectrometry analysis
Peptides were analyzed on a Q Exactive HF mass spectrometer (ThermoFisher
Scientific) coupled with an UltiMate 3000 Nano UHPLC system and EASY-Spray source.
Whole proteome samples were collected using data dependent acquisition (DDA) and
data independent acquisition (DIA). Enriched acetylome peptides were analyzed by
DDA. Tryptic digests were spiked with iRT standards (Biognosys) and separated by
reverse phase (RP)-HPLC on a PepMap RSLC C18 nano column (2 µm particle size, 75
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μm ID, 50 cm length) at 50°C. Mobile phase A consisted of 0.1% formic acid and mobile
phase B of 0.1% formic acid/acetonitrile. Peptides were eluted into the mass
spectrometer at 210 nL/min with each RP-LC run comprising of a gradient from 1 to 5%
B in 15 min, then 5-45% B in 110 min for DDA and 140 min for DIA.
For DDA, the mass spectrometer was set to repetitively scan m/z from 300 to
1400 for one full MS scan followed by data-dependent MS/MS scans on the twenty most
abundant ions. For full MS scans, the resolution, AGC target, and maximum injection
times were set at 120,000, 3e6, and 32 ms, respectively. For MS/MS scans, the
resolution, AGC target, maximum injection time, and isolation window were set at 15000,
2e5, 32 ms, and 1.4 m/z, respectively. 1 microscan was used for each MS/MS scan with
rejection of singly charged ions and unassigned charge states and a normalized collision
energy of 27.
For DIA, the mass spectrometer completed 1 full MS scan from 300 to 1650 m/z
with a resolution, AGC target, and maximum injection time of 120,000, 3e6, and 60 ms,
respectively. This was followed by 22 (DIA) isolation windows with varying sizes at
30,000 resolution, an AGC target of 3e6, injection times set to auto, and loop count and
MSX count of 1. The default charge state was 4, the first mass was fixed at 200 m/z and
the normalized collision energy (NCE) for each window was stepped at 25.5, 27, and 30.
Sequence database search
The DDA raw files were searched against a rat protein sequence database
including canonical and manually reviewed isoform sequences from the Uniprot
Knowledgebase using MaxQuant version 1.6.1.0 with the following set parameters: fixed
modifications: carbamidomethyl (C); decoy mode: revert; MS/MS tolerance: FTMS 20
ppm; false discovery rate for both peptides and proteins: 0.01; minimum peptide length:
7; modifications included in protein quantification: acetyl (protein N-term), oxidation (M);
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peptides used for protein quantification: razor and unique. The search result from
MaxQuant was used to generate a spectral library for DIA analysis. A separate spectral
library was generated for each DIA raw file using DirectDIA mode in Spectronaut.
Subsequently, the DIA raw files were searched against a merged library using the
default settings in Spectronaut. Protein intensity values measured at the MS2 level were
then exported for downstream statistical analysis using Perseus 1.6.6.0 (Max Planck
Institute of Biochemistry).
Statistical analysis
Protein intensity values were log2 transformed and normalized by subtracting the
median for each sample. Exploratory analysis of protein contents was completed to
determine the number of proteins detected in each group and the variance between
groups was plotted using a principal component analysis plot. Differentially expressed
proteins were determined using a Student’s t-test and volcano plots were generated to
visualize affected proteins while comparing different groups of samples. Further
enrichment analysis was completed using heat maps to show hierarchical clustering of
differentially expressed proteins. For functional analysis, Fisher’s exact test with
Benjamini-Hochberg FDR (false discovery rate) to control for multiple hypothesis testing
was used to determine biological processes that were found to be significantly enriched
or depleted. Values of the enrichment factor less than 1 indicate depletion.
6.2.4. EV RETENTION AND BIODISTRIBUTION
The retention of EVs in the heart and biodistribution of EVs after cardiac
injection using either saline or an injectable hydrogel as a delivery vehicle for EVs was
assessed in vivo. EVs were isolated from MSCs treated with the standard preconditioning regimen (21% O2, serum-free MSC growth media) and characterized using
NTA as described above. 1 dose of EVs per rat corresponded to 9.33 x 109 particles in
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110 µL saline. EVs were labeled with ExoGlow-Vivo EV Labeling Kit (near IR, System
Biosciences) according to manufacturer instructions. Free dye was removed using
exosome spin columns (MW 3000; ThermoFisher Scientific). For EVs delivered in saline,
solutions of labeled EVs were loaded into ½ mL, 27G x ½” syringes (BD). For EVs
delivered with the injectable hydrogel, AdHA and CDHA components were prepared as
described above with solutions of labeled EVs, mixed, and then loaded into ½ mL, 27G x
½” syringes (BD).
A left lateral thoracotomy in the fourth intercostal space was performed as
described in Chapter 3.6 to allow for the delivery of labeled EVs in saline or
encapsulated in an injectable hydrogel to the apex of the heart in delivery sites that
would mimic delivery after MI. For this study, EV retention and biodistribution was
investigated without MI. Animals were recovered and at specified timepoints after
injection (5 minutes, 1 day, 7 days, or 14 days), organs (heart, lungs, spleen, kidneys,
liver, stomach, small intestine, and large intestine) were explanted and epi-fluorescence
was quantified by imaging explanted organs using an IVIS Spectrum (PerkinElmer). For
the initial timepoint (day 0), hearts that were explanted earlier that day were injected with
EVs and immediately imaged. For each timepoint and delivery system (saline or
injectable hydrogel), 4 biological replicates were used. Images were analyzed using
Living Image 4.5.2 (PerkinElmer). After background correction, regions of interest
around each organ were selected for each image, measured, and fluorescence in units
of radiant efficiency were analyzed. Fluorescent signal was blanked with readings from
hearts without any labeled EV injections. All animal protocols were approved by the
University of Pennsylvania Institutional Animal Care and Use Committee.
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6.2.5. RAT MI MODEL
EVs isolated from MSCs pre-conditioned with GF+hypoxia were delivered in a rat
MI model in either saline or with an injectable hydrogel and cardiac remodeling was
assessed after 4 weeks. Using a previously established MI model described in detail in
Chapter 3.6 of this thesis, ligation of the left anterior descending artery was used to
induce a permanent infarct encompassing approximately 30% of the left ventricle in a
rat. Animals were divided into one of four treatment groups: PBS (saline), PBS + EVs
(EVs delivered in saline), Gel (injectable hydrogel alone without EVs), and Gel + EVs
(injectable hydrogel with encapsulated EVs). EV dosage per animal was 80 µg of EVs as
quantified by protein content in 110 µL saline. All treatment groups were prepared in ½
mL, 27G x ½” syringes (BD) and injected in equally spaced 5 x 20 µL injections into the
border zone of the infarct immediately after confirmation of infarct induction. After 4
weeks, animals were sacrificed and hearts were explanted, washed in PBS, and frozen
in O.C.T. Compound (Tissue-Tek) at -80°C. Tissue sections of 10 µm thickness were
obtained using a cryostat starting at the apex of the heart to above the papillary muscles
and then further evaluated for tissue remodeling and vascular structures. All animal
protocols were approved by the University of Pennsylvania Institutional Animal Care and
Use Committee.
6.2.5.1. TISSUE REMODELING
To assess tissue remodeling, sections of cardiac tissue at the mid-papillary level
were stained with Masson’s Trichrome Stain kit (Sigma-Aldrich) per manufacturer
instructions. After staining, slides were imaged using a flatbed scanner and images were
analyzed using ImageJ (NIH). For scar fraction, the freehand line tool was used to
measure the endocardial circumference of the left ventricle, the epicardial circumference
of the left ventricle, the length of the endocardial infarct, and the length of the epicardial
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infarct. Only transmural infarct lengths were measured, and a transmural infarct was
defined as a portion of the left ventricular wall with at least 50% of the thickness of the
wall delineated as scar. Scar fraction was then calculated as the average of the infarct
length as a proportion of circumference for the epicardial and endocardial sides. For scar
thickness, the width of five evenly spaced points of the transmural infarct was measured
and averaged. At least three images were quantified and averaged per animal for one
biological replicate.
6.2.5.2. VASCULAR STRUCTURES
For quantification of vascular structure density and size, sections of cardiac
tissue at the mid-papillary level were assessed via immunohistochemical staining for von
Willebrand factor (vWF-FITC, ab8822, Abcam, 1:400) and a-smooth muscle actin (aSMA-AF594, ab202368, Abcam, 1:400) with wheat germ agglutinin (WGA-AF647,
W32466, ThermoFisher Scientific, 1:300) to delineate scar and the infarct region and
DAPI (D1306, ThermoFisher Scientific, 1:1000) for cell nuclei. Sections were imaged at
10x on a fluorescent microscope and at least 6 images of the infarct, 12 images of the
border zone, and 6 images of the remote region were quantified and averaged per
animal for one biological replicate. Images were analyzed using ImageJ (NIH).
The number of vWF+ structures, vWF+ structure size, and vWF+ area was
determined by first creating a binary mask via thresholding with the Otsu method, then
using the Close function to improve connectivity between structures. Particles greater
than or equal to 7.5 µm2 in area were counted and measured. For the number of
vWF+aSMA+ structures, vWF+aSMA+ structure size, and vWF+aSMA+ area, a similar
analysis was completed but prior to counting particles, an image representing vWF and
aSMA co-localization was created using the “AND” operator in the Image Calculator
function on the binary masks of the vWF and aSMA channels.
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6.2.6. STATISTICS
All statistical analyses were conducted using GraphPad Prism 8 software.
Outliers were removed using the ROUT test with Q = 5% and statistical significance was
determined using a two-tailed Student’s t-test or one-way ANOVA with post-hoc Tukey’s
multiple comparisons test when appropriate.

6.3 RESULTS AND DISCUSSION
6.3.1. MSC MORPHOLOGY AFTER PRE-CONDITIONING
Rat MSCs were pre-conditioned in one of four treatment conditions: standard (A,
21% O2 with serum-free MSC growth media), hypoxia (B, 1% O2 with serum-free MSC
growth media), growth factor (GF, C, 21% O2 with serum-free pro-angiogenic growth
factor-supplemented media), or GF+hypoxia (D, 1% O2 with serum-free pro-angiogenic
growth factor-supplemented media). Treatment conditions were applied for 72 hours.
Before and after the pre-conditioning regimen, images were taken of MSCs (Figure
6.2a) and cell number and morphology (cell spread area, cell shape index, and cell
aspect ratio) were quantified (Figure 6.2b-e).
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Figure 6.2. MSC number and morphology after pre-conditioning. (a) Brightfield
images of pre-conditioned rat mesenchymal stem cells (rMSCs) before and after 72
hours of pre-conditioning treatments. Quantification of (b) cell number per area, (c) cell
spread area, (d) cell shape index, and (e) cell aspect ratio before and after preconditioning for all treatments. Solid fill: before pre-conditioning; Pattern fill: after preconditioning; Mean ± SD; Scale bar: 200 μm; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001; GF: growth factor.
The number of cells per area was significantly lower after treatment for all
conditions except for GF (Figure 6.2b). Cell death was expected in all conditions
because MSCs were cultured without serum to facilitate EV collection, a requirement to
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eliminate the introduction of EVs from serum into the experimental sample. Specifically,
for EV collection cells must either be cultured in serum-free conditions or with EVdepleted serum, which can still differ from normal serum in its cell proliferative
capacity.31 Cells cultured under serum-free conditions have been shown to undergo
apoptosis.32 These results suggest that culturing MSCs with pro-angiogenic growth
factors can help maintain cell viability under serum-free conditions; however, hypoxic
conditions reduces viability, even in the presence of growth factors.
Changes in cell morphology were also observed after the various treatment
conditions were applied to MSCs. For all treatment groups, cell spread area significantly
decreased, indicating that cells became more compact (Figure 6.2c). For the standard
treatment group, cell shape index decreased, while hypoxia and GF treatments led to
increases in cell shape index, indicating that cell shapes became more circular (Figure
6.2d). Standard, hypoxia, and GF treatments led to decreases in cell aspect ratio
(Figure 6.2e). GF+hypoxia treatment led to no change in cell shape index or cell aspect
ratio. Decreases in cell spread area taken together with the changes in cell shape index
and cell aspect ratio suggest that standard, hypoxia, and GF treatments resulted in more
rounded cells, while GF+hypoxia treatment resulted in more compact cells of similar
shape. MSC cell shape has been shown to be related to MSC differentiation33, so
changes in cell morphology could be indicative of a changing MSC phenotype induced
by the pre-conditioning treatments.
6.3.2. EV CHARACTERIZATION
MSC EVs were isolated from conditioned media by polymer precipitation, and
NTA was used to evaluate EV size, size distribution, and concentration. All treatment
groups produced EVs with similar mode diameters of 90-110 nm (Figure 6.3a-b).
Exosomes, a subset of EVs, are characterized as particles with diameters ranging from
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50-150 nm6, and a majority of particles from all treatment groups were within this size
range (Table 6.1). The total number of EVs isolated from each treatment group during
one EV isolation was similar (Figure 6.3c), and did not seem to trend with the number of
cells present after treatment shown in Figure 6.2b.
However, the amount of protein per EV varied between groups, and the amount
of protein in EVs isolated from MSCs pre-conditioned with GF+hypoxia was significantly
higher than that from MSCs pre-conditioned with hypoxia or GF alone (Figure 6.3d,
Table 6.1). EVs, and specifically exosomes, are thought to contain proteins, RNAs, and
lipids but exert their therapeutic efficacy primarily through proteins, so high protein
concentrations could be beneficial depending on actual protein content.34 On average,
the GF+hypoxia group had the highest protein content, followed by the standard
treatment group.
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Figure 6.3. EV characterization: size, yield, protein content. Extracellular vesicles
(EVs) isolated from pre-conditioned rat mesenchymal stromal cells (rMSCs) were
characterized using nanoparticle tracking analysis (NTA) for EV (a) size, (b) size
distribution (shaded region represents typical exosome size, 50-150 nm), and (c) yield.
(d) EV protein content quantified using a bicinchoninic acid (BCA) assay. Mean ± SE;
*p<0.05, **p<0.01; GF: growth factor.
Table 6.1. Exosome size and protein content for all pre-conditioning regimens.

Group
A. Standard
B. Hypoxia
C. GF
D. GF + hypoxia

% particles with 50-150
nm diameter
75.5
70.9
85.3
90.7

GF: growth factor.

195

Protein content
(μg per 1011 particles)
242 ± 31
165 ± 7
180 ± 5
294 ± 31

6.3.2.1. IN VITRO ANGIOGENESIS
A Matrigel angiogenesis assay was used to evaluate the in vitro angiogenic
potential of EVs isolated from MSCs pre-conditioned with all four treatment conditions,
and saline was used as a negative control. Representative images of hUVEC tubule
formation for all samples (Figure 6.4a) and quantification of the number of nodes and
tubules per area (Figure 6.4b-c) show that treating hUVECs with MSC-derived EVs from
standard, GF, and GF+hypoxia groups significantly increased the formation of vascular
structures compared to the control group. On average, the GF+hypoxia group had the
highest number of nodes and tubules per area, followed by the standard group. For
further evaluation of EV contents using proteomics, only the GF+hypoxia and standard
groups were evaluated based on in vitro results from the Matrigel angiogenesis assay
and assessment of amount of protein in EVs. For in vivo studies of EV therapeutic
efficacy for cardiac repair, only the GF+hypoxia group was evaluated.

Figure 6.4. Matrigel angiogenesis assay. (a) Representative images of hUVEC tubule
formation after treatment with EVs from all pre-conditioning groups. Quantification of (b)
number of nodes and (c) number of tubules per area. Mean ± SD; Scale bar: 500 μm;
*p<0.05, **p<0.01 compared to control; GF: growth factor, hUVEC: human umbilical vein
endothelial cell, EV: extracellular vesicle.
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6.3.2.2. PROTEOMICS
EVs isolated from MSCs pre-conditioned with standard and GF+hypoxia
treatments were further characterized using mass spectrometry techniques and
proteomics to determine the protein contents of these groups of EVs. 1675 proteins were
identified in the standard group, and 1277 proteins were identified in the GF+hypoxia
group; of these proteins, 1244 were common between both groups (Figure 6.5a).
However, a principal component analysis (PCA) found two distinct protein populations,
noted by their separation (green: GF+hypoxia; red: standard) dots on the PCA plot,
especially with regard to component 1 which accounts for 69.5% of variance in the data
(Figure 6.5b). This suggests that pre-conditioning MSCs with different treatments alters
protein content in EVs isolated from these MSCs.
A Student’s t-test was used to compare proteins found in EVs isolated from
standard treatment and GF+hypoxia treatment and a volcano plot was used to visualize
the results (Figure 6.5c). In this plot, the negative log of the p-value is plotted versus the
difference in expression between the two groups expressed as the log (base 2) of the
fold change, so positive values indicate that a protein is over-expressed in standard EVs
and negative values indicate that a protein is over-expressed in GF+hypoxia EVs. On
this plot, red dots represent proteins that are statistically significantly over-expressed in
standard EVs, and green dots represent proteins that are statistically significantly overexpressed in GF+hypoxia EVs. Some of the greatest differences include proteins
associated with the genes Adamts1, Lama435, and Col4a1, all of which have been
implicated in angiogenesis. For example, Adamts1 is upregulated by VEGF and may be
an endogenous regulator of endothelial cell proliferation36, while mutations in Col4a1
have been shown to cause defects in blood vessel formation.37 This suggests that
specific proteins related to angiogenesis are over-expressed in GF+hypoxia EVs.
197

(a)

33 1.25 1244

GF+hypoxia

(b)

431

Standard

GF+hypoxia
Standard

(c)
Adamts1
Lama4
Col4a1

Figure 6.5. Exploratory proteomics analysis. (a) Venn diagram of the number of
proteins detected in each group. (b) Primary component analysis (PCA) plot showing
variance between groups. (c) Volcano plot of significantly differentially expressed
proteins (some gene labels shown). Red and green dots represent proteins significantly
more expressed in standard or GF+hypoxia group, respectively. GF: growth factor.
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The results from the Student’s t-test can also be visualized using a heat map to
show hierarchical clustering of proteins that are differentially expressed in each group
(Figure 6.6a). As a result of hierarchical clustering, proteins that are more similarly
expressed are grouped near each other in the dendrogram. This leads to the formation
of two separate clusters of proteins- one that is over-expressed in standard EVs (Cluster
2) and one that is over-expressed in GF+hypoxia EVs (Cluster 1). Profile plots of protein
expression levels by sample show these similar patterns in the expression levels of
protein from each cluster (Figure 6.6b). By annotating proteins using a gene ontology
database, a Fisher’s exact test was used to determine biological processes that were
enriched in each of these clusters and the biological process, enrichment factor, and
false discovery rate (FDR) are reported here (Figure 6.6c). For enrichment factor,
values less than 1 indicate depletion and the FDR is used instead of a p-value to correct
for multiple comparisons, with FDR < 0.05 to indicate significant differences. Biological
processes associated with extracellular matrix organization, cell adhesion, wound
healing, positive regulation of cell migration, and regulation of cell proliferation are
examples of processes enriched in GF+hypoxia EVs (Cluster 1), while actin nucleation,
amino acid activation, actin cytoskeleton organization, intracellular protein transport, and
vesicle-mediated transport are enriched in standard EVs (Cluster 2). GF+hypoxia EVs
are enriched with proteins related to angiogenesis-related processes, while standard
EVs are enriched with proteins related to protein synthesis and transport. While these
lists are not exhaustive and there are many other biological processes, molecular
functions, and cellular component categories that are enriched in proteins found in these
clusters, these results continue to indicate that pre-conditioning treatment can change
EV protein contents, and that priming MSCs with GF+hypoxia results in EVs that contain
proteins that are enriched in angiogenesis-related processes.
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Figure 6.6. Enrichment proteomics analysis. (a) Heat map showing hierarchical
clustering of proteins that are differentially expressed in each group. High expression is
shown in red and low expression is shown in green. Clusters of interest are highlighted
in the dendrogram (pink, blue). (b) Profile plots of proteins within each cluster are distinct
for each treatment group: Cluster 1 (pink) shows proteins strongly expressed in
GF+hypoxia group (n=5); Cluster 2 (blue) shows proteins strongly expressed in standard
group (n=4). Intensity scale represents distance from center. (c) List of relevant
biological processes that are enriched in each cluster. GF: growth factor; EF: enrichment
factor; FDR: false discovery rate.
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6.3.3. IN VIVO RETENTION AND BIODISTRIBUTION
EV retention in rats was compared for near IR-labeled EVs delivered to the heart
using either saline or an injectable hydrogel as a delivery vehicle. While the initial
fluorescent signal was similar for ex vivo rat hearts injected with labeled EVs in both
saline and gel, after 14 days more signal was detected from hearts that were injected
with labeled EVs in gel than in saline (Figure 6.7a). Fluorescence signal is measured in
units of radiant efficiency, which normalizes efficiency (the ratio of photons emitted to
photons absorbed) by illumination power and allows for the comparison of images taken
at varying instrument settings. The average radiant efficiency is the total radiant
efficiency for a specific region of interest divided by the area of that region of interest.
Quantifying fluorescence intensity in units of average radiant efficiency showed
that the fluorescence intensity of labeled EVs decreased over time for both the injectable
hydrogel and saline groups, but that the signal for the injectable hydrogel group was
higher at each measured timepoint (Figure 6.7b; for gel vs saline groups, p=0.10 at 5
minutes and p=0.14 at day 14). After only 5 minutes, EV fluorescence intensity in the
heart decreased dramatically for both gel and saline groups, and the average radiant
efficiency at 5 minutes for the saline group was significantly lower than at the initial
timepoint (for gel p=0.09). As with cells, this is likely due to mechanical ejection of
therapeutics from the beating heart and leakage into the coronary vasculature.8 The
delivery of EVs with injectable hydrogels showed trends for improved EV retention, and
targeted, sustained EV delivery may be important for therapeutic efficacy.38,39

201

Figure 6.7. in vivo EV retention. (a) Representative images of rat hearts injected with
near IR-labeled EVs in saline or an injectable hydrogel at day 0 and day 14. (b)
Quantification of fluorescence signal over time in units of average radiant efficiency for
near IR-labeled EVs delivered to the heart in saline or an injectable hydrogel. Mean ±
SE.
Biodistribution of EVs after cardiac delivery was also explored for different
timepoints for EVs delivered with saline or with an injectable hydrogel. Representative
images of organs showing fluorescent signal from labeled EVs delivered to the heart
showed that the distribution of labeled EVs in other organs varied based on delivery
vehicle and time after injection (Figure 6.8a). At day 1, EVs delivered in saline were
found in high quantities in the kidneys, stomach, small intestine, and large intestine,
suggesting that since these EVs were not well-retained in the heart, they accumulated in
the kidneys. By day 7, the strongest EV signal was in the stomach and at day 14, EV
signal concentration was localized to the stomach, small intestine, and large intestine
(Figure 6.8b). In general, saline delivery of EVs showed high localization initially to the
kidneys followed by localization to the digestive tract over time.
For EVs delivered with an injectable hydrogel, EV signal patterns were similar at
day 1 but there was a larger portion of EVs remaining in the heart. At later day 7 and day
14 timepoints, EVs were again distributed similarly to saline and concentrated in the
stomach, small intestine, and large intestine, but also in the heart (Figure 6.8c). Here,
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EV distribution was spread more evenly, with some localization to the kidneys initially
and to the digestive tract but also retention in the heart. For the translation of EV
therapies, it is important to understand the localization of EV therapies after delivery to
anticipate off-target effects. Studies by other groups have shown that a number of
factors such as EV cell source, EV dose, and even mode of EV delivery can affect
biodistribution and tissue localization.40

Figure 6.8. in vivo EV biodistribution. (a) Representative images of biodistribution of
near IR-labeled EVs after delivery to the heart in saline or injectable hydrogel at day 1,
day 7, and day 14 timepoints. Quantification of fluorescence signal in organs in units of
average radiant efficiency for near IR-labeled EVs delivered in (b) saline or (c) injectable
hydrogel to the heart at day 1, day 7, and day 14 timepoints. Mean ± SE; 1: heart, 2:
lungs, 3: spleen, 4: kidneys, 5: liver, 6: stomach, 7: small intestine, 8: large intestine.
6.3.4. RAT MI MODEL
Following MI, EVs isolated from MSCs pre-conditioned with GF+hypoxia were
delivered to the heart using either saline or an injectable hydrogel as a delivery vehicle.
Saline and injectable hydrogel alone were also investigated as controls. The mortality
rate after MI and injection of any of the four treatment groups (PBS, Gel, PBS + EVs, or
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Gel + EVs) was 21.3% (10 of 47 animals). However, 27% of the remaining animals (10
of 37 animals) did not have transmural infarcts, which was discovered upon staining
sections of cardiac tissue with Masson’s trichrome; these animals were excluded from
further analysis. At least 4 biological replicates remained for each of the treatment
groups (PBS: n=5, Gel: n=11, PBS + EVs: n=4, Gel + EVs: n=7).
Masson’s trichrome staining showed a large variation in scar fraction and scar
thickness for all treatment groups (Figure 6.9). For instance, within the gel group, there
were some sections which showed a very thin ventricular wall and an infarct fraction of
greater than 50%, while other sections were thicker and had infarct fractions of less than
25%. Quantification of scar fraction (Figure 6.10a) and scar thickness (Figure 6.10b)
yielded no significant differences in either metric for any of the treatment groups. The
largest range in scar fraction was found in the gel group, which had values from about
0.1 to 0.7. Variations in infarct induction likely led to a large range in infarct severity,
which is represented here by scar fraction. Future studies should focus on creating
repeatable infarcts to provide a reliable baseline for testing therapeutic efficacy.
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Figure 6.9. Cardiac remodeling. Representative images of tissue sections taken from
the mid-papillary level of all rats from all treatment groups after staining with Masson’s
Trichrome. In these images, red is healthy muscle tissue and blue is infarct tissue or
scar. Note the large variations in infarcts across a group, likely indicating variable infarct
reduction, which then limited the ability to quantify remodeling outcomes.
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Figure 6.10. Quantification of cardiac remodeling. (a) Scar fraction and (b) scar
thickness 4 weeks after delivery of treatment groups. Mean ± SD; EVs: extracellular
vesicles.
While there were no differences in global cardiac remodeling for any of the
treatment groups, there were variations in the density and size of vascular structures.
Immunohistochemical staining for vascular structures probed for vWF, an endothelial cell
marker, and aSMA, which is expressed by smooth muscle cells. While vWF is present in
the lumens of most vascular structures ranging from capillaries to arteries, aSMA is
generally only present in more mature vascular structures such as arterioles and
arteries.41,42 However, both vWF+ and vWF+aSMA+ structures contribute to enhanced
perfusion of the myocardium. Representative images from all treatment groups of
immunohistochemical staining in the infarct (Figure 6.11a-d), border zone (Figure
6.11e-h), and remote (Figure 6.11i-l) regions for vascular structures are shown here.
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Figure 6.11. Vascular structures. Representative images of staining for vascular
structures in the infarct (a-d), border zone (e-h), and remote (i-l) regions after delivery of
PBS (a, e, i), gel (b, f, j), PBS + EVs (c, g, k), or gel + EVs (d, h, l) to the heart. EVs:
extracellular vesicles.
Quantification of the number and size of vascular structures is shown in Figure
6.12. Interestingly, there was often increased vWF+ or vWF+aSMA+ staining and larger
vascular structures located in the infarct region than in the border zone and remote
regions, irrespective of treatment group. For instance, vWF+ area was significantly
greater in the infarct region than in the border zone or remote regions for all treatment
groups (Figure 6.12e). Except for PBS, vWF+ structure size was also significantly
greater in the infarct region than in the border zone or remote regions for all treatment
groups (Figure 6.12c). vWF+aSMA+ area was significantly greater in the infarct than
remote regions for the Gel group and significantly greater in the infarct than border zone
or remote regions for the Gel + EVs group (Figure 6.12f). vWF+aSMA+ structure size
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regions for the Gel + EVs group (Figure 6.12d).
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Figure 6.12. Quantification of vascular structures. Number of (a) vWF+ and (b)
vWF+⍺SMA+ structures, (c) vWF+ and (d) vWF+⍺SMA+ structure size, and (e) vWF+ and
(f) vWF+⍺SMA+ area in infarct, border zone (BZ), and remote regions after delivery of
PBS, gel, PBS + EVs, or gel + EVs. Mean ± SD; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001; vWF: von Willebrand factor; ⍺SMA: ⍺-smooth muscle actin, EVs:
extracellular vesicles.

A study by Gkontra, et al tracked microvascular changes in the infarct region
after MI and found that in a pig ischemia/reperfusion model of acute MI, an initial dilation
of vessels in the infarct region after 1 day is followed by constriction of vessels at 3 days,
and then a pruning of microvessels and dilation or arterialization of the remaining
vasculature at 7 days.43 They also found that changes in microvasculature in remote
regions are not as drastic. This suggests that the majority of changes in vascular
structure after MI may occur in the infarct region as a response to the ischemic injury,
which could account for the increased vWF+ area and vWF+ structure size.
Vascular structures in the infarct region also differed in size and density among
treatment groups. vWF+ structure size was significantly larger in the infarct region for the
PBS + EVs than the PBS group, and for the Gel + EVs group than the PBS or Gel
groups (Figure 6.12c). vWF+ area was also significantly greater in the infarct region for
the Gel + EVs group compared to the PBS group (Figure 6.12e). For the analysis of
more mature vascular structures, vWF+aSMA+ structure size was significantly larger in
the infarct region for the Gel + EVs group compared to the PBS or Gel groups (Figure
6.12d).
Taken together, these results suggest that therapeutic delivery to the border
zone can impact the size and density of vascular structures in the infarct region, which
may be due to the increase in microvascular changes that happen in the infarct region
when compared to more remote regions of the myocardium.43 These results also
suggest that the delivery of MSC-derived EVs in saline or an injectable hydrogel
increases vasculature compared to the delivery of saline or an injectable hydrogel alone
and that the delivery of EVs specifically increases the size of both vWF+ and
vWF+aSMA+ structures, which is important because larger vascular structures can be
more constructive for increased perfusion. The in vivo angiogenic potential of MSC209

derived EVs corroborates the in vitro results shown by the Matrigel angiogenesis assay,
and other groups have shown that the delivery of MSC-derived EVs can promote
neovascularization after MI.12

6.4 CONCLUSION
Rat MSCs were pre-conditioned in one of four treatment conditions- standard,
GF, hypoxia, and GF+hypoxia. Pre-conditioning MSCs led to changes in cell number per
area and cell morphology, generally resulting in more compact and rounded cells for all
treatment conditions. EVs isolated from MSCs pre-conditioned with aforementioned
treatment conditions had varying protein content, and EVs isolated from MSCs preconditioned with GF+hypoxia had significantly greater protein content than EVs isolated
from MSCs pre-conditioned with hypoxia or GF. EVs isolated from MSCs treated with
standard, GF, and GF+hypoxia conditions significantly increased tubule formation in a
Matrigel angiogenesis assay. Proteomics analysis of EV protein contents determined
that EVs isolated from MSCs pre-conditioned with standard or GF+hypoxia conditions
had statistically different expressions of many proteins, and that EVs produced in these
conditions contributed to two different populations of EVs, with GF+hypoxia EVs being
enriched for proteins involved in biological processes related to angiogenesis. Injectable
hydrogel delivery of EVs improved EV retention in the heart when compared to saline
delivery of EVs, and the delivery of EVs isolated from MSCs treated with GF+hypoxia
significantly increased vascularization in the infarct region when delivered after MI.
Further studies should more carefully explore differences in EV content for preconditioning treatment conditions, including analyzing miRNA content using sequencing,
and focus on investigating changes in cardiac function with injectable hydrogel delivery
of EVs after MI.
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CHAPTER 7
CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS

7.1 OVERVIEW
This dissertation describes the use of an injectable, hyaluronic acid (HA)
hydrogel for the improved retention of cells and cell-derived therapeutics delivered to the
heart after myocardial infarction (MI). The injectable hydrogel utilized in this thesis is
comprised of HA that is modified separately with adamantane (guest) and b-cyclodextrin
(host) molecules, which form supramolecular hydrophobic interactions upon mixing that
disassemble upon the application of shear forces.1 This allows the hydrogel to be shearthinning and rapidly self-healing, which permits injection and immediate stabilization of
the gel at the injection site, respectively. Synthesis and characterization of this injectable
hydrogel is described in Chapter 3, followed by the application of this hydrogel for the
delivery of endothelial progenitor cells (EPCs) in Chapter 4. In Chapter 5, this injectable
hydrogel is combined with covalently crosslinked microgels for the delivery of IL-10, and
in chapter 6, the injectable hydrogel is used as a delivery vehicle for mesenchymal
stromal cell (MSC)-derived extracellular vesicles (EVs) to the heart. The rest of this
chapter will describe the major conclusions of each of these studies, as well as the
limitations of the studies and potential future directions for further exploration.

215

7.2 SPECIFIC AIM 1
DEVELOP METHODS TO CHARACTERIZE SHEAR-THINNING AND SELF-HEALING
HYDROGELS AND THEIR POTENTIAL FOR INJECTABILITY IN BIOMEDICAL
APPLICATIONS.
7.2.1. CONCLUSIONS
In this chapter, we developed methods for the synthesis and characterization of
the guest-host injectable hydrogel that was used in subsequent chapters for the delivery
of cell-based therapeutics. Further, we described general methods for the rheological
characterization of injectable hydrogels, and showed that material properties such as
modulus, yield strain, viscosity, and shear stress could be varied by changing hydrogel
formulation. Two methods for measuring the injection force required to extrude an
injectable hydrogel from a syringe were developed and used to investigate how hydrogel
formulation, flow rate, needle gauge, and needle length modulated injection force. A
protocol for cell encapsulation and cell culture of injectable hydrogels was also
developed, along with methods for evaluating cell viability after encapsulation and
injection from a syringe, and used to illustrate how hydrogel formulation and injection
parameters affect cell viability. Finally, best practices for hydrogel injection in a rat MI
model were developed, including identification of injection locations and needle
placement to prevent hydrogel leakage from the myocardium and methods for tissue
processing to best preserve hydrogels in tissues.
An enumeration of these methods is important because careful hydrogel
characterization is crucial for the clinical translation of injectable hydrogel therapies.
Practically, hydrogels that require too much force for a typical operator to inject are not
going to be testable in preclinical animal models, much less in clinical trials. Also,
injectable hydrogels designed for cell delivery need to be tested for cell viability after
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injection, since forces that cells experience during injection can lead to cell death.2
Especially for cell delivery, changes in seemingly unimportant injection parameters such
as flow rate, needle gauge, and needle length lead to variations in injection forces that
could greatly affect cell viability and need to be considered in preclinical studies. In
addition, small animal models are challenging, and techniques need to be established
for the delivery of injectable hydrogels to the heart to ensure reproducibility in both
injection location and volume. We describe these methods here for the characterization
of injectable hydrogels and use in an in vivo model to highlight the considerations that
need to be made when engineering an injectable hydrogel for any clinical application.
7.2.2. LIMITATIONS AND FUTURE DIRECTIONS
One of the key limitations of this thesis is the use of the same injectable hydrogel
and nearly the same material formulation for all studies. While this initial formulation was
optimized for cell delivery, other material formulations may be better suited for growth
factor or EV delivery, and considerations for those factors will be described later in this
chapter in sections 7.4.2 and 7.5.2, respectively. In addition, the range of material
properties (e.g., modulus) that can be obtained with this injectable hydrogel was
relatively small (~1-10 kPa), so to increase the stiffness of this hydrogel, secondary
crosslinking mechanisms could be considered.3,4 In general, stiffer hydrogels (20-40
kPa) have been shown to be more beneficial for limiting infarct expansion than softer
hydrogels (1-10 kPa), so the incorporation of a secondary crosslinking mechanism may
be desired.3,5
Also, the injectable hydrogel described was tuned for high cell viability through
trial-and-error permutations of material formulations and injection parameters that were
tested for high cell viability. However, it may be useful to create a model that correlates
flow properties of the injectable hydrogel to cell viability. For instance, Yan et al
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determined that b-hairpin peptide-based hydrogels have a central wide plug flow region
that allows for high cell viability after injection.6 In this way, the flow profiles of injectable
hydrogels could be used to screen material formulations and injection parameters prior
to the encapsulation of cells, which could greatly improve the time required to screen a
large number of hydrogel conditions. Unfortunately, due to technical limitations (the
technique described requires a confocal microscope with a high speed camera) we were
unable to develop this model, but being able to screen a large number of hydrogel
conditions would still be useful, especially as the incorporation of cells in bioinks for 3D
printing grows in popularity.
Finally, there are many limitations to the rat MI model described in this chapter.
Since the same model is also utilized in subsequent chapters, these limitations also
apply to those chapters but will be described once here. For infarct induction, permanent
ligation of the left anterior descending artery has little clinical relevance for humans,
since acute MI is often treated with thrombolytics or angioplasty to restore blood flow.7
Thus, an ischemia/reperfusion injury much more closely models MIs and their clinical
standard of care in humans.7 Also, in rat MI models, infarcts can vary from 4-59% of the
left ventricle even with no discernible variation in surgical technique, likely due to
variations in anatomy from animal to animal.8 Differences in baseline infarct size can
make treatment comparisons difficult or even impossible if variation in infarct size is too
large. Using echocardiography, it can be possible to measure baseline cardiac function
after infarct induction for all animals to reduce infarct variability9, but this technique is not
possible if the therapeutic is injected immediately after infarct induction, as it is in this
model. Immediate delivery of a therapeutic after MI also has little to no clinical relevance,
as it does not match the clinical scenario, and other groups have shown that delaying
the delivery of therapeutics can improve their efficacy, likely due to improved targeting of
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the phases of ventricular remodeling after MI.10,11 Also, depending on the therapeutic
mechanism of action, the ideal delivery window may vary.
Toward clinical translatability, the use of injectable hydrogels as delivery vehicles
allows for minimally invasive, percutaneous delivery, but hydrogel formulations need to
be tuned for flow through a catheter. In addition, considerations need to be made for
delivery method (e.g., intracoronary vs intramyocardial) and the risks associated with
each of these methods (e.g., embolization, myocardial injury). In addition, subsequent
experiments in large animals such as pigs will improve the clinical relevance of these
studies since pig cardiac anatomy and physiology much more closely resembles that of
humans, but these models are costly and are not appropriate for therapeutic screening.7
Also, studies of immune response, hydrogel degradation byproducts, and potential
toxicity should be investigated, particularly for hydrogels formed from derivations of
naturally-occurring materials.

7.3 SPECIFIC AIM 2
DELIVER ENDOTHELIAL PROGENITOR CELLS (EPCS) USING AN INJECTABLE
HYDROGEL TO THE HEART AFTER MI.
7.3.1. CONCLUSIONS
In this chapter, we used the injectable hydrogel described in the previous aim to
deliver EPCs to the heart in a rat model of MI, particularly as EPCs have been previously
shown by our group to promote vascularization.12 We found that the delivery of EPCs
with an injectable hydrogel significantly improved EPC localization to the border zone
region of the infarct when compared to the delivery of EPCs in saline, and that this
improved localization was correlated with significant improvements in vascularization,
cardiac geometry, and cardiac function. In this study, we were able to validate the use of
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our injectable hydrogel as a cell delivery vehicle, and also show that improved cell
retention at the injection site improves cardiac outcomes after MI, which is useful for
improving the efficacy and thereby the translatability of cell therapies to the clinic.
7.3.2. LIMITATIONS AND FUTURE DIRECTIONS
The EPCs used in this study were primary cells isolated from the bone marrow of
syngeneic rats, and isolation from, on average, one rat was required to obtain enough
EPCs for one dose. While EPCs are already a heterogenous cell population13, the use of
primary cells means that multiple EPC isolations from multiple rats needed to be pooled
for each surgery date in this study. In the future, utilizing an alternate cell type, such as
mesenchymal stromal cells, which can be subcultured and delivered allogeneically14,
may reduce cell heterogeneity and be more applicable for clinical translation.
While the injectable hydrogel used in this study was optimized for cell viability,
mechanisms for cell-mediated hydrogel degradation could be engineered into the gel to
allow for more effective cell delivery. For instance, matrix metalloproteinases (MMPs)
are up-regulated in the heart after MI15 and are expressed by EPCs.16 An MMPdegradable peptide could be incorporated into the injectable hydrogel to allow for MMPmediated hydrogel degradation and cell delivery.17
Further studies could also investigate the efficacy of multimodal therapies
whereby cells are combined with other factors to improve their therapeutic effect. For
instance, Saif et al delivered pro-angiogenic growth factors (vascular endothelial growth
factor, hepatocyte growth factor, and angiopoietin-1) with human cord blood
vasculogenic progenitor cells in a murine hindlimb ischemia model, and found that the
combined therapy was more effective for vascularization and increased perfusion than
either therapy alone.18 In addition to pro-angiogenic factors, pro-survival factors such as
insulin-like growth factor-1 may also be useful to improve the viability of delivered
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cells.19,20 However, more complex therapies would likely have a more complicated
regulatory pathway, so the benefits of combination therapies should be significant.

7.4 SPECIFIC AIM 3
DESIGN AND EVALUATE INJECTABLE MICROGEL/HYDROGEL COMPOSITES
FOR INTERLEUKIN-10 (IL-10) DELIVERY TO THE HEART.
7.4.1. CONCLUSIONS
In this aim, injectable microgel/hydrogel composites were designed for IL-10
delivery to the heart. In this case, the injectable hydrogel described in Aim 1 was used
as a bulk injectable hydrogel to encapsulate microgels and improve microgel retention at
the injection site.21 IL-10, an anti-inflammatory cytokine22,23, was used as a model
therapeutic. Covalently crosslinked microgels were designed for IL-10 release,
incorporating factors such as dithiol crosslinkers with varying stability to control microgel
degradation and IL-10 release and thiolated heparin for IL-10 sequestration during the
microgel formation process. The delivery of the composite hydrogel with IL-10 to the
heart after MI significantly reduced inflammation (macrophage levels) and improved
cardiac repair (vascularization, function, geometry) compared to the delivery of saline.
The injectable composite hydrogel delivery system described in this aim decouples
hydrogel injectability from sustained therapeutic delivery, and could be modified for the
release of multiple growth factors with complex release profiles toward more effective
molecular therapies.
7.4.2. LIMITATIONS AND FUTURE DIRECTIONS
For growth factor encapsulation in bulk hydrogels, engineering growth factorhydrogel interactions as well as tailoring the mesh size of the bulk hydrogel are
important when designing hydrogels for growth factor release. In the case of composite
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hydrogels, it can be important to tailor the relationship between the mesh size of the bulk
hydrogel and the diameter of the microgels. In most cases, microgel diameter is much
larger than hydrogel mesh size to allow for entrapment of microgels within the bulk
hydrogel. In this case, the release of encapsulated therapeutics from the microgel are
mediated either by release first from the microgels and then diffusion through the bulk
gel, or by release of microgels from the bulk gel.24 Therefore, to further control
therapeutic release from the composite hydrogel system, mechanisms of degradation for
the bulk gel could also be designed. For example, the incorporation of MMP-degradable
crosslinks could be useful for hydrogel degradation, especially when delivered to the
heart after MI.17
For varying therapeutic release from microgels, crosslinker degradability,
molecule tethering, and microgel size could be explored. For crosslinker degradability,
we evaluated both a stable crosslinker and a hydrolytically-degradable crosslinker, but
there are many other types of crosslinkers that could be used depending on the
application (e.g., proteolytically degradable, light sensitive25) to control molecule release.
IL-10 was sequestered in microgels via charge using thiolated heparin, but there are
many other protein-peptide or protein-protein interactions that could be leveraged for
growth factor encapsulation.26 Additionally, the microgels we studied were of one size
(60 µm diameter). Varying microgel size could alter microgel degradation and molecule
release kinetics by changing the surface area to volume ratio, and change composite
material properties due to differences in packing. Microgel size can be varied by either
changing the geometry of the microfluidic device or by modifying fluid flow rates through
the device.
The injectable composite hydrogel delivery system described in this aim could be
used for the complex delivery of factors in situations when the temporal or spatial27
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control of growth factor delivery is important, such as in angiogenesis.28,29 The modular
nature of this system allows for the incorporation of varying amounts of multiple
microgels of different sizes. As with any growth factor therapy, a dosing study is also
important for clinical translation.

7.5 SPECIFIC AIM 4
DEVELOP

PRE-CONDITION

PROTOCOLS

FOR

THE

ISOLATION

OF

EXTRACELLULAR VESICLES (EVS) FROM MESENCHYMAL STROMAL CELLS
(MSCS) AND DELIVER TO THE HEART USING AN INJECTABLE HYDROGEL.
7.5.1. CONCLUSIONS
In this aim, EVs isolated from pre-conditioned MSCs were delivered to the heart
using the injectable hydrogel described in Chapter 3. MSCs were treated with proangiogenic growth factors and cultured in hypoxic conditions to improve their
vasculogenic potential. EVs isolated from pre-conditioned MSCs increased the formation
of vascular structures in vitro compared to saline. Pre-conditioned EVs also had altered
protein contents when compared to standard EVs, and proteins found in pre-conditioned
EVs were involved in biological processes related to angiogenesis. Injectable hydrogel
delivery of EVs to the heart improved EV retention compared to the delivery of EVs in
saline, and, in a rat MI model, the delivery of pre-conditioned EVs to the heart using an
injectable hydrogel significantly increased the formation of vascular structures. In this
study, we were able to alter MSC EV contents through pre-conditioning, which had
implications for improving the efficacy of cell-derived therapeutics for cardiac repair. In
addition, this aim further showcased the use of this injectable hydrogel for EV delivery to
the heart.11,30
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7.5.2. LIMITATIONS AND FUTURE DIRECTIONS
A large barrier for EV translation is EV heterogeneity and the diversity of
methods in EV isolation, which can greatly affect EV purity. In this study, great care was
taken to ensure that each EV isolation produced EVs of similar quality- for example,
mode size, size distribution, quantity of protein, and metrics of in vitro angiogenesis were
compared for each isolation and only isolations that were similar to each other and met
set standards were used downstream in proteomics and in vivo experiments. Currently,
there is no standard in the field for EV isolation, and the method used for EV isolation in
this study, polymer precipitation, has benefits for cost and ease but also generally leads
to the isolation of non-EV proteins and contamination from the polymer precipitation
reagent.31 Other EV isolation methods, such as ultracentrifugation coupled with density
gradient centrifugation, could be explored to reduce the presence of contaminants and
isolate more pure EVs. For scale-up of EV production, bioreactors have been shown to
increase EV yield by 100-fold compared to traditional cell culture methods through
enhancements in cell culture surface area, medium perfusion, and mass transport.32
Additional characterization of EV contents could also be useful for understanding
the mechanisms driving the therapeutic benefits of EV delivery. While proteomics
studies are becoming more commonplace for EV analysis33, using miRNA-seq34 or RNAseq35 to investigate RNA contents of EVs may also be useful, and a careful examination
of EV contents is important toward developing standards for EVs in a therapeutic
context.
Typically, the release of molecules from hydrogels is dependent on the hydrogel
mesh size in relation to the size of the encapsulated molecule, with release mediated
through diffusion and potential degradation mechanisms.24 Release can also be affected
by affinity between the hydrogel and encapsulated molecule, so that EV-hydrogel
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interactions could be engineered to further sustain EV delivery. For example, in the case
of our guest-host hydrogel, EVs could be functionalized with adamantane (guest) groups
that could interact with excess b-cyclodextrin (host) groups on HA and sequester EVs.36
Further studies should also investigate the effects of EV dose on therapeutic efficacy.

7.6 OVERALL SUMMARY
Injectable hydrogels can improve the targeted delivery of cells, cytokines, and
EVs to the heart after MI to enhance outcomes of cardiac repair (vascularization,
function, geometry). This thesis describes the development of more effective therapies
for cardiac repair through the use of an injectable hydrogel for improved retention, and
enumerates techniques that can be applied for the translation of these therapies to the
clinic, where delivery challenges, such as the local and sustained release of
therapeutics, have often precluded success in clinical trials. While the work described in
this thesis contributes to the body of knowledge surrounding the use of biomaterials as
therapeutic delivery vehicles, some of the greatest challenges remaining for clinical
translation include the development of a catheter-based, minimally invasive delivery
method for the delivery of hydrogels to the heart and manufacturing and reproducibility
of cell-based therapies. As cell-based therapies and biomaterials evolve, we anticipate
that the work featured in this thesis can help guide the development of more effective
therapeutics for the heart, as well as toward widespread biomedical applications where
injectable therapies are useful.
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